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Introduction 
Every year approximately 10000 new cases of colorectal cancer are diagnosed in 
The Netherlands, of which 3300 are located in the rectum.1 Diagnosis is usually 
established by history taking, physical examination, followed by multiple additional 
investigations (laboratory, colonoscopy, (contrast-enhanced) pelvic MRI, abdominal 
and chest CT or chest X-ray). These modalities are used for both local and distant 
staging of the rectal cancer.2 
 
Local recurrence has been one of the main problems after treatment of rectal 
cancer. The risk for local recurrence has been reported to be as high as 40%, mainly 
caused by a suboptimal surgical technique in which the mesorectal envelope was 
bluntly resected, leading to incomplete resections and tumour spill.3 With the 
introduction of the total mesorectal excision (TME), resulting in an accurate dissection 
of the whole mesorectal envelope along the mesorectal fascia or ‘the holy plane’, the 
local recurrence rate reduced substantially to 10% in some expert centres.4 
As a local recurrence is often associated with debilitating symptoms, requiring, if 
resectable at all, extensive salvage surgery, efforts were made to further improve the 
local recurrence rate. The Swedish rectal cancer trial and Dutch TME trial assessed the 
influence of neoadjuvant 5x5 gray (Gy) radiation additional to surgery on local 
recurrence and found that preoperative radiation significantly reduced local recurrence 
rates from 26-27% in the non-irradiated group to 9-11% in the irradiated group.5, 6 
Subgroup analyses in the Dutch TME trial revealed that patients with stage I disease 
(T1-2N0) did not benefit from neoadjuvant 5x5 Gy radiation, because their risk for 
local recurrence already is very low. Furthermore, patients with stage III disease 
(TxN+) benefited from preoperative radiation, but still had a relatively high risk for 
local recurrence in spite of the radiation (11.2%).6 For these high-risk patients more 
intensive neoadjuvant treatment could be considered, such as combined chemo- and 
radiotherapy (chemoradiation). Sauer et al. randomized patients between preoperative 
and postoperative chemoradiation and found that preoperative chemoradiation reduced 
the risk for local recurrence significantly from 13% in the postoperative group to 6% in 
the preoperative group.7 In summary, these studies show that preoperative 
(chemo)radiation significantly reduces the risk for local recurrence in patients with 
intermediate and high risk tumours. 
 
Based on the results of the aforementioned studies patients can be stratified into 
three risk groups: (1) the low-risk tumours, which are confined to the bowel wall (T1-2) 
without nodal metastases (N0), (2) the intermediate-risk tumours, which are T3 
tumours without mesorectal fascia (MRF) involvement and maximally 3 nodal 
metastases (N1) or very distal T2-3Nx tumours and (3) the high risk or locally 
advanced T3-4Nx tumours, which threaten or involve the MRF and/or tumours with 
more than 3 nodal metastases (N2). The treatment can be based on these risk groups. 
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The low risk patients undergo immediate TME without any neoadjuvant treatment. 
The patients with an intermediate risk for local recurrence undergo neoadjuvant 5x5 
Gy radiation with subsequent TME and the high risk group undergoes a long course of 
chemoradiation followed by TME or more extensive surgery after an interval of 6-8 
weeks. Within the group of low risk tumours there is the prognostically favourable 
small T1 tumour, which may be treated with transanal endoscopic microsurgery 
(TEM). The only T1 tumours that are eligible for local treatment with TEM are well 
to moderately differentiated, do not show lymphatic or venous invasion and invasion 
depth into the submucosa must be restricted to the superficial two thirds.1, 8 Staging of 
rectal cancer is generally performed with MRI and/or endoscopic ultrasound.  
 
With a total mesorectal excision (TME) the rectum is resected with the 
mesorectum, the surrounding fat containing the mesorectal lymph nodes. This surgical 
treatment is associated with high rates of surgical complications, morbidity and 
mortality. The most common complications are infection, abscess, ileus or anastomotic 
leakage (11-20%). Long term morbidity includes urinary incontinence (3-15%), sexual 
dysfunction (5-70%), faecal incontinence or stoma (temporary or permanent).9 Average 
peri-operative mortality rate is 4%, but in the elderly this rate increases up to 12%.10 
Following surgical resection some centres administer adjuvant chemotherapy to 
patients with an increased risk for distant metastases, e.g. patients with metastatic 
nodes, T4 tumours or tumours with a poor differentiation grade, lymphatic or venous 
invasion at histopathology. However, the evidence for adjuvant chemotherapy in rectal 
cancer is relatively weak and there is a high variability in the administration of 
adjuvant chemotherapy between different centres and countries.  
 
Response to neoadjuvant chemoradiation 
Neoadjuvant chemoradiation induces downsizing or even downstaging of rectal 
cancer. Downsizing is a volume reduction of the tumour while downstaging is an 
improvement of the T, N and/or M-stage due to substantial response of the cancer to 
the chemoradiation. Downstaging can be determined clinically, radiologically and/or 
histologically. After neo-adjuvant chemoradiation the degree of response (i.e. 
downsizing and/or downstaging) is evaluated with MRI, CT and/or endoscopy (+/- 
biopsy). A complete response of the tumour and lymph nodes (i.e. no residual tumour) 
is encountered in 15-20% of patients. A complete response is traditionally defined after 
surgery as absence of viable tumour and tumoural lymph nodes in the resected 
specimen, a so called pathologic complete response (pCR).11, 12 Although it is generally 
believed that patients with a pCR have a good prognosis, individual studies give 
conflicting results with some studies reporting failure to detect significantly improved 
survival.  
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Treatment after neoadjuvant chemoradiation 
Local treatment 
Current practice is to treat all patients with radical surgery (TME), regardless of 
the response to chemoradation. The rationale is twofold. First, there is the uncertainty 
that a small percentage of patients who are clinically diagnosed as having complete or 
good response may actually have residual viable tumour at histological examination. 
Second, there are currently only a limited number of studies available that evaluated 
less invasive treatment after chemoradiation. An often discussed option in case of a 
good or complete response to chemoradiation is a local excision or transanal endoscopic 
microsurgery (TEM). Generally, a TEM is reserved for adenomas or T1 tumours with 
favourable prognosis, as mentioned earlier. Several studies have suggested and 
evaluated the use of TEM after CRT, with promising results. The largest (randomized) 
study to date has compared laparoscopic TME with TEM for small residual tumours 
after CRT and reported a local recurrence and distant metastasis rate after 5 years of 
7% in both treatment groups.13 
Another option is the so-called wait-and-see policy, as first introduced by Habr-
Gama et al.14-16. This study is the only one that describes the long-term clinical 
outcome after omission of surgery in clinical complete responders. In this study 
patients with suspected clinical complete response (cCR), as defined by digital rectal 
examination, endoscopy and CT, did not undergo surgical intervention but a wait-and-
see policy with intensive follow-up. All patients without clinical complete response 
underwent surgery. Habr-Gama et al. found that there was no significant difference 
between the patients undergoing a wait-and-see policy on the one hand and operatively 
managed patients on the other hand, regarding the risk for local failure or survival. The 
local failure rate after wait-and-see-policy was 18% after a median follow-up period of 4 
years and 3 months. The majority of local failures (85%) occurred in the first year. An 
issue in the study by Habr-Gama is that of the 122 patients that had a cCR 6-8 weeks 
after chemoradiation, only 99 had a sustained cCR after one year. These 99 patients 
were defined as ‘true cCR’ and included in the wait-and-see policy group. The 23 
patients that did not have sustained cCR and were operated, were included in the 
control group (surgery). The design and results of this study lead to a number of 
considerations.14-18 First, there is the question whether with current up-to-date imaging 
the results can be reproduced or even improved. Improvement of selection of complete 
responders would probably lead to a decrease in the proportion of patients with tumour 
regrowth during the first year after chemoradiation. Therefore, the question arises 
whether the selection and follow-up procedures can be optimised. Second, there is 
currently no evidence on the extent of improvement in quality of life with wait-and-see 
policy compared to standard surgery.  
Prevention and detection of metastasis 
Despite all the advances in local treatment of rectal cancer, so far only one study 
could demonstrate an improvement in overall survival of patients with rectal cancer.19 
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The lack of substantial survival benefit from the improvement of local treatment 
strategies can probably be attributed to the incidence of distant metastasis in rectal 
cancer patients; at diagnosis up to 25% of patients have synchronous metastartic 
disease and another 25% of patients develop metachronous metastases later on.20 The 
cornerstone in the reduction of metachronous metastatic disease after surgical 
treatment in many solid tumours is adjuvant chemotherapy. The use of adjuvant 
chemotherapy in rectal cancer is mainly based on extrapolation of results from trials in 
patients with colon cancer only or trials in which only a minority of patients had rectal 
cancer. Therefore, the strength of evidence for adjuvant chemotherapy in rectal cancer 
is weaker than in colon cancer. Moreover, there is a lack of evidence for the use of 
adjuvant chemotherapy in patients who have been treated with neoadjuvant 
chemoradiation. In these patients chemoradiation-induced downstaging changes the 
very basis that guides the decision-making about administration of adjuvant 
chemotherapy; the downstaging may mask the presence of prognostically unfavourable 
factors at diagnosis, which harbours a risk for undertreatment of patients. Basing the 
decision about adjuvant chemotherapy on primary staging is not very reliable either, 
because primary staging is only moderately accurate. Therefore, more evidence on the 
value of adjuvant chemotherapy in patients treated with neoadjuvant chemoradiation is 
needed. Also, it is necessary to evaluate the magnitude of benefit across subgroups with 
different response to chemoradiation.   
 
Another important aspect in the management of distant metastases is early and 
accurate detection. Major progress has been made and is still being made in the 
curative operative treatment of distant metastasis. Therefore, it becomes increasingly 
important to exactly determine the presence and extent of metastatic disease, both at 
diagnosis and during follow-up, in order to select potential candidates for curative 
treatment. Currently, follow-up of patients who have been treated with curative intent 
for their rectal cancer, consists of regular carcinoembryogenic antigen measurements, 
ultrasound or computed tomography (CT) of the liver and a chest X-ray or CT.1 
Computed tomography is mainly accurate for the detection of liver metastasis, while a 
substantial part of patients develops recurrent disease in other localisations, such as the 
the pelvis or the thoraxor in nodes located outside the mesorectum. For these types of 
recurrence CT is not accurate enough. Thus, there is a strong need for an accurate 
imaging modality to screen the whole body for local and/or distant recurrence.  
Aims of this thesis 
The main aims of this thesis are (1) to evaluate the feasibility of a shift towards less 
invasive local treatment of rectal cancer in patients with complete response to 
neoadjuvant chemoradiation and (2) to identify areas for further improvement of the 
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prognosis of patients with rectal cancer. To accomplish these aims, the following 
objectives are addressed in this thesis: 
 
 To establish the prognosis of patients with a complete response after 
chemoradiation and surgery and to compare it with prognosis of patients with 
residual tumour.  
 
 To evaluate the prognosis and quality of life of patients who have convincing 
evidence of clinical complete response after chemoradiation and are managed with a 
wait-and-see policy with intensive follow-up. 
 
 To acquire knowledge about (changes in) the MR morphology of the rectum in 
patients with a complete response who follow a wait-and-see policy, which can help 
a radiologist in early and accurate identification of a recurrence. 
 
 To describe the short and long-term results of the use of MRI as a tool for 
stratification of treatment for patients with rectal cancer.  
 
 To determine whether and which patients benefit from adjuvant chemotherapy 
after chemoradiation for locally advanced rectal cancer. 
 
 To establish the most accurate whole-body imaging modality to detect recurrence 
during follow-up for (colo)rectal cancer.  
Outline of this thesis 
Chapter 2 will discuss the results of a pooled analysis of individual patient data to 
establish whether complete responders after chemoradiation have a better prognosis 
compared to incomplete responders. In chapter 3 the first results on both functional 
outcome and long-term oncological outcome of a pilot study on wait-and-see policy for 
complete responders after chemoradiation are reported and compared to patients with a 
complete response who did undergo surgery. Chapter 4 describes the MRI follow-up 
features of the rectum during wait-and-see policy. Chapter 5 reports the short and long-
term results of a prospective multicentre study in patients who were treated based on 
their risk for local recurrence as assessed with MRI. These results were compared with 
those of the Dutch TME trial. One objective was to verify that local control is good, 
when MRI is used as a selection tool. A second objective was to evaluate the magnitude 
of the problem with respect to distant metastasis. In chapter 6 the benefit of adjuvant 
chemotherapy is evaluated according to response to chemoradiation with a pooled 
analysis of individual patient data. Chapter 7 describes the results of a meta-analysis 
that compares the diagnostic performance of whole-body staging modalities for the 
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detection of local or distant recurrence in patients with colorectal cancer. Chapter 8 
describes an interview with a patient who follows a wait-and-see policy in order to give 
insight into a patient’s perspective of this new and rather controversial treatment 
strategy. Finally, in chapter 9 the content of this thesis is discussed and 
recommendations for clinical practice and future research are given.  
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Abstract 
Background. Locally advanced rectal cancer is usually treated with preoperative 
chemoradiation. After chemoradiation and surgery, 15-27% of the patients have no 
residual viable tumour at pathology: a pathologic complete response (pCR). The 
purpose of this study is to determine whether patients with pCR have better long-term 
outcome than patients without pCR.  
 
Methods. In Medline and Embase 27 articles were identified regarding long-term 
outcome of patients with and without pCR. These 27 articles were based on 17 different 
datasets. 14 authors agreed to share individual patient data. All patients underwent 
chemoradiation and total mesorectal excision. Primary outcome was 5-year disease-
free-survival (DFS). Kaplan-Meier survival functions were computed and hazard ratios 
(HR) with 95% confidence intervals (95%CI) were calculated, using the Cox 
proportional hazards model. Subgroup analyses were performed to test for effect 
modification by other predicting factors. Interstudy heterogeneity was assessed for 
DFS and overall survival (OS) with forest plots and the Q-test.  
 
Findings. 484 of 3105 included patients had pCR. Median follow-up for all patients 
was 48 months (range 0-277). 5-year crude DFS is 83.3% and 65.6% for patients with 
and without pCR, respectively (p<0.0001). The Q-test and the forest plots did not 
suggest significant interstudy variation. The adjusted HR for pCR for failure is 0.54 
(95%CI:0.40-0.73), indicating that pCR-patients have a significantly increased 
probability of DFS. The adjusted HR for DFS for administration of adjuvant 
chemotherapy was 0.91 (95%CI:0.73-1.12).The effect of pCR on DFS was not modified 
by other prognostic factors.  
 
Conclusions. Patients with pCR have better long-term outcome than patients without 
pCR. pCR might be indicative of a prognostically favourable biological tumour profile 
with less propensity for local and/or distant recurrence and better survival. Further 
research should aim at evaluation of the relationship between biological tumour 
characteristics and response to chemoradiation and prognosis  
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Introduction 
 Locally advanced rectal cancer is usually treated with preoperative chemoradiation 
treatment (CRT) followed by total mesorectal excision (TME).1 The majority of 
patients show substantial downsizing, and in 15–27% no residual viable tumour cells 
can be found in the resected specimen.2,3 Several studies have suggested that this 
pathological complete response (pCR) is associated with a favourable outcome with 
regard to local control, distant recurrence, disease-free survival and overall survival.4-8 
Such a finding is clinically relevant because it relates to the question whether or not to 
omit further adjuvant treatment for good responders, or to intensify treatment in non-
responders. Additionally, it can play a role in the current discussion whether patients 
who respond very well to chemoradiation would benefit from less invasive strategies 
such as local excision or even wait-and-see policy.9,10  
Until now published studies have reported a trend towards a favourable prognosis 
for patients with a pCR, but this trend was often not statistically significant, probably 
due to small sample sizes.3,11 Censoring of subjects in survival analyses even 
aggravated this problem, as fewer patients were left for analysis after longer follow-up 
periods. Moreover, most studies compared responding to non-responding patients and 
did not make a distinction between pCR and other degrees of response.4,7,12 A pooled 
analysis of a large set of individual patient data can solve the aforementioned 
methodological problems: it allows for a large sample size, differences in baseline 
characteristics between patients with and without pCR can be adjusted with 
multivariate analyses and the definition of pCR can be standardised.  
For these reasons, we decided to perform a pooled analysis of studies, in which data 
were reported on the diagnosis, treatment and prognosis of patients with and without 
pCR after chemoradiation. The objective was to evaluate whether a pCR is associated 
with improved 5-year rates of local control (LC), distant-metastasis-free (DMFS), 
disease-free (DFS) and overall survival (OS) compared with patients who did not 
achieve a pCR. 
Methods 
Search strategy and selection criteria 
PubMed, Medline and Embase were searched for relevant articles published from 
1980 through January 2009 with the following search terms: "rectal cancer", 
"response", “radiotherap*”, “chemotherap*”, “chemoradiation”, “radio(-)chemo*”, 
“chemo(-)radio*”, “chemo-radiotherapy”, “radio-chemotherapy”, “regression”, 
“patholog*”, “survival”, “sphincter”, "progn*", “Dworak” and/or “Mandard”. Inclusion 
criteria were as follows: (1) the study had to be published in English, German or Dutch 
language, (2) patients had to have primary rectal cancer treated with preoperative 
chemoradiation followed by surgery, (3) the surgical procedure had to be low anterior 
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resection (LAR), abdominoperineal resection (APR) or a more extended resection, (4) 
data and time to event for local recurrence, metastases and/or death had to be 
provided, and (5) data on pathologic response had to be available.  
One reviewer (MM) checked the titles and abstracts of the identified studies in 
order to select studies potentially meeting the inclusion criteria. Two reviewers (MM 
and PN) independently studied full text copies of the selected studies to decide which 
studies met the inclusion criteria. Additional studies were traced by checking the 
reference lists of the selected studies. 
Finally, 55 eligible studies were identified, of which 28 were excluded for the 
following reasons: 12 studies included patients who were treated preoperatively with 
radiotherapy only13-24, 10 studies did not provide data separately for different 
pathologic response groups25-34, 3 studies concerned patients who had local excision or 
did not have surgery because of good response or comorbidity10,35,36, and 3 studies 
duplicated the results of another publication by the same group8,37,38. No study was 
excluded based on language.  
Selection of individual patient data 
 The corresponding authors of the 27 included studies were invited to participate in 
a collaborative analysis.2-7,11,12,39-57 Author contact revealed that the papers were based 
on 17 different study datasets. Fourteen authors decided to participate and provided 
individual patient data.2-6,11,12,39,43,45,47,50,55,56 Characteristics and results from the 3 non-
included studies are shown in table 1 (originally published as a webappendix). Most 
datasets included variables about age at diagnosis, gender, clinical and pathological T-, 
N- and M-category, type of chemoradiation, radiation dose, date and type of surgery 
(LAR, APR or other surgery consisting of Hartmann’s procedure, anterior, posterior or 
total pelvic exenteration, hemicolectomy or colectomy), radicality of the resection, and 
administration of adjuvant chemotherapy. Data were also available for one or more of 
the following clinical endpoints: local recurrence, distant recurrence, disease-free 
survival, overall survival, and dates to events and/or follow-up times.  
All relevant data from the individual datasets were combined into one dataset. 
Some authors provided datasets with more patients than originally reported in their 
publications. Individual patients were excluded from these datasets if they had 
synchronous metastasis, a radiation dose of ≤25 gray, recurrent disease, incomplete 
resection, or radiation treatment only.  
pCR was defined as ypT0N0M0. Three authors provided data on pCR without 
giving the required data on ypTNM-stage.11,50,55 The published manuscript or author 
contact revealed that pCR was also defined as ypT0N0M0 in these 3 datasets.  
The primary outcome measure of the present study was the cumulative probability 
of DFS after 5 years in patients with a pCR compared to patients without a pCR. 
Secondary outcomes were the cumulative 5-year probabilities of LC, DMFS and OS.  
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Statistical analyses 
 The comparison between patients with pCR and patients without pCR was of 
primary interest in this pooled analysis. Baseline characteristics between pCR- and 
non-pCR patients were compared. Differences were tested for significance using the 
independent samples T-test for the comparison of means, and the Pearson’s Chi-square 
test for the comparison of proportions.  
Heterogeneity between studies was tested using the Q test. Forest plots were used 
to display the study-specific hazard ratios (HRs). 
Cumulative probabilities of 5-year LC, DMFS, DFS and OS were compared for 
patients with pCR and without pCR using Kaplan-Meier survival methods. The log-
rank test was used to test for statistically significant differences. LC was defined as the 
absence of pelvic recurrence, DMFS was defined as the absence of distant metastasis 
outside the pelvis. DFS was defined as the absence of a local and/or distant recurrence 
or death from any cause, whichever came first. OS was defined as the absence of death 
from any cause. Duration of follow-up was calculated as the time from surgery to the 
event of interest or to the last follow-up that was used as a date of censoring. 
Adjustment for differences in baseline characteristics between pCR and non-pCR 
patients was performed using multivariate Cox proportional hazards models with 
stratification for study centre. The proportional hazard assumption was explored by 
graphical methods.  
Hazard ratios with 95% confidence intervals (95%CI) were calculated. All HRs 
corresponding with the pCR variable represent the relative risks of having an event 
during follow-up for patients with pCR compared with patients without pCR. A HR 
below 1 indicates that patients with pCR have a higher probability of LC, DMFS, DFS 
and OS than patients without pCR. Additionally, we performed subgroup analyses to 
test the hypothesis that unfavourable prognostic factors might compromise the 
prognosis in such a way that pCR would no longer have an effect on long-term 
outcome. Analyses were performed with Statistical Packages for Social Science 15·0 
(SPSS) and Stata, release 10; StataCorp, College Station, TX. P-values <0·05 were 
considered statistically significant.  
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Results 
 Table 2 gives details about the 14 studies that were included for the meta-analysis.  
A total of 3105 patients were included of which 484 had a pCR. Chemoradiation 
consisted of 45-50.4 Gray in 25 to 28 fractions of 1·8 Gray with 5-flourouracil (5-FU) 
based chemotherapy in most studies. The interval between chemoradiation and surgery 
was 6-8 weeks in almost all studies. Table 3 provides the characteristics of the included 
datasets separately. Table 4 presents the baseline characteristics for all patients, for 
patients with pCR and for patients without pCR. Mean age (±SD) was 61±12 years and 
64% (1994/3104) of patients were male. pCR rates ranged from 9% to 24% in the 
individual studies. The pooled prevalence of pCR was 16% (484/3105). 25 of 509 
patients (5%) with ypT0 had positive lymph nodes at pathologic examination. Median 
follow-up was 46 months (range: 0-187) for patients with pCR and 48 months (range: 
0-277) for patients without pCR. Clinical staging was generally performed with 
computed tomography and/or endorectal ultrasound. Three studies used magnetic 
resonance imaging (MRI).11,12,47 The T-stage before CRT was significantly more often 
a cT1 or cT2 tumour in the patients with pCR. Patients with pCR had clinical T1 and 
T2 tumours significantly more often than patients without pCR (11% vs. 4%, 
p<0.0001). The percentages of patients with a clinically positive lymph node status 
were similar for patients with and without pCR. LAR was performed significantly more 
often than APR in patients with pCR (69% vs. 63%, p=0.030). Adjuvant chemotherapy 
was administered significantly less often to patients with pCR (39% vs. 56%, p<0.0001). 
Additional information about the proportions of patients with pCR according to 
different tumour and treatment characteristics is shown in table 5 (originally published 
as a webappendix).  
Study-specific hazard ratios for DFS and OS were available for 11 and 12 studies, 
respectively. Two studies47,50 did not provide data on DFS and in one study, due to 
absence of events in the pCR group56, neither the HR for DFS nor the HR for OS could 
be calculated. For the same reason the HR for OS could not be calculated in another 
study.45 The p-value from the Q-test for OS was non-significant (0.62), but for DFS the 
p-value was near 0.05 (p=0.052). However, the forest plots for DFS and OS (figure 1) do 
not suggest significant interstudy variation among the estimated hazard ratios. 
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Parameter All Pathologic 
complete 
response 
No pathologic 
complete 
response 
p-value 
Mean age (years) 61±12 62±11 61±12 p=0.79 
 Missing 2% (49/3105) 2% (9/484) 2% (40/2621)  
Gender (male %) 64% (1994/3104) 65% (315/484) 64% (1679/2620) p=0.24 
 Missing 0% (1/3105) 0% (0/484) 0% (1/2621)  
Clinical T-stage     
 T1 0% (12/2785) 2% (7/462) 0% (5/2323) 
 T2 5% (145/2785) 9% (41/462) 4% (104/2323) 
 T3 83% (2301/2785) 81% (374/462) 83% (1927/2323) 
 T4 12% (327/2785) 9% (40/462) 12% (287/2323) 
p<0.0001 
 Missing 10% (320/3105) 5% (22/484) 11% (298/2621)  
Clinical N-stage     
 N+ 59% (1699/2858) 59% (277/466) 59% (1422/2392) p=0.10 
 Missing 8% (247/3105) 4% (18/484) 9% (229/2621)  
Distance ab ano     
 0-5 cm 52% (1327/2533) 56% (237/421) 52% (1090/2112) 
 5-10 cm 42% (1071/2533) 40% (167/421) 43% (904/2112) 
 >10 cm 5% (135/2533) 4% (17/421) 6% (118/2112) 
p=0.15 
 Missing 18% (572/3105) 13% (63/484) 19% (509/2621)  
Type of surgery     
 Low anterior resection 64% (1947/3029) 69% (326/473) 63% (1621/2556) 
 Abdominoperineal 
 resection 
26% (802/3029) 22% (102/473) 27% (700/2556) 
 Other 9% (280/3029) 10% (45/473) 9% (235/2556) 
p=0.030 
 Missing 2% (76/3105) 2% (11/484) 2% (65/2621)  
Adjuvant chemotherapy 53% (1398/2642) 39% (155/402) 55% (1243/2240) p<0.0001 
 Missing 15% (463/3105) 17% (82/484) 15% (381/2621)  
Median follow-up time 
(months) 
48 (0-277) 46 (0-187) 48 (0-277) p=0.058 
 Missing 3% (96/3105) 4% (17/484) 3% (79/2621)  
Table 4. Baseline characteristics of all patients and for patients with pathologic complete response 
compared to patients without pathologic complete response. P-values < 0·05 are considered to be 
statistically significant. 
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Figure 1. Forest plot with the hazard ratios and 95%CI for DFS (left) and OS (right) for each 
individual study.  
Univariate analyses 
Kaplan-Meier survival functions for LC, DMFS, DFS and OS for patients with and 
without pCR are shown in figure 2. Because not all datasets evaluated and/or provided 
all 4 outcome measures, the number of patients at risk can differ between outcome 
measures.  
pCR after chemoradiation is associated with a lower risk for local recurrence. In the 
group with pCR 12/455 local recurrences were found, compared to 202/2478 in the 
non-pCR group. The 5-year risk for local recurrence was 2.8% in the pCR group and 
9.7% in the non-pCR group (p<0·0001). The crude HR was 0.33 (95%CI: 0.19-0.60) in 
favour of pCR patients.  
5-year DMFS was 88.8% for patients with pCR and 74.9% for patients without 
pCR (p<0.0001) with a crude HR of 0.40 (95%CI: 0.29-0.55). 38/419 pCR patients had 
distant metastasis vs. 512/2257 patients in the non-pCR group.  
5-year DFS was 83.3% and 65.6% for pCR and non-pCR, respectively (p<0.0001). 
The crude HR for DFS was 0.44 (95%CI: 0.34-0.57), which is in favour of pCR patients. 
Disease recurred in 61/419 pCR-patients and in 747/2263 non-pCR patients.  
5-year OS was 87.6% for pCR (53 deaths in 465 patients) and 76.4% (614 deaths in 
2538 patients) for non-pCR patients (p<0.0001). The crude HR for OS was 0.51 
(95%CI: 0.38-0.67) in favour of pCR patients.  
Multivariate analyses 
 Table 6 presents the results from a multivariate Cox proportional hazards model 
with stratification for study centre. Only 8 authors (n=2416 patients) provided data on 
all relevant baseline characteristics, such as clinical T- and N-stage, distance from the 
anal verge, type of surgery and administration of adjuvant chemotherapy. Therefore, 
the multivariate analyses were based on data from these 8 centres.2-6,12,39,43 
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Figure 2. Kaplan-Meier survival curves for patients with (pCR) and without pathologic 
complete response (non-pCR). A: local-recurrence free survival, B: distant-metastasis free 
survival, C: disease-free survival, D: overall survival. Not all study centres provided data for all 4 
outcome measures, which explains the discrepancies of numbers at risk between outcome measures. P-
values were determined by log-rank test. HR=hazard ratio, 95%CI=95% confidence intervals.  
 
The adjusted HR of 0.54 (95%CI: 0.40-0.73) for DFS indicates that after adjustment for 
other relevant prognostic factors, patients with pCR still have a significantly higher 
probability of DFS than patients without pCR. The adjusted HR for LC is 0.41 (95%CI: 
0.21-0.81), for DMFS the adjusted HR is 0.49 (95%CI: 0.34-0.71), and for OS it is 0.65 
(95%CI: 0.47-0.89), all indicating that pCR-patients have better prognosis than non-
pCR patients.  
32 
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Parameter All Pathologic 
complete 
response 
Missing p-value 
Clinical T-stage     
 T1 0% (12/2785) 58% (7/12) 
10% (320/3105) p<0.0001 
 T2 5% (145/2785) 28% (41/145) 
 T3 83% (2301/2785) 16% (374/2301) 
 T4 12% (327/2785) 12% (40/327) 
Clinical N-stage     
 N0 41% (1159/2858) 16% (189/1159)   
 N+ 59% (1699/2858) 16% (277/1699) 8% (247/3105) p=0.10 
Distance ab ano     
 0-5 cm 52% (1327/2533) 18% (237/1327) 
18% (572/3105) p=0.15  5-10 cm 42% (1071/2533) 16% (167/1071) 
 >10 cm 5% (135/2533) 13% (17/135) 
Type of surgery     
 Low anterior resection 64% (1947/3029) 17% (326/1947) 
2% (76/3105) p=0.030  Abdominoperineal 
 resection 
26% (802/3029) 13% (102/802) 
 Other 9% (280/3029) 16% (45/280)   
Table 5. Proportions of patients with pCR according to tumour and treatment characteristics. 
Additional analyses with the separate components of pCR: ypT0 and ypN0. To evaluate whether the 
favourable prognosis of pCR is due to the ypN0 component only we performed an additional 
multivariate analysis with the 2 components of pCR (ypT0 and ypN0) entered separately in the 
model instead of the variable pCR. The adjusted hazard ratio for disease-free survival for ypT0 was 
0·65 (95%CI 0.48-0.87) and for ypN0 the adjusted hazard ratio for disease-free survival was 0.41 
(95%CI 0.34-0.49). This reflects that both ypT0 and ypN0 attribute to the favourable effect of pCR 
on disease-free survival.  
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Table 6 also provides information on the independent effect of other prognostic 
factors on the studied endpoints. The multivariate analyses with respect to DFS show 
that patients with clinical T4 stage have a significantly higher risk of disease 
recurrence (HR=1.51 95%CI: 1.19-1.90), compared to patients with clinical T3 stage. 
Patients with a clinically positive nodal status also have a significantly increased risk of 
disease recurrence (HR=1.23, 95%CI: 1.02-1.50). Type of surgery is significantly 
Factor Disease-free 
survival 
Hazard Ratio 
(95% CI) 
Local control 
Hazard Ratio 
(95% CI) 
Distant 
metastasis free 
survival 
Hazard Ratio  
(95% CI) 
Overall Survival 
Hazard Ratio (95% 
CI) 
Pathologic response     
 Residual disease 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 
 Pathologic 
 complete response 
0.54 (0.40-0.73) 0.41 (0.21-0.81) 0.49 (0.34-0.71) 0.65 (0.47-0.89) 
Age 0.99 (0.99-1.00) 0.99 (0.98-1.01) 0.98 (0.98-0.99) 1.01 (1.00-1.02) 
Gender     
 Male 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 
 Female 0.87 (0.73-1.05) 1.25 (0.87-1.78) 0.84 (0.68-1.05) 0.83 (0.68-1.03) 
Clinical T-stage     
 T1 0.89 (0.12-6.37) NE 1.18 (0.16-8.50) 1.39 (0.19-9.98) 
 T2 0.58 (0.33-1.01) 0.55 (0.17-1.73) 0.80 (0.46-1.39) 0.48 (0.25-0.93) 
 T3 100 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 
 T4 1.51 (1.19-1.90) 1.22 (0.74-2.02) 1.43 (1.07-1.91) 1.44 (1.11-1.89) 
Clinical N-stage     
 N0 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 
 N+ 1.23 (1.02-1.50) 1.70 (1.10-2.63) 1.20 (0.95-1.52) 1.24 (1.00-1.53) 
Distance from anal 
verge 
   
 ≤ 5 cm 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 
 > 5 cm  1.19 (0.99-1.45) 0.90 (0.60-1.35) 1.11 (0·88-1.40) 1.28 (1.03-1.59) 
Type of Surgery     
 Low anterior 
 resection 
1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 
 Abdominoperineal 
 resection 
1.50 (1.21-1.85) 1.45 (0.94-2.23) 1.54 (1.20-1.98) 1.83 (1.45-2.32) 
 Other 1.72 (1.17-2.54) 2.05 (0.99-4.24) 1.36 (0.84-2.22) 2.11 (1.38-3.23) 
Adjuvant chemotherapy     
 No 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 
 Yes 0.91 (0.73-1.12) 0.98 (0.63-1.51) 1.03 (0.80-1.34) 0.68 (0.54-0.86) 
Table 6. Adjusted hazard ratios with 95% confidence intervals (95%CI) from multivariate Cox 
proportional hazards model.  
A hazard ratio below 1 indicates that patients have a lower probability of an unfavourable event. 
ref=reference variable; NE=not estimable; cm=centimetres.  
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associated with prognosis as well: compared with low anterior resection, the prognosis 
of patients who have had APR or another type of surgery is poorer (HR=1.50 95%CI: 
1.21-1.85 and HR=1.72 95% CI 1.17-2.54, respectively). The administration of adjuvant 
chemotherapy did not have an additional favourable effect on DFS (HR=0.91 95%CI: 
0.73-1.12), although it was associated with significantly improved OS (HR 0.68, 95%CI: 
0.54-0.86). We performed an additional multivariate analysis with addition of the 
variable ‘tumour length’ (as a proxy for tumour volume), which was provided by 3 
datasets (n=1189).6,12,43 The adjusted HR for DFS was 0.51 (95%CI: 0.33-0.80), in 
favour of patients with pCR. Furthermore, to evaluate whether the favourable effect of 
pCR on prognosis was due to either the ypT0 or ypN0 component in pCR only we 
performed an additional multivariate analyses with ypT0 and ypN0 as separate factors 
in the model instead of the pCR variable. This analysis revealed that both ypT0 and 
ypN0 attribute significantly to the improved disease-free survival in patients with pCR 
(more details are supplied in the webappendix).  
Subgroup analyses 
 The results of the subgroup analyses (figure 3) indicate that the favourable effect of 
pCR on prognosis was not modified by baseline characteristics or treatment variables. 
Discussion 
 This pooled analysis of individual patient data from multiple study centres shows 
that patients with a pCR after chemoradiation have a significantly improved long-term 
outcome in terms of LC, DMFS, DFS and OS compared to patients with residual 
disease. The effect of pCR on long-term outcome was not influenced or modified by 
clinical T- or N-category, administration of adjuvant chemotherapy, distance from the 
anal verge or type of surgery.  
One of the earliest studies reporting that patients with a pCR or good response 
after chemoradiation for rectal cancer had better long-term outcome than patients with 
little or no response was published by Chari et al.8 Since then, several reports have 
confirmed these findings, but some studies reported similar or worse outcome for 
patients with a pCR.2,47,51 A recent long-term analysis in a large population of 566 
patients with a pCR by Capirci et al. contributed evidence that patients with a pCR 
have a favourable prognosis with 5-year rates of DFS and OS of 85% and 92%, 
respectively. Their study, however, did not compare outcome with a control group of 
patients with residual disease.58 Our pooled analysis confirms the high 5-year DFS and 
OS in patients with pCR.  
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One appealing explanation for the good prognosis after pCR is that a pCR after 
chemoradiation is indicative of a prognostically favourable biological tumour profile 
with less propensity for local recurrence, distant metastases and a better survival 
compared with patients with less response. Several efforts have been made to identify 
tumour markers that can predict response to chemoradiation. Rödel et al. reported that 
the pre-treatment apoptotic index (percentage of apoptotic tumour cells in the total 
number of tumour cells) may be a predictor of pCR.59 Other biological factors that have 
been evaluated as potential predictors of response and long-term outcome, are, among 
others, p53, EGFR, Ki-67, p21, and Bax/bcl-2. Finally, microarray studies of genetic 
profiles have been compared between responding and non-responding tumours.60 
Although these studies are promising, the results are still premature and the studies 
were conducted in small samples.  
An alternative hypothesis is that the favourable effect of pCR on prognosis might 
be explained by a strong correlation between pCR and a small pre-treatment volume.61 
However, after we entered tumour length together with the other relevant prognostic 
variables the multivariate analysis showed that pCR was still significantly associated 
with better DFS (HR 0.51, 95%CI: 0.33-0.80). Based on this finding, it seems unlikely 
that the favourable effect of pCR on prognosis is due to a correlation with smaller pre-
treatment volume. However, this analysis was performed with data from 3 datasets 
(n=1189) only and thus the result should be interpreted with caution. 
In this analysis pCR was defined as ypT0N0M0. Nevertheless, local recurrence still 
occurred in 12 patients with pCR after surgery, corresponding with a 5-year risk of 
local recurrence of 2.8%. The individual data of these 12 patients did not reveal any 
clinical clues to explain these local recurrences. The pCR in these 12 patients can be 
considered as errors in pCR assessment. This can be due to evaluation errors by the 
pathologist, or because tumour was left behind in the patient at surgery (e.g. lateral 
lymph nodes). The reported interobserver agreement for histological examination of 
rectal cancer specimens after chemoradiation is good, ranging from 0.64 to 0.74, with 
the best agreement for determination of pathologic complete response.62,63 Irrespective 
of the exact cause of the local recurrences after pCR, the finding indicates that a pCR 
does not guarantee a zero risk of local recurrence.  
Clinical implications 
 The finding that patients with a pCR have a more favourable prognosis than 
patients with residual disease raises the question whether achieving a pCR should be a 
goal in the treatment of rectal cancer. More aggressive neoadjuvant treatment, such as 
higher radiation doses and boosts, continuous venous infusion of concurrent 
chemotherapy29,64, additional neoadjuvant chemotherapy65, and more potent 
radiosensitizers66,67 could be considered for this purpose. Another more simple option 
for increasing pCR rates is to lengthen the interval between chemoradiation and 
surgery.68,69 The finding in this study that a pCR is associated with a good prognosis, 
however, is based on data from studies which evaluated response at 6-8 weeks after 45-
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50.4 Gy radiation with 5-FU based chemotherapy. The question whether patients that 
achieve a pCR after different neoadjuvant regimens also have a favourable prognosis 
cannot be answered by this pooled analysis and remains a subject for further study. 
Furthermore, as long as the long-term outcome of patients who achieve a pCR after 
more aggressive types of neoadjuvant treatment is not clarified, we risk overtreating 
and exposing patients to additional morbidity when implementing more aggressive 
neoadjuvant treatments to obtain a higher pCR rate.  
A good response after chemoradiation offers opportunities for more sphincter 
sparing procedures, but more controversial organ sparing options such as local excision 
of the tumour or a wait-and-see approach (i.e. omission of surgery) in case of a clinical 
complete response could also be considered, provided complete responders can be 
accurately selected with imaging and endoscopy. Even though current and future 
studies have to provide definite evidence about the oncological safety, these less 
invasive alternative options offer obvious functional benefits compared to standard 
TME. With regard to long-term oncological outcome, the new aforementioned less 
invasive treatments will have to compete with the excellent prognosis of pathological 
complete responders after standard resection.  
Patients with a pCR received adjuvant chemotherapy less often than patients 
without a pCR (39% versus 56%, p<0·0001) and still had a better prognosis than 
patients without a pCR. This raises the question whether patients with a pCR benefit 
from adjuvant chemotherapy. The results of the multivariate analyses indicate that 
after adjustment for other prognostic factors the administration of adjuvant 
chemotherapy had no independent effect on DMFS or DFS. However, administration 
of adjuvant chemotherapy was associated with significantly better OS (HR 0.68, 95%CI 
0.54-0.86). These puzzling findings may be explained by so-called confounding by 
indication, a well-known problem in non-randomized studies. This confounding by 
indication can result in lack of comparability of prognosis between patients who 
received adjuvant chemotherapy and those who did not. Maybe the decision whether or 
not to administer adjuvant chemotherapy was also guided by patient factors that were 
not incorporated in the multivariate analyses, such as comorbidity. In the subgroup of 
patients with pCR we repeated the multivariate analyses for DFS and found that the 
HR for adjuvant chemotherapy was 0.88, 95%CI 0.39-2.02. Because of the wide 
confidence interval it is difficult to draw conclusions on the benefit of adjuvant 
chemotherapy for patients with pCR. Collette et al. reported on a study that 
randomized patients to undergo adjuvant chemotherapy or not after (chemo)radiation 
and surgery for rectal cancer. They found an overall HR for adjuvant chemotherapy of 
0.85 for DFS, comparable to our findings. In a subgroup analysis the degree of 
downstaging modified the effect of adjuvant chemotherapy on DFS: patients with 
ypT0-2 tumours benefited from adjuvant chemotherapy, whereas patients with ypT3-4 
tumours did not. The authors explained this interesting finding by the hypothesis that 
tumours that respond well to preoperative 5-FU based chemoradiation will also be 
sensitive to 5-FU based adjuvant chemotherapy.70 At present there is no definite 
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evidence on the benefit of adjuvant chemotherapy after a complete response. Both our 
study and the study from Capirci et al. suggest little or no benefit of chemotherapy.58 
Until further evidence becomes available, it is up to the clinicians how to decide for an 
individual patient. In practice, the decision will often be based on risk factors for local 
or distant recurrence, such as the clinical pre-treatment staging (usually cN-status) or 
the response to chemoradiation. 
Limitations 
 There are some limitations to this analysis. First, although we identified 17 
individual datasets in our search, authors from 14 datasets participated. Two of three 
studies that declined participation reported similar results.44,46 The other study 
reported no difference in 5-year LC and DFS between pCR and non-pCR and a non-
significant difference in 5-year overall survival in favour of patients with pCR.51 
However, as stated by the authors, due to limited sample size the power to find a 
statistically significant difference was only 25%. Therefore it is unlikely that non-
inclusion of these 3 studies has introduced bias. Additionally, two very recent papers 
that were published after our search and analyses are in agreement with our main 
findings. Although lacking the statistical power, both the studies of Roh et al. and Chua 
et al. report better outcomes for complete responders.65,71 A second limitation of this 
meta-analysis is that there are differences between studies caused by variations between 
centres in approaches to diagnosis and treatment. Although pathologic examination 
was performed in accordance with the TNM staging system in all studies, it cannot be 
guaranteed that pathological examination and pCR evaluation was uniform in all 
studies. In the analysis we accounted for these differences in diagnosis and treatment 
by stratification by centre.  
Conclusion 
 Patients with a pCR after chemoradiation have improved long-term outcome 
compared to patients with residual pathologic disease. We believe that a pCR after 
chemoradiation is indicative of a prognostically favourable biological tumour profile 
with less propensity for local or distant recurrences and a better survival than for 
patients with tumours that respond less. This hypothesis needs to be substantiated by 
studies on the relationship between biological tumour characteristics and response to 
chemoradiation and prognosis.  
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Abstract 
Background. Neoadjuvant chemoradiation for rectal cancer can result in complete 
disappearance of tumour and involved nodes. In these patients without residual tumour 
on imaging and endoscopy (complete clinical response, cCR) wait-and-see-policy 
(omission of surgery with follow-up) might be considered instead of surgery. The 
purpose of this prospective cohort study was to evaluate feasibility and safety of wait-
and-see policy with strict selection criteria and follow-up.  
 
Methods. Patients with a cCR after chemoradiation were prospectively selected for 
wait-and-see policy with MRI and endoscopy+biopsies. Follow-up was performed 3-6 
monthly and consisted of MRI, endoscopy and CT. A control group of patients with a 
pathologic complete response (pCR) after surgery was identified from a prospective 
cohort study. Functional outcome was measured with the MSKCC bowel function 
questionnaire and Wexner incontinence score. With Kaplan-Meier curves long-term 
outcome was estimated.  
 
Findings. 21 patients with cCR were included for wait-and-see policy. Mean follow-up 
is 25(±19) months. One patient developed a local recurrence, which could be salvaged 
with surgery. The other 20 patients are alive without disease.  
The control group consisted of 20 patients with a pCR after surgery, who had a 
mean follow-up of 35(±23) months. Cumulative probabilities of 2-year disease-free 
survival and overall survival are 93% and 91%, respectively.  
 
Conclusions. Wait-and-see policy with strict selection criteria, modern imaging and 
follow-up is feasible and results in promising outcome, which is at least as good as that 
of patients with a pCR after surgery. The proposed selection criteria and follow-up 
could form the basis for future randomized studies. 
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Introduction 
 In approximately 15-20% of the patients who undergo neoadjuvant chemoradiation 
(CRT) for locally advanced rectal cancer, no residual tumour is reported at histology 
after a standard resection: a pathologic complete response (pCR).1 Whether in these 
patients surgery could have been omitted was an intriguing but mostly theoretical 
question until Habr-Gama et al. reported their results from their so-called ‘wait-and-
see policy’.2 In this study, patients with low rectal cancer who achieved a clinical 
complete response after CRT were closely followed, without undergoing surgery. 
Long-term results were compared with a control group without clinical complete 
response in whom a total mesorectal excision (TME) was performed. After a mean 
follow-up of 60 months the results for the wait-and-see group were impressive: a 5-year 
overall survival and disease-free survival of 93% and 85%, respectively.2,3 
These encouraging results of Habr-Gama were generally viewed with caution, and 
physicians were reluctant to treat patients non-operatively, mainly because of the lack 
of a sufficiently accurate technique to identify patients with a clinical complete 
response, and because no other study has reproduced the results.4,5  
The aim of this study is to evaluate the safety and the benefits of omission of 
surgery combined with intensive follow-up (wait-and-see policy) for clinical complete 
responders after CRT with regard to local recurrence, disease-free survival, overall 
survival and bowel function compared to patients who achieved a pCR after surgery. A 
second aim was to evaluate a selection process and follow-up schedule with up-to-date 
MR-techniques.  
Methods 
Patient inclusion and selection 
 Since 2004 the option of a wait-and-see policy was discussed with patients with a 
clinical complete response (ycT0N0) after CRT. The wait-and-see policy was presented 
as experimental and controversial, while it was stressed that a TME is the standard 
treatment with the best oncological control. All patients who preferred the wait-and-
see policy over surgery gave informed consent. In 2009 this pilot was continued in a 
prospective cohort study, approved by the medical ethical committee and registered in 
clinicaltrials.gov (NCT00939666). All previously treated patients were also included.  
Treatment stratification was based on primary staging with with MRI, consisting 
of standard T2-weighted imaging. Additionally, nodal status was evaluated with MRI 
enhanced with either Ultrasmall Superparamagnetic Particles of Iron Oxide before 
2006 or gadofosveset trisodium since 2006.6,7 Diffusion-weighted MR imaging (DWI), 
used to distinguish tumoural tissue (high signal on DWI) from normal rectal wall (low 
signal on DWI), was added to the staging and restaging protocol in 2006.8 
Chemoradiation was indicated for all patients with locally advanced rectal cancer, 
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defined as a (1)T4 tumour or a T3 tumour with a threatened/involved mesorectal 
fascia, and/or (2) > three involved nodes, and/or (3) a very distal tumour with 1-3 
involved nodes. Chemoradiation consisted of 28 fractions of 1.8 Gy combined with 
2x825 mg/m2 capecitabine. Six to eight weeks after chemoradiation response 
evaluation was performed with the same MRI sequences as above. When on post-CRT 
MRI no residual tumour or only an area of fibrotic signal was visible (figure 1), an 
endoscopy was performed to assess the endoluminal tumour remnant.  
 
 
Figure 1. Example of a patient included for wait-and-see policy. 1A: Sagittal T2-weighted image of 
the primary distally located tumour (T) before treatment. 1B: Tumour at endoscopy before treatment. 
1C: Post-chemoradiation sagittal T2-weighted image with the arrows indicating a slightly thickened 
hypo-intense bowel wall, suggesting fibrosis. 1D: Residual scar after chemoradiation. The black arrow 
indicates a pale, white area, typical of a clinical complete response. The white arrow marks 
teleangiectasia, also a typical sign of a clinical complete response. 
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Figure 2. Ventral tumour (T) on a T2-weighted axial image of the distal rectum before chemoradiation 
(left), showing the mucosa (white arrow) and the muscularis propria (black arrow). After 
chemoradiation (right image) no residual tumour with iso-intense signal or fibrosis with hypo-intense 
signal is visible. Again, the white arrow indicates the mucosa and the black arrow indicates the 
muscularis propria. Now, an additional layer of edema (*) has become visible, the submucosal layer, 
situated between the mucosa and muscular layer (online only).  
 
 
Figure 3. Example of a patient not eligible for wait-and-see policy despite remarkable response 
on MRI. 3A: Distal tumour (T) before treatment at a T2-weighted sagittal image. 3B: The tumour at an 
axial T2-weighted image before treatment. 3C: Post-chemoradiation image with edema (*) and a hypo-
intense fibrotic area (black arrow, also on image 3D) at the former tumour location. At high b-value 
diffusion–weighted imaging (3E) the distinction a small area with higher signal is visible (white arrow), 
suggestive of residual tumour. 3F: Obvious residual tumour at endoscopy after chemoradiation (black 
arrows). After total mesorectal excision, histology revealed a ypT2N0 tumour.  
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The definition of a clinical complete response was:  
1. Substantial downsizing with no residual tumour or residual fibrosis only (with low 
signal on high b-value DWI, if available), shown in figure 1. Residual wall 
thickening due to edema only was also an indication for a possible clinical complete 
response (figure 2), and 
2. No suspicious lymph nodes on MRI, and 
3. No residual tumour at endoscopy or only a small residual erythematous ulcer or 
scar (figure 1), and 
4. Negative biopsies from the scar, ulcer or former tumour location, and  
5. No palpable tumour, when initially palpable with digital rectal examination. 
If patients did not meet all of the abovementioned criteria they were regarded as 
non-complete responders. Figure 3 shows an example of a non-eligible patient for wait-
and-see policy. 
Follow-up 
 An intensive follow-up protocol was incorporated into the wait-and see policy, 
consisting of digital rectal examination, MRI, endoscopy (with biopsy), CT of the chest 
and abdomen (for distant metastasis imaging) and carcinoembryogenic antigen 
measurements. The follow-up schedule is shown in table 1.  
Patients received ‘adjuvant’ chemotherapy, consisting of intravenous oxaliplatin 
130 mg/m2 on day 1 and capecitabine 1000 mg/m2 twice daily from day 1-14, when 
they had a positive nodal status at primary staging. Chemotherapy was administered in 
6 (3-week) cycles.  
 
  CEA DRE Endoscopy MRI* CT for distant staging 
Year 1 4x 4x 4x 4x 2x 
Year 2 4x 2x 2x 2x 1x 
Year 3 4x 2x 2x 2x 1x 
Year 4 2x 2x 2x 2x 1x 
Year 5  2x 2x 2x 2x 1x 
Table 1. Follow-up schedule for patients following wait-and-see policy. *indicates that this is 
different from the standard follow-up after total mesorectal excision. 
Control group 
 For the comparison of short- and long-term outcome, patients with a pathologic 
complete response (pCR; ypT0N0) after CRT and TME were identified from a 
multicenter prospective cohort study performed by our research group, in which MRI 
based tailored treatment for rectal cancer was evaluated.9  
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Statistical analysis 
 Information on baseline characteristics was collected. Treatment-related 
complications and morbidity were recorded and classified according to the classification 
of Dindo et al.10 Functional outcome was measured with the Memorial Sloan Kettering 
Cancer Center (MSKCC) bowel function questionnaire11 and the Wexner incontinence 
score for evaluation of faecal incontinence.12 Mean scores were compared between the 
wait-and-see patients and pCR control group with the independent samples T-test to 
compare continuous variables and χ2 test to compare proportions.  
Cumulative proportions of local recurrence, disease-free and overall survival were 
evaluated with Kaplan-Meier curves and were compared between patients with wait-
and-see policy and operated patients with the log rank test. Local recurrence was 
defined as a recurrence in the pelvis; disease-free survival as the absence of a local and 
distant recurrence, and death from any cause; and overall survival as the absence of 
death from any cause. Duration of follow-up was calculated as the time from the MRI 
after CRT to the event of interest or to the last follow-up date (censoring date). 
All statistical analyses were performed with Statistical Package for the Social 
Sciences (SPSS) version 16.  
Results 
 From 2004-2010, 192 patients with locally advanced rectal cancer were treated 
with CRT. Twenty-one patients had a clinical complete response and were included for 
wait-and-see policy. Fourteen patients (67%) were male and the mean age at diagnosis 
was 65(±9) years. Mean time between CRT and response evaluation was 6.5(±3) 
weeks. Mean follow-up is 25(±19) months. Patients with a clinical complete response 
expressed a strong preference for wait-and-see policy over the resection, mostly 
because of the possibility to avoid major surgery or a permanent colostomy.  
The control group consisted of 20 patients who had a pCR after CRT and TME, of 
which 16 were male (80%). Of these patients, five had a suspected complete response at 
post-CRT imaging, but underwent surgery because in the early study period wait-and-
see policy was not always considered. The other fifteen patients were referred for 
surgery because MRI showed a suspected major residual tumour mass or thickened 
rectal wall with (partly) iso-intense signal (n=8, figure 4), residual involved nodes 
(n=2), residual spicular stranding into the mesorectal fat or to the mesorectal fascia 
(n=4) or residual activity on diffusion-weighted MRI (n=1). Mean age was 64(±10) 
years. Mean time between CRT and response evaluation was 6.2(±2.1) weeks. Mean 
follow-up is 35(±23) months. Baseline (and treatment) characteristics for patients who 
followed the wait-and-see policy and the pCR control group are shown in table 2 and 3, 
respectively.  
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Figure 4. A tumour before chemoradiation (left image, *). After CRT the tumour has been replaced 
with a residual wall thickening. Because of this fibrotic mass, this was not considered an unequivocal 
complete response. Histology showed a pathologic complete response. 
 
Patient Age Gender cT 
stage 
cN 
stage 
Distance from 
ARJ (cm) 
Adjuvant 
chemotherapy 
FU 
(months) 
Planned surgical 
procedure* 
1 70 Male 3 1 0 Yes 67 APR 
2 62 Male 3 2 0 Yes 60 APR 
3 67 Female 4 1 0 Yes 54 APR 
4 75 Male 2 1 0 Yes 48 APR 
5 51 Male 3 2 1 Yes 39 APR 
6 52 Male 3 2 0 Yes 33 APR 
7 65 Male 3 2 5 Yes 33 LAR 
8 49 Female 2 2 3 Incomplete 23 LAR 
9 64 Male 3 0 5,5 Yes 22 LAR 
10 62 Female 3 2 6 Yes 19 LAR 
11 78 Female 3 0 8 No 15 LAR 
12 58 Female 4 1 0 Yes 13 APR 
13 65 Male 3 2 6,5 Yes 13 LAR 
14 70 Male 3 2 10 Yes 13 LAR 
15 56 Male 3 1 3,5 Yes 12 LAR 
16 61 Male 2 0 3 No 12 LAR 
17 60 Male 1 2 4 Yes 12 LAR 
18 69 Male 3 0 1,5 Yes 12 APR 
19 77 Female 2 0 0 No 10 APR 
20 79 Female 3 0 0 No 7 APR 
21 65 Male 2 1 3 Yes 5 LAR 
Table 2. Characteristics of patients following wait-and-see policy. *Planned surgical procedure is the 
surgical intervention which would have been performed (based on the post-chemoradiation images) when 
patients would not have followed wait-and-see policy. ARJ= anorectal junction; FU= follow-up time; APR= 
abdominoperineal resection; LAR= low anterior resection.  
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Short-term and functional outcome 
 Ten of 21 patients (48%) initially had distally located tumours which would have 
required an abdominoperineal resection with a permanent colostomy. In these ten 
patients this procedure could be avoided with the wait-and-see policy. One patient 
following wait-and-see policy developed a severe stenosing inflammation in the 
sigmoid colon after 14 months of follow-up, necessitating an anterior sigmoid resection 
above the former tumour location in the rectum. This inflammatory stenosis was 
possibly related to the chemoradiation. The operation was complicated by an 
anastomotic leakage that eventually healed, and temporary faecal incontinence after 
ileostomy closure.  
Nine patients from the pCR control group required a definitive and 11 a temporary 
colostomy. In 10/20 patients (50%) no complications occurred after surgery. In 7 cases 
(35%) major complications occurred, such as anastomotic leakage, intra-abdominal 
abscess or respiratory failure. In 3 patients (15%) minor complications occurred, such as 
urinary retention or wound infection. Data on short-term outcome are shown in table 3.  
 
 
Figure 5. Bowel function based on several items from the MSKCC bowel function questionnaire 
and the Wexner incontinence score for patients with a clinical complete response following wait-
and-see policy and patients with a pathologic complete response after total mesorectal excision.  
* indicates that the difference was statistically significant.  
 
The MSKCC bowel function score showed a clear difference between patients from 
the pCR control and the wait-and-see group (figure 5). Bowel function from operated 
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patients was significantly more influenced by food intake (p=0.043), they used pads 
(p=0.045) and colonic irrigation (p=0.001) more frequently, had less control over flatus 
(p=0.036) and reported more change in their bowel habits compared to the situation 
prior to diagnosis than patients undergoing wait-and-see policy (p=0.014). 
Furthermore, patients with a wait-and-see policy had a lower mean Wexner 
incontinence score of 0.8 vs. 3.5 (p=0.182) and a lower mean defecation frequency of 
1.8/day vs. 2.8/day (p=0.323) compared to patients from the pCR control group.  
Long-term outcome 
 Of the 21 patients following wait-and-see policy one developed a small endoluminal 
local recurrence without nodal recurrence after 22 months of follow-up (figure 6). 
Endorectal ultrasound showed a T1 tumour. He was primarily offered a low anterior 
resection, but eventually preferred transanal endoscopic microsurgery, which resulted 
in a complete resection of the recurrence. The other 20 patients are alive and disease-
free. The cumulative probability of 2-year disease-free survival (DFS) and 2-year 
overall survival (OS) are 89% (95% confidence interval (CI) 43-98%) and 100%, 
respectively. 
 
 
Figure 6. Patient who developed a local recurrence after 22 months of follow-up. Before 
chemoradiation (A, B) a midrectal T3 tumour (*) is visible. After chemoradiation at MRI (C) a small hypo-
intense area is visible (white arrows) and at endoscopy a small ulcer with yellow covering is visualised 
(arrow, D). After 22 months of follow-up at T2-weighted MRI (E, F) no change is visualised (black 
arrows), while at endoscopy (G) and diffusion-weighted imaging (H) there is a suspected recurrence 
(arrow).  
 
Two of the patients from the pCR control group died. One patient died of 
complications associated with colostomy closure surgery one year after TME. The 
other patient died after 5 years of follow-up of metastatic disease, diagnosed after 3 
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years of follow-up. None of the operated patients had a local recurrence. Cumulative 
probability of 2-year DFS is 93% (95% CI 59-99%) and for 2-year OS the cumulative 
probability is 91% (95% CI 59-99%).  
Cumulative probabilities for DFS and OS were not significantly different between 
the wait-and-see and operated patients (p=0.770 and p=0.228 for DFS and OS, 
respectively). Kaplan Meier curves are shown in figure 7. 
 
 
 
Figure 7. Disease-free (A) and overall survival (B) for patients with a clinical complete response 
following wait-and-see policy and patients with a pathologic complete response after total 
mesorectal excision (pCR). 
Discussion 
 A wait-and-see policy for complete responders after CRT for rectal cancer based on 
strict selection and follow-up with endoscopy and up-to-date imaging is feasible and 
appears safe. In this small series, only one small local recurrence was found that could 
be easily salvaged. No distant metastases were found. The oncological outcome after 
wait-and-see policy was comparable to that of patients with a pCR after surgery, while 
functional outcome was significantly better.  
To the best of our knowledge this is the second study reporting on a wait-and-see 
policy after a clinical complete response, and it confirms the good results of Habr-Gama 
et al. In their first publication they report a local recurrence rate of 19% in the first 
year2, while we encountered one local recurrence after 22 months of follow-up and none 
in the first year of follow-up. Although this observation could be caused by chance, it 
could also result from the restrictive selection. Any sign of residual mass on MRI was 
considered as possible residual tumour. On the other hand, this restrictive selection led 
to missing a complete response with MRI in 15 of 20 patients with a pCR after surgery. 
However, the strict selection criteria may have led to a higher chance of selecting true 
complete responders.  
The one patient with a local recurrence had a very small endoluminal recurrence 
(figure 7). Initially, after CRT he had a very small shallow depression with a yellow 
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covering, thought to be a healing complete response. After 7 months the rectal wall 
normalised. In retrospect this slow-healing ulcer might have been an indication that the 
tumour had not disappeared completely. A small number of local recurrences will be 
inherent to a wait-and-see approach, but a good follow-up enables early detection and 
treatment with a complete resection. Our follow-up schedule was less intensive than in 
the Brazilian study. While the follow-up schedule of Habr-Gama et al. mainly focussed 
on frequent endoscopies with biopsies combined with 6-monthly abdominal CT during 
the 1st year2, the schedule of the present study consisted mainly of MRI and endoscopy 
at a lower frequency, which resulted in an excellent patient compliance.  
Lymph node assessment with MRI played an important role in the selection and 
follow-up. A recent pooled analysis showed that in ypT0 patients, there is still a 5% 
incidence of positive lymph nodes.1 Therefore, accurate lymph node imaging in both 
the selection and follow-up is important for prevention and early identification of nodal 
recurrences. The use of contrast-enhanced MRI has helped in predicting nodal 
involvement.  
Many clinicians argue that a local excision of the residual scar after CRT is a much 
safer approach than a wait-and-see policy, because it provides reassurance about the 
presence or absence of residual tumour. While it is undoubtedly true that it provides a 
more accurate assessment of the tumour remnant, there are some downsides to a local 
excision. First, there is a small chance of a false pCR finding through a sampling error. 
Second, there is the reverse problem of the unknown clinical significance of a very 
small number of tumour cells in the fibrosis. It has been shown that the longer the 
interval after CRT, the higher the response rate is.13-1517-19 It is therefore likely that 
not all patients who have a very limited amount of residual tumour cells after local 
excision will suffer from a recurrence when treated non-operatively. Another downside 
of local excision after CRT is that it has a higher complication rate than a primary local 
excision, with more wound dehiscences, readmissions, bleeding and pain.16-1814-16 It 
may therefore be a better approach not to do a routine local excision in all complete 
responders but to reserve this procedure for the patients in whom it remains unclear 
whether or not the response is complete.  
As expected, patients who did not undergo surgery had better functional outcome 
than operated patients. This difference was largest for control over flatus and for the 
change in bowel habits compared to the situation prior to diagnosis. All the patients 
with a pCR after surgery had changed bowel habits compared to prior to diagnosis and 
up to 65% of patients still had bowel dysfunction at the time of the questionnaire. 
These results are comparable to results from a recent publication by Pucciarelli et al., 
who reported that up to 78% of patients still have problems with bowel function one 
year after CRT and surgery.19  
Although in our population no patients died from the primary rectal resection, one 
patient died of an anastomotic leakage after colostomy closure. Reported mortality after 
TME is about 4% for all patients, but with increasing age the postoperative mortality 
rapidly increases up to 11.8% for patients >85 years. Furthermore, a recent report 
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showed that for the elderly the risk of death within 6 months after surgery is even 2-3 
times higher than the traditional 1 month mortality.20 When evaluating the different 
treatment options for a given patient, both the oncological outcome and the treatment-
related morbidity and mortality should be considered. In this regard, wait-and-see 
policy could be of specific value for the elderly and for patients with comorbidity. In our 
experience, however, also younger patients have an interest in a wait-and-see approach.  
Limitations 
 There are some limitations to this study. First, the sample size is small. This is, 
however, the first study to reproduce results for a wait-and-see policy since the report 
from Habr-Gama et al. Second, the follow-up is short and late recurrences can occur.3 
With a mean follow-up over 2 years and 18/21 patients having at least one year of 
follow-up it can be concluded that the selection procedure and follow-up schedule are 
feasible and that the preliminary outcome is as good as in the landmark paper.2 Last, 
the evaluation of functional outcome included only a small part of the patients who 
underwent surgery, because of the presence of a colostomy in the other patients. It is 
nevertheless clear that the functional results after a wait-and-see policy are better than 
after standard rectal surgery.  
Future perspectives 
 Ideally, wait-and-see policy for a clinical complete response should be compared to 
standard TME through a randomised controlled trial (RCT), evaluating both 
oncological and functional results. However, some issues might complicate the 
execution of an RCT. First, a non-inferiority design will have to be used, addressing 
the primary concern that survival will not be compromised. This requires a very large 
sample size that will be difficult to achieve. Second, we observed that many patients 
who have a clinical complete response, even when explicitly informed about the 
experimental nature of the wait-and-see approach, express a strong preference not to 
undergo TME. Apparently, patients and doctors have different perceptions of the 
balance between oncological risk and gain in quality of life. For optimal shared 
decision-making doctors would like to have more objective high quality evidence, while 
many patients do not like the loss of control in an RCT over such an important 
decision. Patient refusal of participation in a RCT might jeopardize its feasibility. 
‘Second best’ evidence can be provided by well documented prospective large cohort 
studies.  
Given the good results of wait-and-see policy in selected patients, it is logical to 
study how to increase the probability for a clinical complete response after CRT, e.g. by 
increasing the biological radiation dose to the tumour with an simultaneous integrated 
boost21, or by the use during and after CRT of biological modifiers that sensitize the 
more radioresistant tumours.22,23 However, these intensified approaches should be 
incorporated into individualized strategies, in which only the predicted non-responding 
tumours are included in order to avoid overtreatment in those patients with a high 
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likelihood for a clinical complete response. Furthermore, a broader inclusion of patients 
for neoadjuvant CRT – e.g. inclusion of smaller tumours – would probably increase the 
number of clinical complete responses, since smaller tumour size is an important 
predictive factor of response.24 However, this can also lead to overtreatment with an 
increased risk of treatment-related morbidity.  
Conclusion 
 Wait-and-see policy for clinical complete responders after CRT for rectal cancer, 
with strict selection criteria and follow-up with up-to-date imaging is feasible and safe. 
Outcome is at least comparable to that of patients with a pCR after surgery. The 
proposed selection criteria and follow-up can be used in future trials aimed at providing 
more evidence on wait-and-see policy. 
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Abstract 
Background. A wait-and-see policy instead of standard surgery for rectal cancer 
patients who achieve a complete tumour response after chemoradiation treatment is 
highly controversial. It is not clear yet how patients should be monitored once they are 
managed non-operatively and whether follow-up by MR imaging has any potential 
role. The aim was to describe the rectal wall MRI morphology during short-term and 
long-term follow-up in patients with a clinical complete tumour response undergoing a 
wait-and-see policy without surgical treatment. 
 
Methods. As part of an observational study in our center, a cohort of 19 carefully 
selected patients with a clinical complete response after chemoradiation was managed 
with a wait-and-see policy and followed regularly (3-6 monthly) by clinical 
examination, endoscopy + biopsies and a rectal MRI. The MR morphology of the 
tumour bed was studied on the consecutive MR examinations. The main outcome 
measure was the morphology of the tumour bed on the consecutive MRI examinations 
performed during short-term (≤ 6 months) and long-term (> 6 months) follow-up.  
 
Findings. Patients with a complete tumour response after chemoradiation presented 
with either a normalised rectal wall (26%) or fibrosis (74%). In the latter group, three 
patterns of fibrosis were observed (full thickness, minimal or spicular fibrosis). The 
morphology patterns of a normalised rectal wall or fibrosis remained consistent during 
long-term follow-up in 18/19 patients. One patient developed a small, endoluminal 
recurrence, which was salvaged with transanal endoscopic microsurgery. In 26% of 
patients an edematous wall thickening was observed in the first months after 
chemoradiation, which gradually decreased during long-term follow-up. Median 
follow-up was 22 months (range 12-60). 
 
Conclusions. Four MR patterns of a persistent complete response of rectal cancer after 
chemoradiation were identified. These MR features can serve as a reference for the 
follow-up in a wait-and-see policy. 
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Introduction  
 The standard treatment for patients with locally advanced rectal cancer consists of 
a long course of neoadjuvant chemoradiation (CRT) followed by surgical resection.1 In 
recent years there is a highly controversial trend to opt for more conservative, organ-
saving treatments in patients who show a very good response to neoadjuvant 
treatment.2-4 Observational cohort studies have shown that a wait-and-see policy can be 
a good alternative to surgery without compromising the outcome in carefully selected 
patients with clinical evidence of a complete response of both the tumour and lymph 
nodes.2,5,6 There are, however, several issues that need to be addressed in this clinical 
context. First, it is yet unclear which clinical selection method is the most accurate for 
identification of clinical complete responders after CRT and whether and how imaging 
can be of additional benefit. For this purpose ongoing studies are evaluating the 
potential role of tumour markers, endoscopy +/- biopsies and morphological and 
functional imaging techniques.7-13 Second, there is no evidence yet as to how and how 
frequently patients should be monitored once they are managed non-operatively. Third, 
even if imaging proves to be beneficial for the selection and monitoring of the complete 
responders, information on morphological changes that may occur during long-term 
follow-up imaging is lacking, making it difficult to understand which of these changes 
could be indicative of tumour re-growth. 
The aim of this study was to establish (changes in) the MR morphology of the 
rectum in patients with a complete tumour response after non-operative management 
and follow-up with MRI. The study describes the evolution of tumour morphology on 
MRI during short-term (≤ 6 months) and long-term (> 6 months) follow-up in patients 
with a clinical complete response who chose a wait-and-see policy in our unit. To the 
best of our knowledge this is the first report on this subject. We aim to share the MR 
characteristics of these patients at the moment of their selection (6-8 weeks after 
completion of CRT) and at regular MRI performed during their clinical follow-up.  
Methods 
Study design 
 In our unit patients with locally advanced rectal cancer are routinely treated with a 
preoperative long course of neoadjuvant chemoradiation (50.4 Gy radiation + 2 x 825 
mg/m2/d capecitabine) when on primary staging MRI there is [1] a T3-4 tumour with 
a threatened or involved mesorectal fascia, [2] > 3 metastatic lymph nodes, and/or [3] 
tumour in the distal rectum (≤ 5 cm from the anorectal junction). Since 2004, in 
addition to standard rectal cancer surgery, an alternative wait-and-see approach has 
been offered to rectal cancer patients who show a clinical complete response (ycT0N0) 
after CRT. The response after chemoradiation was assessed with a combination of 
MRI, endorectal ultrasound, digital examination and endoscopy with biopsies. Patients 
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were identified as complete responders when there was [1] substantial tumour 
downsizing with no residual tumour or with fibrosis only on restaging MRI performed 
6-8 weeks after CRT, [2] no suspicious nodes on post-chemoradiation MRI, [3] no 
residual tumour at endoscopy with negative biopsies, and [4] no palpable tumour at 
digital rectal examination when palpable at primary presentation. The evaluation of 
response and the diagnosis of a clinically complete response was established 6-8 weeks 
after completion of chemoradiation treatment. Patients with a complete response who 
were offered a wait-and-see policy were well informed on the controversial and 
investigational nature of this non-operative approach and the associated benefits and 
risks. All but one patients who were offered the wait-and-see policy chose the wait-and-
see policy, mainly because of the opportunity to avoid major surgery and the potential 
risk of a permanent colostomy. Patients were monitored 3-monthly during the first 
year and 6-monthly during the following years with clinical examination, serial 
carcinoembryonic antigen (CEA) measurements, CT for evaluation of distant 
metastases and endoscopy and rectal MRI for evaluation of local recurrence.  
 
Repetition time / echo time (ms) 8456 / 130 
Number of slices 30 
Slice thickness 3 
Slice gap 2 
Flip angle (degrees) 90 
In plane resolution (mm x mm) 0.78 x 1.14 
Echotrain length 25 
Number of signal averages (NSA) 6 
Acquisition time (min) 6.03 
Table 1. ‘Standard’ rectal MRI protocol: T2W FSE in 3 planes.  
Patients were imaged at 1.5T (Intera; Philips Medical Systems, Best, The Netherlands), using a 
phased array surface coil. Patients did not receive a bowel preparation or spasmolytics. At primary 
staging, the axial images were angled perpendicular to the tumour axis as identified on the sagittal 
MRI. The coronal images were angled parallel to the tumour axis. For the follow-up MRIs, the 
imaging planes from the primary staging MRI were repeated in order to obtain identical imaging 
planes.  
 
MR imaging and image evaluation: 
 Patients underwent a standard pelvic MRI (1.5T) as routinely used for the clinical 
staging of rectal cancer patients. The protocol is described in table 1. As part of ongoing 
research, patients underwent an additional diffusion-weighted MR sequence (STIR 
fatsupression, b-values 0,500,1000 s/mm2, TR/TE 4829/70 msec, EPI factor 53, 4 
NSA, 2.50 x 3.11 x 5.00 mm acquisition voxel size, 50 slices, 10.37 minutes acquisition 
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time). For each patient, the morphology of the tumour was evaluated on the primary 
staging MRI. The aspect of the tumour bed after chemoradiation was examined on the 
first restaging MRI performed 6-8 weeks after completion of CRT and on each 
consecutive follow-up MRI (3-monthly during the first year of follow-up and 6 
monthly during the following years). All MR images were evaluated by an experienced 
pelvic MR reader, who recorded the size/volume, shape, aspect of the border and signal 
intensity of the tumour area on the T2-weighted MR images. Images were compared 
with the earlier follow-up images to establish changes over time. On high b-value 
diffusion-weighted MRI, the presence (suggestive of tumour) or absence (suggestive of 
complete response) of high signal intensity within the tumour bed was recorded (figure 
1).14,15 
 
 
Figure 1. Diffusion-weighted MR Imaging. Axial T2-weighted (a,c) and high b-value (b1000) 
diffusion-weighted (b, d) images of a patient before and after chemoradiation treatment. Before 
chemoradiation, a tumour (T) showing intermediate signal intensity is visible on T2-weighted MRI (a). 
On the corresponding diffusion image (b) the tumour can be identified as a clearly defined area of high 
signal intensity compared to the low signal intensity of the surrounding tissues. After chemoradiation, a 
normalised two-layered rectal wall (arrowheads) is visible on T2-weighted MRI (c) and no residual 
tumour can be detected. On the corresponding diffusion image (d) there is no remaining high signal 
intensity and the patient was identified as having undergone a complete response.  
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Results 
The study group 
 So far, nineteen patients have chosen the non-operative approach and are being 
followed within a defined study protocol.5 The initial tumour stage at primary 
presentation consisted of cT1-2 in five patients, cT3 in twelve patients and cT4 in two 
patients. The cN stage was N0 in five patients, N1 in four patients and N2 in ten 
patients. In thirteen patients the initial tumour was located < 5 cm from the anorectal 
junction, in five patients it was located 5-10 cm from the anorectal junction and in one 
patient > 10 cm from the anorectal junction. At the time of writing, the follow-up 
period ranged between 12 and 60 months (median follow-up 22 months) and the 
number of follow-up MR examinations ranged accordingly between 3 and 11 (table 2). 
 
 Post-CRT (6-8 weeks after completion of CRT)  
 Fibrosis No Fibrosis  
 Minimal Full thickness Irregular 
Normalised wall 
wawall wall 
TOTAL 
Small volume and/or 
polypoid tumour 
6 (32%) 0 (0%) 1 (5%) 2 (10%) 9 (43%) 
Large volume and/or 
bulky tumour 
1 (5%) 3 (16%) 3 (16%) 3 (16%) 10 (57%) 
P
re
-C
R
T
 
TOTAL 7 (37%) 3 (16%) 4 (21%) 5 (26%) 
19 
(100%) 
Table 3. Pre- and post-chemoradiation MR morphology of 19 patients with a clinical complete 
response. 
Small volume and/or polypoid tumours were defined as T1-2 or borderline T3 tumours with a 
maximum tumour length of < 5 cm. Large volume and/or bulky tumours were defined as T3 or T4 
tumours with a maximum tumour length of ≥ 5 cm.  
MRI findings at short-term (≤ 6 months) follow-up: 
 Generally, four distinct groups of MR features could be identified at short-term 
follow-up (table 3). In 14 of the 19 patients (74%), at least some area of dark signal 
intensity was shown on the first MRI performed 6-8 weeks after completion of CRT in 
the irradiated tumour bed, suggestive for fibrosis. Three patterns of fibrosis could be 
distinguished, the aspects of which depend on the initial tumour morphology at 
primary MR staging (figure 2). The fourth pattern, which was observed in 5 of the 19 
patients (26%), consisted of a completely normalised rectal wall. At endoscopy, patients 
typically showed either a normalised rectal wall or a small white area of scar tissue at 
the location of the former tumour (figure 3). 
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Figure 2. Patterns of fibrosis. Schematic view of three types of tumours (T) before treatment (a-c) and 
the corresponding patterns of fibrosis (d-f) that were frequently observed after chemoradiation treatment. 
In patients with relatively small, often polypoid tumours (a), minimal areas of residual fibrosis were 
mostly observed after CRT, which remained limited to the bowel wall (d: ‘minimal fibrosis’). In patients 
with more bulky tumours, mostly extending over 50% of the rectal circumference (b), the tumours often 
underwent massive fibrotic changes, but showed a relatively small decrease in volume (e: ‘full thickness 
fibrosis’). In patients with more irregular, spiculated tumour types (c), varying degrees of volume 
reduction were observed. The fibrotic residue remained ill-defined and spiculated, similar to the aspect of 
the primary tumour (f: ‘irregular fibrosis’).  
 
 
Figure 3. Typical white scar at endoscopy. Axial T2-weighted MR image (a) and corresponding 
endoscopic view (b) of a patient, managed with a wait-and-see policy, at 1 year after completion of 
chemoradiation treatment. On the MRI a small fibrotic rim is visible within the rectal wall (arrow). At 
the corresponding endoscopy, a typical area of white scar tissue is visualised at the location of the former 
tumour. 
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Pattern 1: ‘Minimal’ fibrosis 
 Relatively small volume and/or polypoid tumours (cT1-2 or borderline T3, tumour 
length < 5 cm) predominantly showed a marked decrease in tumour volume. On the 
restaging scan performed (6-8 weeks) after CRT these tumours typically regressed to a 
minimal area of residual fibrosis which remained restricted within the layers of the 
rectal wall, causing minimal local thickening of the rectal wall (figure 4). This type of 
‘minimal’ fibrosis was observed in 7/19 (37%) of the patients. 
 
 
Figure 4. ‘Minimal fibrosis’ during short-term and long-term follow-up. Axial T2-weighted MR 
images of a rectal cancer patient before chemoradiation treatment (a), 6-8 weeks after completion of 
chemoradiation treatment (b) and at two years follow-up (c). A small polypoid tumour is visible in the 
distal rectum before treatment (a). After chemoradiation (b) the tumour has disappeared. The rectal wall 
now shows some edematous thickening, which can be recognized as a three layered pattern, consisting of 
the inner dark layer of mucosa (black arrow), a bright layer of submucosa (*) and the outer dark layer of 
the muscular rectal wall (white arrow). There is also a small residual dark area of fibrosis (black 
arrowhead). At two years follow-up (c), the edematous thickening has disappeared and the bowel wall 
has turned normal, except for at the site of the tumour bed (black arrowhead), which remained dark, 
indicative of fibrosis.  
 
Pattern 2: ‘Full thickness fibrosis’  
 In three patients (16%) with relatively bulky tumour types (T3-4, tumour length ≥ 
5 cm), often growing over a large circumference of the rectal lumen, only little 
reduction in tumour size was observed. The shape of the irradiated tumour bed 
followed that of the initial tumour and remained relatively consistent during the 
follow-up period. The initially grey tumour on MRI became fully dark, suggestive of 
fibrotic transformation of the tumour. These cases were classified as a ‘full thickness’ 
fibrotic transformation of the primary tumour (figure 5). 
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Figure 5. ‘Full thickness fibrosis’ during short-term and long-term follow-up. Axial T2-weighted 
MR images of a rectal cancer patient before chemoradiation treatment (a), 6-8 weeks after completion of 
chemoradiation treatment (b) and at 1½ year of follow-up (c). Before treatment (a) there is a tumoural 
thickening extending over ±50% of the rectal circumference. After chemoradiation (b),only a small 
volume reduction has occurred and the shape of the wall thickening remained unchanged. However, the 
tumour has turned fully dark indicative of fibrosis (black arrowheads). At 1½ year follow-up (c) the 
fibrotic area remained unchanged and showed only a very subtle further decrease in volume. 
 
Pattern 3: ‘Irregular fibrosis’ 
 In four patients (21%) with irregularly shaped, spiculated and ill-defined tumours 
(T3-4, tumour length ≥ 5 cm), varying degrees of volume reduction were observed. In 
some of these patients there was remarkable reduction in tumour volume, whereas in 
others there was only small decrease in volume. In all four patients, however, the 
tumour bed turned dark because of fibrosis. The initial tumour shape with irregular and 
spiculated borders persisted (figure 6).  
 
 
Figure 6. ‘Irregular fibrosis’ during short-term and long-term follow-up. Axial T2-weighted MR 
images of a rectal cancer patient before chemoradiation treatment (a) 6-8 weeks after completion of 
chemoradiation treatment (b) and at 1 year of follow-up (c). Before treatment (a) there is a tumour in the 
mid-rectum with irregular borders and spiculations into the mesorectal fat. After chemoradiation (b) 
there is hardly any volume reduction but an area of hypointense signal intensity, suggestive of fibrosis 
(arrows), has replaced the initially isointense tumour area. This fibrosis follows the shape of the primary 
tumour with irregularly shaped borders and spiculations. At 1 year of follow-up (c), the shape of the 
fibrotic thickening persisted and showed only minimal shrinkage.  
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Pattern 4: Normalised rectal wall 
 In 26% of the patients the rectal wall was completely normal at MRI performed 6-8 
weeks after CRT and no residual tumour mass or fibrosis was detected (figure 1). In 
contrast to the above mentioned patterns of fibrotic changes, in which there was a clear 
correlation with the initial tumour size and features at MRI before chemoradiotherapy, 
no such correlation was found in rectal tumours which fully disappeared after CRT. 
Some of these patients initially showed relatively large, bulky tumours, while others 
showed small polypoid tumours (table 3).  
MRI findings at long-term (> 6 months) follow-up 
 Interestingly, in the 14 patients in whom a residual area of fibrosis was detected 
after CRT, the aspect of the fibrosis remained largely unaffected during long-term 
follow-up, the longest follow-up period at the time of writing being 60 months (table 
2). No changes were observed regarding the shape, delineation or hypointense signal 
intensity of the fibrotic areas during repeated follow-up MRIs and a further volume 
decrease – if any – was only very subtle. In the patients in whom the tumour vanished 
at MRI and the rectal wall normalized, this normal wall persisted on consecutive MRIs 
at longer follow-up and no long term evolution into fibrosis was observed (table 3).  
Edema 
 In the first months after completion of chemoradiation treatment, a small group 
(5/19; 26%) of the patients showed an edematous rectal wall, visible as a characteristic 
three layered pattern of dark mucosa, bright submucosa and dark muscular wall. In all 
patients the edematous thickening gradually decreased during the remaining follow-up 
period (figure 4).  
Persistent complete response versus recurrent tumour 
 One patient from the study group developed a small endoluminal recurrence after 
22 months of follow-up (table 2). Endorectal ultrasound indicated a T1 tumour and the 
patient was salvaged with transanal endoscopic microsurgery. At present, this patient 
is disease free, but only with a follow-up of 2 months after the procedure. For 
illustrative purposes, we report on two additional patients outside the study group in 
whom the tumour locally recurred after respectively 17 and 24 months of follow-up. 
These two patients were not part of the study group as they presented with 
synchronous distant (liver) metastases at their initial diagnosis. They both received a 
long-course of neoadjuvant chemoradiation after which they were curatively treated for 
their liver metastases. On the restaging MRI performed 6-8 weeks after completion of 
CRT, a dark area of fibrosis was visible in the irradiated tumour bed and no residual 
tumour could be detected. Both patients chose not to undergo TME surgery. During 
their long-term follow-up the volume of the previously fibrotic tumour bed increased 
and the signal intensity changed from black (indicating fibrosis) to grey (indicating 
tumour) on the T2-weighted MR images. In addition, areas of high signal intensity, 
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indicative of recurrent tumour, developed on the diffusion-weighted images (figure 7). 
In the patient with the small local recurrence in the wait-and-see study group, the T2-
weighted MR images did not yet reveal any significant changes in the morphology of 
the rectal wall. The diffusion-weighted MRI, however, showed a small area of high 
signal intensity, compatible with the tumour recurrence.  
 
 
Figure 7. Local tumour recurrence during follow-up. Axial MR images of a patient who was non-
operatively managed but developed a local recurrence during follow-up. The pretreatment T2-weighted 
MRI (a) shows a grey tumour in the proximal rectum. After chemoradiation, the tumour shrunk and the 
rectal wall turned fibrotic (b). After two years of follow-up, a grey mass was again visible within the 
previously fibrotic tumour bed (c), suggestive of a recurrent tumour. On the corresponding high b-value 
diffusion-weighted MR image (d), the recurrent tumour could easily be recognised as an area of 
markedly high signal intensity. The presence of recurrent adenocarcinoma was proven by tumour 
biopsy.  
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Discussion 
 In many countries, MRI is part of the standard workup for the staging of rectal 
cancer at primary diagnosis.1 In recent years patients with locally advanced rectal 
cancer who receive preoperative chemo and/or radiation therapy have shown 
phenomenal response with downstaging and downsizing of the tumour. This opens the 
debate whether a resection is still necessary in all patients. It is in this setting that a 
restaging MRI after chemoradiation could be helpful. Until now, the main aim of a 
restaging MRI has been to provide the surgeon a roadmap to determine his resection 
plane and to decide whether a less extensive resection can be performed in tumours 
that have regressed from the mesorectal fascia.16 Given the current trend towards 
minimally invasive treatments for the good responders after CRT, a more precise 
imaging assessment of response is mandatory in order to improve the selection of these 
patients and the response monitoring at follow-up. Although selection of patients is 
generally based on clinical examination and endoscopy with biopsy, imaging could help 
in increasing the confidence for appropriate selection of the right patients. In our 
hospital the imaging method used for restaging is MRI. In addition to a restaging MRI 
shortly after CRT, the study protocol of a wait-and-see approach for a clinical complete 
tumour response with frequent follow-up5 allowed us to also monitor the evolution of 
MR features during long-term follow-up. We believe that all multidisciplinary team 
members, including colorectal surgeons, need to understand the MR images and 
patterns of response. 
This study aimed at describing and illustrating the evolution of the tumour bed on 
consecutive MRIs in a selected group of rectal cancer patients with a clinical complete 
tumour response after chemoradiation who were managed with a wait-and-see policy. 
The MRI of the rectum in these patients at the moment of their selection (6-8 weeks 
after completion of CRT) and the period thereafter showed interesting evolution 
patterns. The MR morphology of the complete tumour responders 6-8 weeks after 
CRT was typically that of either a dark fibrotic wall thickening or, in a smaller number 
of patients, a normalised rectal wall. Given the difficulties of MRI in the interpretation 
of fibrosis, the feature of a normalised wall on post-CRT MR images will likely be the 
criterion with the highest positive predictive value for identifying a complete response 
by imaging. In our study, there was no clear correlation between the initial tumour 
morphology before treatment and the chance of a completely normalised rectal wall 
after CRT. It may be that in some tumours the biological tumour profile rather than 
the morphological characteristics determines the way the tumour will react to 
chemoradiation. In contrast, the morphological pattern of the fibrotic areas did follow 
that of the primary tumour before onset of treatment. These patterns could be 
categorized as ‘full thickness’, ‘minimal’ or ‘irregular’ fibrosis and remained consistent 
over the years. When the tumour has completely disappeared and the wall returned 
normal after post-CRT MRI, this normal wall persisted over the years. When during 
the first months after CRT the wall showed an edematous thickening, this edema 
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gradually disappeared during longer follow-up. All together, if the morphology 
(normalised wall or fibrosis) as identified on the first restaging MRI remained 
consistent during long-term follow-up, this could be considered a sign of a persistent 
complete response. Although our study was not designed to systematically compare 
patients with a complete response to patients with recurrent tumour, we did find that in 
patients with recurrent disease, areas of intermediate signal intensity began to develop 
within the fibrotic scar bed on the T2-weighted images. This is in concordance with 
previous reports that showed that the development of areas of intermediate signal 
intensity during follow-up was predictive for the presence of a local tumour 
recurrence.17,18 The small recurrence in the wait-and-see patient was noted on diffusion-
weighted MRI as a newly developed area of high signal intensity, while the T2-
weighted images did not yet reveal any significant changes in morphology. It has 
previously been suggested that diffusion-weighted MRI may be superior to 
conventional MRI in the detection of (small) malignant tumours, particularly within 
areas of post-radiation fibrosis.14,15,19 Diffusion-weighted MRI could thus be a valuable 
adjunct to standard imaging in the detection of recurrent tumour during the non-
operative follow-up of rectal cancer patients, although the true value of DWI in this 
particular clinical setting will need to be addressed by further studies. 
There are some limitations to our study design. First, a ‘definite’ histological 
diagnosis of a complete response could not be obtained since none of the patients 
underwent surgical resection. In the clinical setting of a wait-and-see approach, the 
usual gold standard of histology is inherently not available, and an extensive clinical 
follow-up as applied in our study may serve as a surrogate reference standard. Ideally 
the follow-up period should have been at least 2 years for all patients, given the fact 
that the majority of tumour recurrences are known to likely occur within the first two 
years after treatment.20 Our results should therefore be considered preliminary and 
larger patient groups with longer follow-up are required in order to draw more definite 
conclusions. Second, the aim of our study was to study the evolution of the MR 
morphology of patients with a known complete response and not to study the potential 
of MRI in the initial identification and selection of complete responders, which has 
already been the subject of previous studies, including a study from our center.14,15  
Conclusion 
four MR patterns of a persistent complete response of rectal cancer after 
chemoradiation are identified. These MR features can serve as a reference for the 
follow-up of patients treated with a wait-and-see policy. 
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Abstract 
Background. The purpose of this multicenter cohort study was to evaluate whether 
tailor-made treatment of primary rectal cancer based on MRI can reduce the number of 
incomplete resections and local recurrences and improve recurrence-free and overall 
survival.  
 
Methods. From February 2003 until January 2008 296 patients were enrolled. All 
underwent preoperative MRI using a lymph node specific contrast agent to predict 
CRM, T- and N-stage. Based on expert reading of the MRI, patients were stratified in 
different risk groups for local recurrence: (a) low risk (CRM >2mm and N0 status), (b) 
intermediate risk and (c) high risk (close/involved CRM, N2 status or distal tumours). 
Mainly based on this MRI risk assessment patients were treated with (a) surgery only 
(TME or local excision), (b) preoperative 5x5 Gy + TME, and (c) a long course of 
chemoradiation therapy followed by surgery after a 6-8 week interval. The number of 
complete resections (CRM >1 mm) was determined by histopathological evaluation of 
the resection specimen. 
 
Findings. Overall 228 patients underwent treatment with curative intent: 49 with 
surgery only, 86 with 5x5 Gy and surgery and 93 with chemoradiation and surgery. 
The number of complete resections was 218 (95.6%). At a median follow-up of 41 
months the 3- year local recurrence rate, disease-free survival rate and overall survival 
rate is 2.2%, 80% and 84.5% respectively.  
 
Conclusions. With a differentiated multimodality treatment based on dedicated 
preoperative MR imaging, local recurrence is no longer the main problem in rectal 
cancer treatment. The new challenges are early diagnosis and treatment, reducing 
morbidity of treatment and preferably prevention of metastatic disease. 
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Introduction 
In the past decades studies have shown that the risk for recurrence after resection 
of rectal cancer is substantially reduced with the surgical technique of the Total 
Mesorectal Excision (TME). In this technique, popularized by Heald, the tumour is 
removed as a complete package including the surrounding mesorectal fat and lymph 
nodes.1 Additionally, neoadjuvant (chemo)radiation has improved local control and, in 
some studies, survival2-5. Intensifying treatment of rectal cancer however is at the 
expense of treatment-induced morbidity and even mortality. Therefore, 
individualization of treatment taking into account characteristics such as age, co-
morbidity, stage and location of the tumour might provide an optimal balance between 
minimizing treatment related morbidity and best oncological outcome. Until now, 
there is however no definite evidence that the outcome is better than applying a single 
standard treatment for all patients. Subgroup analyses within the large randomized 
trials can provide clues as to what factors can be used to guide treatment decisions for 
individual patients. In most of the trials patients with stage I disease (T1-2N0) have a 
negligible risk for local recurrence, and therefore do not need preoperative irradiation6. 
On the other hand, in patients with a combination of unfavorable characteristics like a 
tumour extending into the mesorectal fascia, positive lymph nodes and a very distal 
location, a short course of preoperative radiation and immediate surgery does not 
provide enough protection against local recurrence, and a long course of preoperative 
chemoradiation is required2, 3, 6. 
Reliable preoperative imaging is essential for a differentiated treatment according 
to risk factors for local recurrence. Although endorectal ultrasound is good in assessing 
the extent of the primary tumour in small lesions7, MRI has repeatedly shown to 
provide the best information on the relation of the tumour to the mesorectal fascia8-12. 
Assessing nodal involvement however has been suboptimal, and until now all three 
imaging modalities (EUS, CT and MRI) lack sufficient accuracy for clinical decision-
making13. MRI studies with lymph node-specific contrast agents have shown promising 
results for prediction of nodal involvement14, 15. This would enable MRI to assess the 
two most important risk factors for local recurrence: relation of the tumour to the 
mesorectal fascia and nodal stage. 
The primary aim of our prospective cohort study was to assess the outcome as 
defined by the number of complete resections of a differentiated treatment protocol for 
rectal cancer, based on MRI. The secondary aim was the assessment of long-term 
outcome as defined by three-year local recurrence, disease-free and overall survival, 
compared to the data of the Dutch TME trial.  
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Methods 
Patients 
Between February 2003 and January 2008 a prospective multicentre cohort study 
was performed in patients with primary rectal cancer in whom a differentiated 
treatment protocol was primarily based on MRI. In February 2003 the study started as 
a single centre pilot study at Maastricht University Medical Centre, and was continued 
as a multicentre study from December 2005 onwards (n=117). Three regional hospitals 
joined the study: Laurentius Hospital Roermond (start of inclusion: 12-2005, n=38), St. 
Jans Hospital Weert (start of inclusion: 12-2005, n=17) and VieCuri Medical Center 
Venlo (start of inclusion: 02-2006, n =58). Institutional review board approval was 
obtained for all hospitals. All patients gave a written informed consent. 
Inclusion criteria: Histologically proven adenocarcinoma of the rectum. 
Exclusion criteria: Patients were excluded from the study if they had locally 
recurrent rectal cancer, were pregnant, were younger than 18 years, had a contra-
indication for MR imaging (pacemaker, neurostimulator, insulin pump, certain vascular 
clips (e.g. used in brain surgery), cochlear implants, metal fragments in the eye or any 
other metal implant not securely fixed or electronic device), or did not give informed 
consent for participation. For the present analyses that include long-term outcome, 
patients who received palliative treatment or who had a previous or coexisting 
malignancy were excluded. 
MR imaging  
All patients underwent a pelvic MRI with standard T2W TSE sequences in 3 
orthogonal directions (sagittal, axial and coronal) and an axial 3D T1W gradient echo 
(GRE) sequence. For nodal staging an axial T2*W GRE was performed with 
Ultrasmall Super Paramagnetic Iron Oxide (USPIO), a lymph node specific contrast 
agent). The USPIO MR contrast agent (Sinerem, Guerbet Laboratories, Roissy, 
France) consists of low molecular weight iron oxide coated with dextran. Sinerem was 
administered at a dose of 2.6 mg Fe/kg by slow intravenous infusion during a period of 
45 minutes, 24-36 hours before the MRI scan. No side-effects were recorded during or 
after infusion. Imaging was performed on a 1.0/1.5T MR scanner. Patients did not 
receive bowel or other preparation. Total scan time was approximately 40 minutes.  
Image evaluation 
All MRI scans were read by both a local radiologist and an expert reader, and 
evaluated for T-stage, N-stage, involvement of the mesorectal fascia and height of the 
tumour. USPIO images were read for the prediction of nodal status by predefined 
criteria based on contrast uptake, size and shape.16, 17  
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Treatment stratification and strategy 
In a multidisciplinary meeting the treatment plan for each individual patient was 
determined based on the clinical information, MR imaging of local disease and imaging 
for distant disease. Patients with widespread metastatic disease and/or a very poor 
general condition that precluded major surgery were considered for palliative 
treatment only, and are excluded from the present analysis. For the other patients the 
tumour was classified on the basis of the MR images patients as ‘low’, ‘intermediate’, 
and ‘high’ risk for local recurrence. Low risk was defined as T1-2N0 or T3N0 with a 
wide CRM (> 2 mm) when localized in the proximal rectum. The definition of a wide 
CRM was chosen on the basis of the widely recognized 1 mm at histology with an 
additional 1 mm safety margin to compensate for small MR measurement errors. High 
risk was defined as tumours with circumferential resection margin < 2mm, distal 
tumours (i.e. < 5 cm from the anal verge) or N2 status. All other tumours were 
considered as intermediate risk (figure 1). Generally, low risk tumours were treated 
with surgery only, intermediate risk tumours were treated with 5x5 Gy preoperative 
radiotherapy followed by surgery within one week after the last radiation fraction, and 
high risk tumours were treated with a long course of chemoradiation (CRT) and 
surgery after a 6-8 week interval.  
 
 
Figure 1. MRI based treatment stratification. CRM=circumferential resection margin. 
 
This CRT consisted of radiation in 28 fractions of 1.8 Gy, on weekdays combined 
with oral capecitabine (825 mg/m2, twice a day for seven days a week), or capecitabine 
with oxaliplatin (oxaliplatin 130 mg/m2 on day one) in patients with synchronous 
distant metastases. Patients underwent surgery 6-8 weeks after the last fraction of 
radiation therapy. One to two weeks before surgery patients underwent a new pelvic 
MRI, to evaluate local status as a roadmap for surgery.  
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Surgery consisted of a low anterior resection or abdominoperineal resection 
according to the TME-principle as described by Heald18. All surgeons were trained in 
high quality TME surgery as a result of the widespread implementation of TME after 
the results of the Dutch TME trial in The Netherlands. In selected cases of early 
tumours a local excision (snare polypectomy or transanal endoscopic microsurgery) 
was performed. For locally advanced tumours, the extent of the resection was based on 
the MR images. For large tumours the TME sometimes had to be extended beyond the 
mesorectal fascia, with an en-bloc resection of surrounding organs when required. 
Adjuvant chemotherapy was generally considered for all locally advanced tumours 
treated with chemoradiation and for tumours with involved nodes at histology. 
Chemotherapy consisted of 6 courses of oral capecitabine (1000 mg/m2 twice daily 
during 2 weeks) with intravenous oxaliplatin 130 mg/m2 at day 1, or capecitabine 
(1000 mg/m2) as monotherapy. 
Histological evaluation 
The resection specimen was evaluated in a standardized way, as described by 
Quirke19. A complete resection (R0) was defined as a circumferential resection margin 
of ≥ 1 mm. For the patients who underwent local excision, a complete resection of the 
tumour at histology as well as a confirmed N0 status at follow-up MRI was considered 
a complete resection. 
Follow-up 
Follow-up after treatment for rectal cancer followed the national guidelines: 
clinical examination every 6 months for the first three years, and yearly until five years 
of follow-up, CEA measurements every 3 months for the first three years, and every 6 
months until five years of follow-up, and liver ultrasonography or CT-scan twice yearly 
in the first year and yearly thereafter until five years of follow-up. For those patients 
who underwent a local excision, follow-up MRI was performed at least after six months 
and one year, in addition to endoscopic follow-up. Local recurrence, distant recurrence, 
death or event-free interval from the day of surgery were collected for all patients. 
Comparison with Dutch TME trial 
Three-year survival data and the number of complete resections were compared to 
the individual data of the Dutch TME trial that were provided by the Dutch TME trial 
group. This was considered as the best available comparison as it is a large prospective 
database in the setting of a randomized controlled trial and reflects the outcome of 
patients with rectal cancer before the widespread use of MRI. The setting for the 
Dutch TME trial was comparable to the set-up of the current cohort study and the 
inclusion and exclusion criteria are very similar. Patients who were in a palliative 
setting were excluded from the Dutch TME trial. A difference in selection criteria 
between both studies is that the present study includes all comers, including the very 
early tumours and the very locally advanced tumours, whereas the Dutch TME trial 
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did not include these two groups. The main difference between the two studies was that 
local staging with MRI was not mandatory in the Dutch TME trial, and was 
performed only in a minority of patients.6 Because of the small but real difference in 
patient population the outcome results were compared without formal statistical 
comparison.  
Statistical analysis 
Baseline characteristics were prospectively collected. Postoperative course and 
complications were scored using the Dindo classification20. For the estimation of long 
term outcome Kaplan Meier survival functions were used. Local control was defined as 
the absence of pelvic recurrence; distant-metastasis free survival as the absence of 
distant metastasis outside the pelvis; disease-free survival as the absence of a local and 
distant recurrence and death from cancer-related cause; and overall survival survival as 
the absence of death from any cause. The chi-square test was used for comparison of 
proportions. All statistical analyses were performed using Statistical Package for the 
Social Sciences (SPSS) (version 16.0; SPSS, Chicago, Ill.) and STATA 11.0. 
Results 
Overall 296 patients were included. Of these patients, 13 were not evaluable 
because of MRI-related problems (artifacts, refusal) (n=5) and refusal of treatment 
(n=8). Of the remaining 283 patients 5 had a previous malignancy, one had a coexisting 
malignancy, and 47 were not treated with a curative intent because of widespread 
unresectable metastatic disease (n=46) and because of very poor general condition 
(n=1).  
Therefore, 230 patients could be included for this study. Sixteen of these patients 
presented with synchronous metastatic disease that was considered potentially curable. 
For these patients the three-year survival estimates are reported separately. Of the 230 
included patients 134 (58%) were male. Mean age (±SD) was 67 (±10.6) years.  
In 31 patients the actual treatment differed from the MRI based proposal. This was 
most often due to advanced age or poor condition of the patient, illustrated by 20 
patients with a locally advanced tumour on MRI who were treated with 5x5 Gy (n=18) 
or surgery only (n=2). In 7 patients surgery without radiotherapy was chosen whereas 
MRI advised short course radiotherapy and 4 patients received a short course of 
radiotherapy whereas MRI advised surgery only. Figure 2 shows the stratification of 
the actual received treatment.  
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Surgery and perioperative period 
Twenty-one patients underwent a local excision, 134 a low anterior resection (11 of 
which with an extended TME), 71 an abdominoperineal resection (25 ‘extended’), 1 
patient a total pelvic exenteration, 1 patients a posterior pelvic exenteration and 2 
patients an other resection. Furthermore, two patients had a clinical complete response 
to chemoradiation, confirmed by repeated biopsies and imaging. These patients 
preferred not to undergo surgery and are currently in a follow-up protocol. They were 
not included in the analysis for complete resections but were included in the analysis of 
long-term outcome.  
All local excisions (n=21) were performed during a short hospital stay of 2-3 days 
(TEM) or in the outpatient clinic (snare polypectomy) and were uncomplicated. For the 
other patients (n= 207), median hospital stay was 11 days (range: 4-199). There were 
123 patients having one or more post-operative complications. The severity of the 
complications is graded using the Dindo-classification21 in table 1.  
As shown in table 1, ten patients died postoperatively during their initial hospital 
stay (Dindo grade V), six of whom within 30 days. The postoperative mortality of all 
patients (including local excision) is 4.3% with a 30-day mortality of 2.6%. In 4 patients 
death was directly related to surgical complications, the other 6 patients died of (often 
multiple) systemic postoperative complications (e.g. myocardial infarction).  
 
 
 
Figure 2. Flowchart of inclusion of patients. TEM=transanal endoscopic microsurgery; TME=total 
mesorectal excision; Gy=Gray; CRT=chemoradiation. 
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 N
No complications 105/228 
Grade I 40/228 
Grade II 22/228 
Grade III A 9/228 
Grade III B 37/228 
Grade IV A 2/228 
Grade IV B 3/228 
Grade V 10/228 
Table 1. Surgical complications according to Dindo et al. Grade 1: any deviation from normal 
postoperative course that does not require treatment other than antiemetics/ analgetics etc; grade 
2: complications requiring pharmacological treatment, e.g. urinary tract infection; grade 3: 
complications requiring surgical/endoscopic/radiological intervention, (a) without general 
anesthesia or (b) with general anesthesia; grade 4: Life threatening complications requiring ICU 
admission, (a) with single organ dysfunction or (b) with multiorgan dysfunction; grade 5: 
complications leading to death of the patient. 
Histological examination  
The number of complete resections and the distribution in the different stages at 
histopathological examination after surgery are shown in table 2. The number of 
complete resections of 95.6% is much higher than the 84.1 in the Dutch TME trial 
(unpublished data). The number of complete resections did not differ significantly 
between the treatment groups in the present trial (p=0.201). An involved margin after 
surgery was seen in 4.4% of patients (n=10), and was due to (a combination of) 1) 
failure in surgical technique: tumour perforation during surgery (n=5) or incomplete 
removal of the entire mesorectum, and/or 2) surgical planning (n=8): insufficient 
attention to MR images after chemoradiation by the surgeon, showing a margin that 
was still at risk. In none of these patients the cause of the incomplete resection could be 
traced to an underestimation of the circumferential resection margin on MRI as 
described by the radiologist. The incomplete resections are summarized in table 3. 
Adjuvant chemotherapy 
Adjuvant chemotherapy was administered to all patients who had primary 
synchronous metastasis (7%,16/230). In the other patients who were treated with 
curative intent adjuvant chemotherapy was administered in 19% of patients treated 
with surgery only, in 20% of patients treated with 5x5 Gy and surgery and in 60% of 
the patients treated with chemoradiation and surgery.  
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 N R0 (%) 0 I II III IV 
Local excision/TME 49/49 (100) 0 34 6 9 0 
5x5 Gy + TME 82/86 (95.3) 0 29 28 23 6 
CRT + surgery1,2 87/93 (93.5) 14 22 23 24 10 
Total 218/228 (95.6) 14 85 57 56 16 
Table 2. Number of complete resections and distribution of AJCC Stage at histology. 
1 AJCC Stage for these patients is stage after neoadjuvant therapy, ypTNM. 
2 2/95 patients of the CRT + surgery refused surgery after CRT and were therefore left out of the 
  analysis of complete resections. 
Follow-up 
The median follow-up was 41 (0-83) months. The three-year local recurrence rate 
was 2.2% (95% C.I.; 0.8-5.7%) for all patients (figure 3), as compared to 6.2% (95% C.I. 
5.1-7.6%) from the individual data of the Dutch TME trial. The seven patients who 
developed a local recurrence are summarized in table 4. None of the local recurrences 
occurred in the group of patients with an incomplete resection.  
Three-year distant-metastasis-free survival, disease-free survival and overall 
survival were 85.5% (95% C.I.; 80-90%), 80.2% (74-85%) and 84.5% (79-89%), 
respectively (see figure 3). Three-year survival estimates for the primary metastasized 
patients that were treated with curative intent were 16% (3-40%), 13% (2-35%) and 
44% (20-66%), respectively.  
The Dutch TME trial shows a three-year distant-metastasis-free, disease-free, and 
overall survival of 79.1% (95% C.I.; 77-81%), 76.8% (75-79%) and 81% (79-83%) 
respectively. Given the fact that in the Dutch TME trial locally very advanced tumours 
were excluded whereas they were included in the present study, there is a suggestion 
that the overall results have improved with the current MRI based strategy.  
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Figure 3. Kaplan Meier survival functions for the three treatment groups.  
Discussion 
This study shows that tailored treatment of primary rectal cancer based on 
preoperative MR imaging leads to a high rate (95.6%) of complete resections and an 
excellent 3-year local control with a local recurrence rate of only 2.2%. Overall survival 
was 84.5%. 
The number of complete resections is much better than older series on rectal 
cancer treatment, and much better than the 84.1% in the Dutch TME trial. The 2.2% 
local recurrence rate also compares favorably with 3.4% of the 5x5 Gy radiation group 
in the Dutch TME trial21 and 4.4% at 3 years in the MRC CR07 trial22. In the trials on 
neoadjuvant chemoradiation for locally advanced tumours the 5 year local recurrence 
rates were 7.6% (Bosset et al) and 6% (Sauer et al)2, 3. A strict comparison is however 
difficult as many series and randomized trials focus on a well-defined group of patients 
with rectal cancer whereas the present study includes ‘all comers’ without any 
selection. It is important to realize that the good results of the current study may be 
related to a number of recent improvements in the treatment of rectal cancer. In the 
Dutch TME trial, which ran from 1996 to 1999, a special emphasis was placed on 
quality assurance of surgical TME technique. With workshops, videos, visits of 
renowned rectal surgeons and a system of continued proctoring the TME technique 
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became standard in most surgical practices. Additionally, up-to-date high resolution 
MR techniques were standard in the current study. MRI shows the proximity of the 
tumour to the important surgical planes in distal rectal cancer, and helps the surgeon 
to perform a complete resection23. MRI also identifies tumours that invade or come 
close to the mesorectal fascia, tumours that are best treated with a long course of 
neoadjuvant chemoradiation rather than a short course of radiotherapy. The Mercury 
Study, a multicenter prospective study that used a MRI based selection similar to the 
present study, reported a 5 year local recurrence rate of 3.3% for the subgroup of 
patients (33% of the entire cohort) with a good prognosis who were treated without 
neoadjuvant therapy, with an overall and disease free survival of 68% and 85% 
respectively24. Although the MR based selection in the Mercury study was similar to 
our study, their treatment policy that followed this selection was much more restricted 
regarding the use of neoadjuvant therapy. In the Mercury study only 32% of patients 
received neoadjuvant therapy compared to 78% in our study. The overall long-term 
outcome results of the Mercury study have not yet been published, and it would be 
interesting to compare the local recurrence rates of these two policies. Another factor 
that may have contributed to the good outcome in the current study is the important 
role in the decision making process of the multidisciplinary team, a factor that is 
considered to be essential in modern rectal cancer treatment25-27.  
Positive margins 
An interesting and puzzling finding in this study is the fact that none of the 
patients with a positive margin at histology developed a local recurrence. A recent 
review confirmed the earlier observations that a positive margin is a risk factor for local 
recurrence, even more so when patients are treated with neoadjuvant chemoradiation28, 
29. The fact that this is not observed in the present study could be just a chance 
observation, or be caused by a too short follow-up time. The strategy in the present 
study was specifically aimed at avoiding a positive margin, making optimal use of MRI, 
sound surgical technique, and with liberal use of chemoradiation for tumours close to 
the mesorectal fascia and for very distal tumours. Maybe the few tumours with positive 
margins that result from such a strategy are different from the tumours with positive 
margins in older series with a much higher rate of incomplete resections. It is therefore 
unclear whether a positive margin can still be used as a surrogate endpoint for local 
recurrence. 
Abdominoperineal resections in rectal cancer surgery are often associated with a 
higher percentage of incomplete resections and an adverse outcome30. Presently, a wide 
cylindrical abdominoperineal resection for distal rectal cancer is therefore advocated in 
literature31, 32, as it would increase the chance for a complete resection. However, in this 
study a cylindrical resection for distal rectal tumours was not performed routinely, 
without apparently compromising outcome, although there were more incomplete 
resections in the APR group as shown in table 3. Neoadjuvant chemoradiation as well 
as dedicated MR imaging as a roadmap to the surgeon might again be responsible for 
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this result. It is also in line with the retrospective analysis of Messenger et al33, in 
which similar incomplete resection and local recurrence rate were found as compared to 
studies advocating a wide cylindrical excision, in a group of patients in which > 50% 
received neoadjuvant chemoradiation.  
This multicentre cohort study of unselected consecutive rectal cancer patients 
illustrates the morbidity and mortality that is associated with rectal cancer surgery. 
One out of five patients required an intervention after initial surgery, ranging from 
drainage of an abscess to relaparotomy because of anastomotic leakage, and the overall 
postoperative mortality is 4%. Old patients and patients with severe comorbidity were 
often treated with the short course radiotherapy (n=20) or even no radiotherapy at all 
(n=7) despite the presence of risk factors for local recurrence, because chemoradiation 
was considered too toxic. This bias or ‘confounding by indication’ can explain the 
higher mortality in the short-course radiotherapy group as compared to the 
chemoradiation group.  
In addition to short-term morbidity, multimodal rectal cancer treatment is also 
associated with long term functional morbidity. This study did not assess the 
defecation and urogenital long term function. Undoubtedly the very low local 
recurrence rate had been achieved at the cost of functional long term morbidity. We 
have the feeling that many patients have been ‘overtreated’ with neoadjuvant therapy, 
and the question is still open how to find the optimal balance between local control and 
good functional outcome. 
Improving survival 
Multidisciplinary efforts to obtain a good local control of rectal cancer have paid off 
well. However, many patients still die of metastatic disease. In the present cohort 21% 
of patients at primary diagnosis presented with metastases, and 15% of the remaining 
patients developed metastatic disease at a later stage. Unfortunately only a minority of 
these patients are ultimately cured, despite aggressive multimodal treatment. Earlier 
detection of metastatic disease, more active systemic therapy and a more individualised 
approach using predictive factors could improve not only disease control, but also long 
term survival, especially when combined with metastasectomies. There is a new 
tendency to address the metastatic disease simultaneously with the primary tumour or 
even before the primary tumour, reflected in neoadjuvant systemic therapy protocols 
and in the surgical ‘liver first approach’ in which metastatic disease is resected before 
the primary tumor34. A major step forward in improving colorectal cancer survival is 
expected from large screening programs, that not only lower the overall incidence of 
colorectal cancer but also the proportion of advanced tumours35, 36. 
Limitations of the study 
The main limitation of this study is that, in contrast to a randomized study, a 
cohort study cannot provide solid proof that a differentiated approach leads to a better 
outcome than a more uniform treatment schedule. Besides accurate and high quality 
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MR imaging other factors contributed to our good outcome: improved TME surgery 
and multidisciplinary treatment. The primary aim of this study was, however, to 
evaluate the outcome of a MRI based treatment approach in this setting of high quality 
TME and multidisciplinary treatment. The study shows that with this approach in our 
setting an excellent local control can be achieved, although we cannot exclude that 
other factors could play a role too. Another limitation is a relatively short median 
follow-up of 3 years. Although 3 years is a well-accepted end-point in oncological 
research, late recurrences can occur after neoadjuvant chemoradiation. A further 
limitation of the study is the practical difficulty of MR staging with the lymph node 
specific contrast agent Ultrasmall Super Paramagnetic Iron Oxide, an agent that is no 
longer available on the market despite promising initial results14, 15, 16. Although with 
standard MR imaging without USPIO the accuracy of the predicted nodal status will 
be slightly lower, the key features in the MR stratification scheme - mesorectal fascia 
invasion, T-stage, and tumour height will be equally accurate. Recent literature shows 
that there is a continued search for good lymph node contrast agents.37 
Conclusion 
With a differentiated multimodality treatment based on dedicated preoperative MR 
imaging, local recurrence is no longer the main problem in rectal cancer treatment. 
The new challenges are early diagnosis and treatment, reducing morbidity of treatment 
and prevention and treatment of metastatic disease.  
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Abstract 
Background. Recently it was suggested that the benefit of adjuvant chemotherapy for 
rectal cancer patients might depend on the response to neoadjuvant chemoradiation 
(CRT). The aim of this study was to evaluate whether the effect of aCT is modified by 
the response to CRT and to identify which patients benefit from aCT after CRT for 
rectal cancer and which patients do not.  
 
Methods. A pooled analysis of individual patient data from 13 datasets on the 
prognostic value of pathologic complete response after CRT was performed. Patients 
were categorised into 3 response groups: pCR (ypT0N0), ypT1-2 tumour and ypT3-4 
tumour. Relevant baseline characteristics were available and were used in multivariable 
regression analyses using Cox proportional hazards models to adjust for differences in 
prognostic factors between subgroups. The primary outcome measure was relapse-free 
survival (RFS).  
 
Findings. 3313 patients were included of which 1723 (52%) received adjuvant 
chemotherapy. 898 patients had a pCR, 966 had a ypT1-2 tumour and 1302 had a 
ypT3-4 tumour. For 147 patients the response category was missing (n=122) or was 
ypT0N+ (n=25). Median follow-up for all patients was 51 (0-219) months. After 
adjustment for differences in prognostic factors, the hazard ratios for RFS with 95% 
confidence interval (CI) for adjuvant chemotherapy were 1,25 (0,68-2,29), 0,58 (0,37-
0,89) and 0,83 (0,66-1,10) for patients with pCR, ypT1-2 tumours and ypT3-4 tumours, 
respectively. 
 
Conclusions. The results demonstrate an association between adjuvant chemotherapy 
and outcome in patients treated with CRT for locally advanced rectal cancer. However, 
the effect of adjuvant chemotherapy differs between subgroups. Patients with a pCR 
after CRT may not benefit from adjuvant chemotherapy, whereas patients with residual 
tumour do. The results strongly support the need for prospective studies on an 
individualized approach to the administration adjuvant chemotherapy, where omission 
of adjuvant chemotherapy in patients with a pCR after CRT could be considered.  
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Introduction 
Currently, adjuvant chemotherapy for colorectal cancer is indicated for patients at 
increased risk for metastatic disease, typically established through postoperative 
histopathological risk factors, like involved lymph nodes, poor differentiation grade or 
lymphatic or venous invasion.1 For rectal cancer, the shift from adjuvant to 
neoadjuvant (chemo)radiation2 has complicated the use of postoperative histopathology 
to determine the indication for adjuvant chemotherapy, as chemoradiation (CRT) often 
leads to downstaging of tumour and nodes. Thus, the histopathological staging often 
no longer reflects the initial stage of the rectal cancer before CRT. Therefore, the 
medical oncologist faces a challenge in deciding which patients with rectal cancer 
should be treated with adjuvant chemotherapy after CRT. First, the decision could be 
based on the pre-CRT imaging. However, the available imaging modalities are only 
moderately accurate in lymph node assessment3, 4, the risk factor that is considered 
pivotal in decision making about adjuvant chemotherapy. Another option is to guide 
the decision on post-CRT histopathological staging, but this strategy carries the risk of 
undertreating patients whose lymph nodes have been sterilised due to the CRT. Last, 
for the sake of simplicity one could argue that if a patient is treated with 
chemoradiation, adjuvant chemotherapy is always warranted, as the patient has locally 
advanced disease. However, this strategy almost certainly leads to overtreatment.  
The question remains as to which patients benefit from adjuvant chemotherapy 
after CRT for rectal cancer.5 A subgroup analysis of a randomized EORTC trial 
suggested that the effect of adjuvant chemotherapy on disease-free survival (DFS) is 
correlated with ypT-staging, which is a measure of response to CRT. Patients with 
ypT0-2 tumours had a significant improvement in DFS when adjuvant chemotherapy 
was administered, whereas patients with ypT3-4 residual tumours had not.6 Another 
report questioned the benefit of adjuvant chemotherapy for pathologic complete 
responders (ypT0N0) after CRT.7  
Therefore, the aim of this study was to evaluate whether the effect of adjuvant 
chemotherapy after CRT is modified by the histopathological stage after CRT using a 
pooled analysis of individual patient data and to identify which patients benefit from 
adjuvant chemotherapy.  
Methods 
Individual patient data from a previous pooled analysis on the prognostic value of a 
pCR after CRT for locally advanced rectal cancer were used. The search strategy, 
identification and selection of these data have been described in detail in an earlier 
publication.8 From the primary literature search, 17 papers were identified of which 14 
authors consented to participation in the previous analysis. For the present analysis, 
information on the administration of adjuvant chemotherapy and/or about the ypT and 
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ypN-stage was missing in three of these 14 datasets. These data could not be provided 
and thus these datasets were not included for the current analysis.9-11  
From one of the three datasets that could not be included at the time of the earlier 
publication, data was available for the current study.12, 13 Additionally, - to increase the 
sample of patients with a pCR after CRT - we contacted the first author of a study on 
the long-term outcome of a large group of patients with a pCR after CRT, who agreed 
to share the dataset.7 Thus, data from 13 centres were included for the present 
analysis.7, 12-24 Baseline staging of patients before treatment consisted of endorectal 
ultrasound and computed tomography mostly. Interval between chemoradiation and 
surgery was generally 6-8 weeks. Surgery consisted of total mesorectal excision for all 
patients. Individual patients were excluded from the current pooled analysis for the 
following reasons: (1) data about administration of adjuvant chemotherapy was 
missing, (2) patients were treated with preoperative radiation only without 
concomitant chemotherapy, (3) radiotherapy dose ≤ 25 Gy, (4) presence of synchronous 
metastasis, (5) locally recurrent disease or (6) an incomplete resection (R1 or R2). 
Included for analysis were data on gender, age, clinical T- and N-stage, distance 
between tumour and anal verge, pathologic T- and N-stage, type of surgery (low 
anterior resection, abdominoperineal resection or other surgery e.g. Hartmann’s 
procedure or exenteration),  type of adjuvant chemotherapy and information on dates of 
events and/or follow-up times to events.  
Based on histopathology of the resection specimen after CRT patients were 
categorised into: (1) pCR, defined as ypT0N0, (2) ypT1-2 and (3) ypT3-4. For an 
additional analysis to evaluate the effect of adjuvant chemotherapy in patients with 
ypN0 and ypN+, patients were categorised into subgroups according to pathological 
N-status (ypN-stage). For 147 patients (4%) the response category was missing 
(n=122) or was not consistent with one of the abovementioned categories (n=25, 
ypT0N+). These data, however, were included in the analysis to evaluate the effect of 
adjuvant chemotherapy in the total group of patients.  
The primary outcome measure was recurrence-free survival (RFS).  Recurrence 
was defined as a local and/or distant recurrence during follow-up.  
 
Statistical analysis 
Baseline characteristics were compared between patients who did and did not 
receive adjuvant chemotherapy. Differences in baseline characteristics were tested for 
statistical significance with the independent samples t-test for the comparison of means 
and the χ2-test for comparison of proportions. Outcome measures were RFS, defined as 
the absence of any recurrence (local or distant) during follow-up; disease-free survival 
(DFS), defined as the absence of both local and distant recurrence and death by any 
cause during follow-up; and overall survival (OS), defined as the absence of death from 
any cause during follow-up. Follow-up time was calculated from the date of surgery to 
the date of the event of interest or the date of last follow-up (censoring date).  
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Multivariable Cox proportional hazards models with stratification for study centre 
were used to adjust for differences in baseline characteristics between patients who did 
and did not receive adjuvant chemotherapy within response groups. The proportional 
hazard assumption was evaluated graphically with log-minus-log plots.25 Trend tests 
based on Schoenfeld residuals were also used to assess departure of proportionality.25 
Hazard ratios (HR) with 95% confidence intervals (CI) were calculated. The HRs that 
correspond with the variable coding for whether the patient received adjuvant 
chemotherapy or not indicate the relative risks of having an event during follow-up. A 
HR<1 indicates that the patients who received adjuvant chemotherapy had a lower 
probability of having an event.  
To evaluate whether the effect of adjuvant chemotherapy was modified by the 
degree of response to CRT an interaction term for adjuvant chemotherapy and 
response to CRT was entered into the multivariable model. The three response groups 
were coded by two dummy variables using the response group with pCR as reference 
group. The HR associated with the interaction terms represent the ratio between the 
HR for response group ypT1-2 (or response group ypT3-4) and the HR of the reference 
group of patients with a pCR, indicating to what extent the effect of adjuvant 
chemotherapy is modified by the response to CRT. A similar analysis was performed 
with an interaction term for ypN-stage and adjuvant chemotherapy.  
Analyses were performed with SPSS 16.0 and STATA 11.0. P-values<0.05 were 
considered statistically significant.  
Results 
 In total 3313 patients were included, of whom 1723 (52%) underwent adjuvant CT. 
There were 898 patients with a pCR, 966 with ypT1-2 tumours and 1302 with ypT3-4 
tumours. Approximately half of the patients with pCR (441/898) came from the study 
by Capirci et al.23 Median follow-up for all patients was 51 (range 0-219) months. 
Median follow-up time for patients with adjuvant CT was 55 months (range 0-188) and 
for patients without adjuvant CT it was 46 months (range 0-219). For patients with 
pCR median follow-up was 47 months (range 0-187), for patients with ypT1-2 tumours 
61 months (range 1-219) and for patients with ypT3-4 tumours it was 49 months 
(range 0-201). Additional information and baseline characteristics per study are shown 
in table 1.  
Baseline characteristics for all patients and patients who did and did not undergo 
adjuvant CT are shown in table 2. Patients who underwent adjuvant CT were 
significantly younger that patients who did not undergo adjuvant CT, a larger 
proportion of patients who underwent adjuvant CT had more distally located tumours, 
underwent a low anterior resection and had more advanced pathologic stages (higher 
ypT- and ypN-stage) than patients who did not undergo adjuvant CT (all p<0.0001). 
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 All 
No aCT  
(n=1590) 
aCT  
(n=1723) 
p-value 
Age (years) 61 (12) 63 (11) 60 (12) p<0.0001 
Gender (male) 64% (2119/3313) 63% (1001/1590) 65% (1118/1723) 0.258 
   Missing 0% (3/3298) 0% (2/1575) 0% (1/1723)  
Clinical T-stage     
   cT1 0% (9/3122) 1% (7/1489) 0% (2/1618)  
   cT2 6% (177/3122) 6% (93/1489) 5% (84/1618) 0.093 
   cT3 83% (2586/3122) 81% (1225/1489) 84% (1361/1618)  
   cT4 11% (350/3122) 12% (179/1504) 11% (171/1618)  
   Missing 6% (191/3313) 5% (86/1590) 6% (105/1723)  
Clinical N-stage     
   cN+ 56% (1729/3103) 56% (846/1508) 55% (883/1595) 0.678 
   Missing 6% (210/3313) 5% (82/1590) 7% (128/1723)  
Tumour height (cm)     
   ≤ 5 cm 50% (1333/2650) 55% (606/1099) 47% (727/1551) <0.0001 
   > 5 cm 50% (1317/2650) 45% (493/1099) 53% (824/1551)  
   Missing 20% (663/3313) 31% (491/1590) 10% (172/1723)  
Type of surgery     
   LAR  70% (2324/3313) 68% (1073/1590) 73% (1251/1723)  
   APR 25% (834/3298) 26% (416/1590) 24% (418/1723) <0.0001 
   Other 5% (155/3298) 6% (101/1590) 3% (54/1723)  
   Missing 0% 0% 0%  
Response category     
   pCR (ypT0N0) 28% (898/3166) 41% (608/1478) 17% (290/1688)  
   ypT1-2 31% (966/3166) 27% (400/1478) 34% (566/1688) <0.0001 
   ypT3-4 41% (1302/3166) 32% (470/1478) 49% (832/1688)  
   Missing 4% (147/3313) 7% (112/1590) 2% (35/1723)  
Pathological N-stage     
   N+ 20% (655/3246) 13% (194/1538) 27% (461/1708) <0.0001 
   Missing 2% (67/3313) 3% (52/1590) 1% (15/1723)  
Median FU time (mo) 51 (0-219) 47 (0-219) 55 (0-188) <0.0001 
Table 2.  Baseline characteristics for all patients and for patients categorized according to 
administration of adjuvant chemotherapy (aCT). Cm=centimetre; LAR=low anterior resection; 
APR=abdominoperineal resection; pCR=pathologic complete response;  FU=follow-up; mo=months. 
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pCR 
(n=898) 
ypT1-2 
(n=966) 
ypT3-4 
(n=1302) 
p-value 
Age (years) 61 (±11) 61 (±11,5) 61 (±12,0) p=0.819 
Gender (male) 66% (589/896) 65% (632/966) 65% (843/1302) p=0.894 
   Missing 0,2% (2/898) 0% 0% (1/1302)  
Clinical T-stage     
   cT1 0,5% (4/878) 0,3% (3/924) 0,1% (1/1215)  
   cT2 8% (71/878) 9% (81/924) 2% (21/1215)  
   cT3 82% (723/878) 84% (776/924) 82% (999/1215) p<0.0001 
   cT4 9% (80/878) 6% (64/924) 16% (194/1215)  
   Missing 2% (20/898) 4% (42/966) 7% (87/1302)  
Clinical N-stage     
   cN+ 50% (431/855) 55% (501/907) 59% (486/1198) p<0.0001 
   Missing 5% (43/898) 6% (59/966) 8% (104/1302)  
Tumour height (cm)     
   ≤ 5 cm 53% (230/434) 54% (491/912) 45% (545/1201)  
   > 5 cm 47% (204/434) 46% (421/912) 55% (656/1201) p<0.0001 
   Missing 52% (464/898) 6% (54/966) 8% (102/1302)  
Type of surgery     
   LAR  76% (680/898) 71% (686/966) 68% (882/1302)  
   APR 22% (196/898) 25% (238/966) 28% (367/1302) p=0.001 
   Other 2% (22/898) 4% (42/966) 4% (53/1302)  
   Missing 0% 0% 0%  
Table 3.  Baseline characteristics for patients categorized according to their response to 
chemoradiation. Cm=centimetre; LAR=low anterior resection; APR=abdominoperineal resection; 
pCR=pathologic complete response. 
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In table 3 information on baseline characteristics are shown and compared between 
response categories. Almost all patients had cT3 tumours before CRT (82% in the pCR 
group, 84% in the ypT0-2 group and 82% in the ypT3-4 group). In every of the 3 
groups approximately half of patients had involved nodes before CRT.  
Table 4 provides information on the prognostic value of ypT- and ypN- staging by 
showing the 5-year Kaplan Meier estimates of RFS, DFS and OS for patients not 
treated with adjuvant chemotherapy according to histological ypTN categories. 
 
  Recurrence free survival Disease-free survival Overall survival 
pCR 90% (87-93) 87% (84-90) 87% (83-90) 
According to ypT-stage 
ypT1-2 84% (79-87) 78% (74-83) 86% (81-89) 
ypT3-4 60% (55-65) 52% (46-57) 63% (58-68) 
According to ypN-stage 
ypN0 81% (79-84) 76% (73-79) 81% (79-84) 
ypN+ 52% (43-60) 47% (38-55) 59% (50-67) 
According to combined ypT- and ypN-stage 
ypT1-2N0 85% (80-88) 79% (74-83) 86% (81-90) 
ypT1-2N+ 78% (59-89) 76% (58-88) 88% (70-95) 
ypT3-4N0 68% (62-74) 59% (52-64) 69% (63-75) 
ypT3-4N+ 43% (32-53) 36% (26-46) 50% (38-60) 
Table 4. 5-year Kaplan Meier estimates (wih 95% confidence intervals) of patients with 
varying response to CRT with regard to T- and N-stage who were not treated with adjuvant 
chemotherapy. pCR=pathologic complete response; RFS=relapse-free survival; DFS=disease-free 
survival; OS=overall survival. 
 
Multivariable analyses  
Multivariable Cox regression analyses were performed with inclusion of the 
following factors as independent variables: age, gender, clinical T-stage and clinical N-
stage before CRT, type of surgery, administration of adjuvant chemotherapy. The 
proportional hazards assumption was not violated. When analyzing the combined data 
of all patients, the adjusted HRs indicated a better prognosis for patients who received 
adjuvant chemotherapy than for patients who did not. The adjusted HR for the effect of 
adjuvant chemotherapy on RFS was 0.81 (95%CI 0.66-0.99), for DFS the HR was 0.75 
(95%CI 0.62-0.90) and for OS the HR was 0.69 (95%CI 0.56-0.85).  
Figure 1 shows the forest plots displaying the HRs and 95%CIs for administration 
of adjuvant chemotherapy per ypT and per ypN-stage for RFS, DFS and OS. For 
patients with a pCR, the hazard ratios vary around ‘1’ with wide 95%CIs. 
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Figure 1. Forest plots displaying the hazard ratios with 95% confidence interval derived from the 
comparison of patients treated with adjuvant chemotherapy and not treated with adjuvant 
chemotherapy (reference group) for the three response groups and for patients with ypN0 and 
ypN+. (a) Relapse-free survival, (b) disease-free survival and (c) overall survival.  
 
For RFS, the HR was 1.25 (95%CI: 0.68-2.29). For DFS and OS the HRs for this 
response group were 0.94 (95%CI: 0.53-1.69) and 0.88 (95%CI: 0.48-1.59), respectively. 
For patients with ypT1-2 and ypT3-4 the HR was <1 for all outcome measures, 
indicating a statistically significant association of adjuvant chemotherapy with an 
improved outcome. For patients with ypN0 the HR for adjuvant chemotherapy on RFS 
was 0.74 (95%CI: 0.57-0.96), while in patients with ypN+ the HR was 0.98 (95%CI: 
0.71-1.36). For DFS similar results were found and for OS the difference in the HRs for 
adjuvant chemotherapy between patients with ypN0 and ypN+ was less pronounced: 
HR 0.67 (95%CI: 0.52-0.87) for ypN0 and HR 0.74 (95%CI: 0.49-1.12) for ypN+. 
To evaluate the robustness of the results for patients with pCR, we repeated the 
analysis without the patients with pCR from Capirci et al.7 The resulting HR of 1.24 
(95%CI: 0.52-2.97) for RFS again suggested no benefit from adjuvant chemotherapy for 
this subgroup.  
Interaction 
For RFS, the HRs for the interaction terms suggest a stronger effect of adjuvant 
chemotherapy in the response groups ypT1-2 (HR= 0.71 with 95%CI:0.38-1.33, 
p=0.280) and ypT3-4 (HR=0.80 with 95%CI:0.45-1.42, p=0.450) than in the subgroup 
with pCR, but the estimated interaction effects do not reach statistical significance. 
This analysis was repeated with an interaction term for ypN status and adjuvant 
chemotherapy. For RFS, the HR for the interaction term was 0.80 (95%CI:0.55-1.16, 
p=0.241), indicating a larger effect of adjuvant chemotherapy in patients with ypN0 
stage. For DFS and OS the interaction HRs were also non-significant.  
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Discussion 
The results indicate that the effect of adjuvant chemotherapy after CRT and 
surgery for rectal cancer depends on the final histological staging. Patients with a pCR 
after CRT do not seem to benefit from adjuvant chemotherapy and as these patients 
already have an excellent prognosis8 there is little or no room for improvement with 
adjuvant chemotherapy. For patients with residual tumour adjuvant chemotherapy 
does improve the long-term outcome, with the largest benefit for the patients with 
ypT1-2 tumours after CRT.  
Although adjuvant chemotherapy is common in many clinical practices, there is 
still no definite answer to the question whether it is effective in patients with locally 
advanced rectal cancer after treatment with CRT. In a recent systematic review of 
randomized trials it was reported that the effect of adjuvant chemotherapy in patients 
with rectal cancer treated with CRT might be limited.26 As no single trial was large 
enough to detect a 5% improvement in 5-year survival, it was recommended to perform 
a meta-analysis using individual patient data to resolve the issue of whether adjuvant 5-
FU-based chemotherapy produces worthwhile benefit in patients who have been 
treated with neoadjuvant CRT and surgery. The results of this present pooled analysis 
with a HR for RFS of 0.81 (95%CI:0.66-0.99) are suggestive of a benefit of adjuvant 
chemotherapy in the total group of patients who received neoadjuvant CRT. This 
finding is in accordance with a trend towards a survival benefit from adjuvant 
chemotherapy that was shown in two randomized trials. From subgroup analyses of the 
QUASAR trial that focused on patients with rectal cancer only a HR of 0.60 (95%CI: 
0.30-1.20) was reported, in favor of adjuvant chemotherapy.27 The previously 
mentioned EORTC trial reported a HR of 0.87 (95%CI:0.72-1.04) for DFS and a HR of 
0.84 (95%CI:0.78-1.13) for OS in favor of adjuvant chemotherapy.28  
Our finding that the effect of aCT is stronger in the ypT1-2 group than in the 
ypT3-4 group is consistent with the results from the subgroup analysis of the EORTC 
trial.28 These subgroup analyses showed a beneficial effect of adjuvant chemotherapy in 
patients with ypT0-2 tumours (HR for DFS=0.64 with 95%CI:0.45-0.91 and HR for 
OS=0.64 with 95%CI 0.42-0.96), and no benefit in patients with ypT3-4 tumours (HR 
1.18 with 95%CI:0.89-1.57 for DFS and 1.19 with 95%CI:0.84-1.68 for OS, p>0.05). 
The authors put forward the hypothesis that the same prognostic factors drive both 
tumour sensitivity for the primary treatment with chemoradiation and sensitivity for 
adjuvant chemotherapy aimed at microscopic distant disease.6 The finding in this 
pooled analysis that adjuvant chemotherapy seems to have an effect in patients with 
ypN0 tumours, but not in patients with ypN+ tumours also supports the hypothesis 
from Collette et al.: when the primary tumour does not respond well to the 
chemoradiation, the micrometastases in the nodes will also lack response to adjuvant 
chemotherapy.6 These findings point to a policy for administration of adjuvant 
chemotherapy in patients with rectal cancer treated with CRT which is at odds with 
the usual approach in colorectal cancer. Currently, in colorectal cancer the decision to 
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administer adjuvant chemotherapy is guided by the pathologic N-stage, where patients 
with pathologic N+ stage have an indication for adjuvant chemotherapy. Unlike 
patients not treated with neoadjuvant CRT, patients with rectal cancer who have been 
treated with CRT and still have a pathologic N+ status do not seem to benefit from 
adjuvant chemotherapy. In these patients adjuvant chemotherapy might be omitted or a 
different chemotherapeutic agent (not 5-FU based) could be considered.  
Limitations 
The results of this pooled analysis should be interpreted with caution because data 
were not derived from randomized trials. Due to confounding by indication the 
distribution of prognostic factors for survival may have differed between patients who 
received adjuvant chemotherapy and those who did not. An attempt was made to 
eliminate this bias by adjustment for these differences in a multivariable Cox regression 
model, but it is possible that some relevant prognostic factors were not captured in 
these multivariable analyses. For instance, no information was available on post-
operative complications or co-morbidity of patients. Both factors may have guided the 
decision to withhold adjuvant chemotherapy. As a result, the group of patients who did 
not receive adjuvant chemotherapy may have had an elevated risk of death due to other 
diseases than rectal cancer. Such an imbalance would result in bias towards favoring 
adjuvant chemotherapy for the outcomes DFS and OS. However, the HRs for RFS are 
less likely to be biased, because this outcome does not comprise deaths and can 
therefore be considered a more valid and thus reliable estimate of effectiveness of 
adjuvant chemotherapy.  
A second limitation is that the majority of patients received 5-FU-based adjuvant 
chemotherapy. It remains unclear whether the results of the present study are 
reproducible with a regimen that includes oxaliplatin.  
A third limitation is that, although the results of the current pooled analysis 
support the presence of differential effects of adjuvant chemotherapy within different 
subgroups, there is no definite proof of treatment-by-response interaction. The HRs for 
the interaction terms suggest a stronger effect of adjuvant chemotherapy in the 
response groups ypT1-2 and ypT3-4 than in the subgroup with pCR, but the estimated 
interaction effects do not reach statistical significance. However, it cannot be concluded 
that lack of statistical significance indicates absence of interaction. Tests for interaction 
are known to have limited power. A sample size calculation showed that to achieve a 
significant interaction effect a sample size of approximately 13000 patients would be 
needed. The substantial differences in effect of adjuvant chemotherapy between the 
response groups strongly suggest the presence of effect modification by response to 
CRT. 
Limitations that are inherent to pooled analyses of non-randomized individual 
patient data can be circumvented by a randomized controlled trial (RCT) or a pooled 
analysis of data from RCTs, However, a very large sample size would be needed to 
detect small but clinically relevant differences in effect between groups who respond 
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differently to CRT, particularly in view of the low prevalence of pCR (15-20%).8 
Therefore, to provide definite evidence with a RCT will be very challenging.  Whilst 
awaiting the results of such a RCT, the results of the current pooled analysis might 
therefore be used when contemplating on the use of adjuvant chemotherapy after CRT 
in individual patients.  
Conclusion 
The results indicate that the effect of adjuvant chemotherapy after CRT and 
surgery for rectal cancer depends on the final histological staging. Patients with a pCR 
after CRT may not benefit from adjuvant chemotherapy, whereas patients with residual 
tumour do. Although the test for interaction did not reach statistical significance, the 
results strongly support further investigation of a more individualized approach to 
administer adjuvant chemotherapy after CRT and surgery based on final pathologic 
staging, where omission of adjuvant chemotherapy in patients with a pCR after CRT 
could be considered.  
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Abstract 
Background. To compare the diagnostic performance of PET, PET/CT, CT and MRI 
as whole-body imaging modalities for the detection of local and/or distant recurrent 
disease in colorectal cancer (CRC) patients who have a (high) suspicion of recurrent 
disease, based on clinical findings or rise in carcinoembryogenic antigen (CEA). 
 
Methods. A meta-analysis was undertaken. Pubmed and Embase were searched for 
studies on the accuracy of whole-body imaging for patients with suspected local and/or 
distant recurrence of their CRC. Additionally, studies had to have included at least 20 
patients with CRC and 2x2 contingency tables had to be provided or derivable. Articles 
evaluating only local recurrence or liver metastasis were excluded. Summary receiver 
operator characteristics (ROC) curves were constructed from the data on sensitivity 
and specificity of individual studies and pooled estimates of diagnostic odds ratios 
(DORs) and areas under the ROC curve (AUCs) were calculated. To test for 
heterogeneity the Cochran Q-test was used. 
 
Findings. 14 observational studies were included which evaluated PET, PET/CT, CT 
and/or MRI. Study results were available in 12 studies for PET, in 5 studies for CT, in 
5 studies for PET/CT and in one study for MRI. AUCs for PET, PET/CT and CT 
were 0.94 (0.90-0.97), 0.94 (0.87-0.98) and 0.83 (0.72-0.90), respectively. In patient 
based analyses PET/CT had higher diagnostic performance than PET with an AUC of 
0.95 (0.89-0.97) for PET/CT vs. 0.92 (0.86-0.96) for PET. 
 
Conclusions. Both whole-body PET and PET/CT are very accurate for the detection 
of local and/or distant recurrent disease in CRC patients with a (high) suspicion of 
recurrent disease. CT has lowest diagnostic performance. This difference is probably 
mainly due to the lower accuracy of CT for detection of extrahepatic metastases 
(including local recurrence). For clinical practice PET/CT might be the modality of 
choice when evaluating patients with a (high) suspicion for recurrent disease, because of 
its best performance in patient based analyses and confident prediction of disease 
status.  
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Introduction 
Nineteen percent of patients with colorectal cancer are diagnosed with distant 
metastasis at initial presentation, which (when undertreated) is associated with a 5-year 
survival rate of 7%.1 Furthermore, local and distant recurrences occur in 30-50% of 
patients during follow-up after primary surgery.2 Whereas in many patients metastatic 
disease cannot be cured, in carefully selected patients a resection of the metastases has 
been reported to result in 5-year survival rates up to 30-40%.3 The therapeutic options 
for colorectal metastases - including surgery and chemotherapy - as well as the clinical 
outcome depend strongly on accurate evaluation and early identification of recurrent 
lesions.  
Metastatic disease in colorectal cancer is most common in liver and lung, but can 
affect the whole body. Whole-body imaging is important in different clinical settings. 
First, at primary staging of colorectal cancer it is important to determine the local and 
distant spread of the tumour to determine the risk profile and the indicated treatment. 
Second, whole body imaging can be used either as part of a surveillance 
programme after surgery for colorectal cancer or when a recurrence is suspected on the 
basis of clinical examinations. In the clinical setting in which patients have suspected 
recurrence, it is unclear which whole-body staging modality is most accurate for the 
detection of a recurrence. Currently, in this specific setting, computed tomography 
(CT) is used to detect recurrence, even though CT has a high false-positive rate for 
pulmonary lesions and high false-negative rate for extrahepatic intra-abdominal lesions 
(e.g. para-aortic nodes).4, 5 Several studies have reported good results for whole-body 
staging with 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) and 
FDG PET/CT.6-8 The experience with magnetic resonance imaging (MRI) is limited. 
So far, there is no consensus on which is the most accurate whole body imaging 
technique for colorectal cancer patients who have a suspicion for recurrence based on 
clinical findings or rise in CEA. Therefore, the objective of the present study is to 
perform a meta-analysis of published studies in order to determine what is the most 
accurate whole-body imaging modality for the detection of recurrent disease in patients 
with colorectal cancer who have suspected local and/or distant recurrent disease and to 
advise which modality is most suitable in clinical practice.  
Methods 
A literature search was performed in Pubmed/MEDLINE and Embase up to May 
2010 using the following search terms: ‘colorectal neoplasm or carcinoma or cancer’, 
‘whole-body imaging or staging’, ‘neoplasm staging’, ‘colorectal’, ‘metastasis’, 
‘recurrence’, ‘positron-emission tomography’ or ‘PET’, ‘magnetic resonance imaging’ or 
‘MRI’,  ‘computed tomography’ or ‘CT’ and ‘PET-CT’ or ‘PET/CT’. PET refers to 
FDG-PET. No language restriction was used. Studies were included when they met 
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the following criteria: (a) focus on metastasis and/or recurrence detection in patients 
with suspected recurrence in the follow-up for colorectal cancer, (b) study population 
included more than 20 patients with colorectal cancer, (c) results were given in a 2x2 
contingency table or this table could otherwise be derived from the article, and (d) 
reference standard combined histology with follow-up. Case reports, reviews, articles 
that evaluated local staging only or detection of liver metastases only, and studies that 
evaluated whole-body imaging at primary staging or for patients with known hepatic 
metastases were excluded. Last, studies which evaluated response to therapy only were 
also excluded.  
Two reviewers (IJGR and MM) independently searched the databases for eligible 
studies. The reviewers checked the titles and abstracts of the identified studies in order 
to select studies which potentially met the inclusion criteria. Thereafter they 
independently studied full text copies of the selected studies to make a decision as to 
which studies met the inclusion criteria. In case of disagreement, consensus was 
reached. Reference lists were checked to find additional eligible studies. Data which 
were extracted from the studies were: (1) number, gender and age of patients, (2) study 
objective, (3) type of reference standard, (4) unit of analysis (lesion or patient based 
analysis), (5) degree of blinding, (6) duration of follow-up, and (7) prevalence of disease. 
Study quality was assessed with the QUADAS checklist for studies of diagnostic 
accuracy included in systematic reviews.9  
Statistical analysis 
Preferably, results from lesion based analyses were used for this meta-analysis, but 
part of the studies only reported data on a patient basis. Based on the results from the 
(derived) 2x2 contingency tables, pooled measures for diagnostic performance, such as 
sensitivity, specificity, diagnostic odds ratio (DOR) and area under the receiver 
operator characteristics curve (AUC), were calculated using random effects models. 
The pooled DOR for each imaging modality was used for the construction of summary 
receiver operating characteristic (SROC) curves. SROC curves account for the so-called 
threshold effect in diagnostic studies, which arises when studies use different cut-off 
points or thresholds to define a positive or negative test result. The DORs combine 
sensitivity and specificity into one measure for diagnostic performance. A DOR of 1 
means that the test has no ability to discriminate. The higher the DOR, the better the 
ability of a test to discriminate between subjects with and without the disease of 
interest. To test differences in diagnostic performance between modalities for statistical 
significance, the relative DOR of one modality compared to another was calculated 
with its corresponding p-value. 
The Cochran Q test was used to test for heterogeneity between individual study 
results. Significance of this test indicates that differences between study results cannot 
solely be attributed to sampling variation. The p-value for heterogeneity was 
considered significant when p<0.10, because heterogeneity tests are known for its lack 
of statistical power. Differences in DORs between studies can also result from 
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differences in design, case mix and analysis. To account for heterogeneity, the DOR 
and AUC for the imaging modalities under study were pooled within subgroups of 
studies. These subgroups were made according to the presence or absence of a specific 
study characteristic that can affect the estimate of the diagnostic performance of a 
modality. 
Pooled estimates of diagnostic performance and relative DORs were calculated 
with MetaDiSc version 1.410, a software programme which implements metaregression 
using a generalization of a model that was proposed by Moses et al.11  
Results 
With the search 82 studies were retrieved, of which a total of 60 articles 
potentially met the inclusion criteria after selection based on titles and abstracts. Out of 
these 60 articles, 46 were excluded12-56, leaving 14 articles for inclusion.2, 6-8, 57-66 The 45 
articles were excluded because of the following reasons. Nineteen articles studied 
patients with primary colorectal cancer or patients with known hepatic metastases.13, 14, 
16, 18, 20, 21, 23, 25, 29, 30, 33-36, 38, 40, 41, 44, 55, 56 Nine studies were excluded because they included 
less than 20 patients with colorectal cancer.12, 15, 19, 22, 24, 26, 31, 32, 50 Six articles were 
excluded because a 2x2 contingency table could not be constructed28, 39, 43, 45, 53, 54, five 
evaluated patients after recent treatment with chemotherapy or evaluated response 
after treatment and were therefore excluded 17, 27, 37, 42, 49 and three were a meta-analysis 
and/or review.47, 48, 52 One was a case report.51 One article evaluated the accuracy of a 
combination of diagnostic modalities to detect lesions without specifying individual 
accuracies per modality and was thus excluded.46 Finally, one study was excluded 
because it only evaluated the clinical reports for PET and did not re-evaluate the 
images for the study.67  Study identification and inclusion are shown in a flowchart in 
figure 1. Results of the quality assessment with the QUADAS checklist are shown in 
table 1.  
Individual study characteristics are presented in table 2. Of the 14 articles included, 
three studied a single modality2, 8, 62 and eleven compared two or three different 
modalities.6, 7, 57-61, 63-66 Grouping the articles according to investigated imaging 
modality, 12 articles studied the performance of PET 
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6-8, 57-62, 64-66, 7 articles studied the performance of CT6, 8, 57, 59, 61, 64, 66, 5 articles studied 
the performance of PET/CT2, 7, 58, 61, 63 and one article studied the performance of 
MRI.63 In two studies which evaluated both PET and CT only part of the thorax and 
abdomen was imaged with CT and therefore only the results for PET were included 
from these studies.59, 66 So, in total results from 5 studies were available for CT. All CT 
studies used intravenous contrast. The number of patients ranged from 24 to 115 
patients per study, with a total of 871 patients evaluated in all included studies. The 
percentage of male patients varied from 46% to 71% and the mean or median or mean 
age ranged from 58-68 years. All studies used histopathology or a combination of 
histopathology, clinical and radiological follow-up, conventional diagnostic modalities 
(X-ray, endoscopy, ultrasound) and surgical exploration as reference method. The 
indication for whole-body imaging was suspected local or distant recurrence based on 
clinical symptoms, rise in carcinoembryonic antigen (CEA) levels, endoscopy findings 
or findings from other imaging methods in all studies for all or the majority of patients.  
Estimates of diagnostic performance, such as sensitivity, specificity, positive and 
negative predictive value, accuracy, DOR and AUC, for all individual studies are shown 
in table 3. 
 
 
Figure 1. PRISMA flowchart describing the identification and inclusion of studies.  
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Summary Receiver Operator Characteristic curves 
 SROC curves for the diagnostic performance of PET, PET/CT, and CT and the 
individual study results are shown in figure 2. PET and PET/CT had the best 
diagnostic performance for recurrence detection, with DORs of 55.2 (95%CI 23.2-
131.2) and 55.3 (95%CI 15.9-191.8), respectively, compared to a DOR of 9.8 (95%CI 
4.2-22.8) for CT. The single study concerning MRI was not included in the regression 
analysis but the results are shown in the graph as a single value. The DOR for this 
MRI study was 35.1 (95%CI 13.5-90.4). The corresponding AUCs for PET, PET/CT  
Author Modality Unit of Analysis Sensitivity Specificity PPV NPV Accuracy DOR 
Arulampalam 2001 PET PbP 93 58 85 78 83 16 
Cohade 2003 PET LbL 88 56 92 43 83 8 
Delbeke 1997 PET Both 94 86 97 73 92 74 
Imbriaco 2000 PET LbL 94 95 96 93 95 222 
Kim 2005 PET Both 74 93 77 92 88 33 
Lonneux 2002 PET Both 97 73 96 80 94 465 
Nakamoto 2007 PET PbP 75 82 84 71 78 12 
Ruhlmann 1997 PET PbP 100 75 94 100 95 236 
Staib 2000 PET PbP 98 91 93 98 95 328 
Valk 1999 PET PbP 96 71 96 71 93 51 
Whiteford 2000 PET PbP 87 68 92 58 84 697 
Willkomm 2000 PET PbP 100 100 100 100 100 14 
Arulampalam 2001 CT PbP 73 75 88 53 74 7 
Imbriaco 2000 CT LbL 74 70 77 67 72 6 
Nakamoto 2007 CT PbP 69 93 93 69 79 51 
Staib 2000 CT PbP 91 72 80 87 82 22 
Valk 1999 CT PbP 78 50 92 24 75 4 
Chen 2007 PET/CT PbP 95 83 96 77 93 64 
Cohade 2003 PET/CT LbL 86 67 94 44 83 11 
Kim 2005 PET/CT Both 89 98 94 96 96 298 
Nakamoto 2007 PET/CT PbP 75 96 96 74 84 23 
Schmidt 2009 PET/CT Both 86 97 96 88 91 136 
Schmidt 2009 MRI Both 73 93 90 79 83 35 
Table 3. Diagnostic performance for all the included studies, sorted by modality. PET = positron emission 
tomography, CT = computed tomography, PET/CT = positron emission tomography combined with computed 
tomography, MRI = magnetic resonance imaging. PPV = positive predictive value, NPV = negative predictive value,  
PbP = patient-by-patient based analysis, LbL = lesion-by-lesion based analysis. If both lesion based and patient based 
results were provided, results for lesion based analyses are shown in this table. 
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Figure 2. Summary ROC curves with all individual study results for all modalities. The single 
study on MRI is displayed as a single value in the graph. PET = positron emission tomography (n=12), 
CT = computed tomography (n=5), PET/CT = combined positron emission tomography and computed 
tomography (n=5), MRI = magnetic resonance imaging (n=1) 
 
 
 
 
Figure 3. Pooled sensitivity (%) and specificity (%), area under the receiver operator 
characteristics curve (AUC, %) and diagnostic odds ratio (DOR) for computed tomography 
(CT), positron emission tomography (PET) and PET/CT with 95% confidence intervals 
indicated by error bars. 
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and CT for recurrence detection were 0.94 (95%CI 0.90-0.97), 0.94 (95%CI 0.87-0.98) 
and 0.83 (95%CI 0.72-0.90), respectively. CT had a significantly lower diagnostic 
performance than PET (p=0.021). Between CT and PET/CT the difference was not 
significant (p=0.10). The difference between PET and PET/CT was not significant 
either (p=0.66). AUC for the single MRI study was 0.92 (95%CI 0.86-0.96). Pooled 
sensitivity and specificity, AUC and DOR for the modalities are shown in figure 3. 
Subgroup analyses 
The Cochran Q test showed that there is significant heterogeneity between study 
results for each imaging modality (p<0.10). This heterogeneity is also illustrated in 
figure 2, which shows substantial scatter of observed pairs of sensitivity and specificity 
of individual studies around the fitted SROC curves. To correct for potential sources of 
heterogeneity subgroup analyses were performed. Pooled estimates of diagnostic 
performance were calculated within subsets of studies that differed with respect to 
factors that potentially can affect diagnostic performance: 1) unit of analysis (patient 
based versus lesion based), 2) prevalence (percentage of patients with malignant disease 
in the studied population) as an indicator of disease spectrum (<75% versus ≥75%), 3) 
blinding to clinical information (yes versus no), 4) design (retrospective versus 
prospective), and 5) year of publication (<2003 versus ≥ 2003). Full blinding was 
defined as blinding to both clinical information and other imaging results. Partial 
blinding was defined as blinding for other imaging results only. In all subgroups CT 
remained the modality with the lowest diagnostic performance. The results of the 
subgroup analyses are displayed in figure 4. PET had significantly lower diagnostic 
performance when a study was published after 2003: AUC was 0.96 (95%CI 0.92-0.98) 
before 2003 vs. 0.87 (95%CI 0.78-0.92) after 2003, p=0.013.  
 
 
Figure 4. Areas under the summary receiver operator characteristics curve with 95% confidence 
intervals (error bars) per modality for subgroups. Prevalence refers to the prevalence of disease in 
the studied population. Fully blinded is defined as reading the images without any knowledge about the 
patient. Clinical info indicates that readers were aware of clinical information about the patients, but had 
no knowledge about results from other imaging studies. In some subgroups columns are missing for one 
or more modalities, because no or only one study was available for that subgroup and thus the subgroup 
analysis could not be performed 
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Discussion 
 In this meta-analysis we compared PET, PET/CT, CT and MRI for whole-body 
staging in patients who have suspected recurrence in the follow-up for curatively 
treated colorectal cancer. We found that PET and PET/CT have high diagnostic 
performance with an AUC of 0.94 for both PET and PET/CT. CT had a significantly 
lower diagnostic performance than PET or PET/CT with an AUC of 0.83. This lower 
diagnostic performance persisted after correction for differences in design and analysis 
of studies. The subgroup analyses showed that in studies in which readers were fully 
blinded (to both clinical information and other imaging results) or in studies which 
were published after 2003 diagnostic performance was lower for PET. The single study 
evaluating MRI showed a high AUC of 0.92. 
PET and PET/CT were the most accurate modalities. PET and PET/CT are 
metabolic imaging techniques that provide information on the nature of a lesion based 
on differences in glucose metabolism. Malignant lesions have a higher glucose 
metabolism and thus a higher uptake of FDG. These changes in metabolism are known 
to precede changes in morphology (which are evaluated with CT), hence the higher 
sensitivity for PET or PET/CT than for CT in the detection of small malignant 
lesions. In figure V an illustration is given of a lesion with high FDG uptake (and thus 
detection with PET) which could not (yet) be identified with CT. FDG uptake is also 
increased in inflammatory tissue and in normal organs such as the brain, the urinary 
tract and bowel, causing false-positive findings. By combining the functional 
information of PET with the morphological information of CT false-positive errors can 
be reduced and superior performance of PET/CT over PET and CT as stand alone 
techniques is expected. Nevertheless, the results of our meta-analysis do not confirm 
superior performance for PET/CT over PET. There are some methodological issues 
related to this finding. Only three studies compared PET/CT with PET within the 
same patient group and therefore most of the data originated from studies without 
direct comparison of both modalities in the same patients.7, 58, 61 Differences in study 
designs between the PET and PET/CT studies could have influenced the results and 
this may have favoured the performance of PET. The results of the three studies that 
did compare PET with PET/CT in the same study population showed a superior 
performance for PET/CT, especially in the patient based analyses.7, 58, 61 In our 
subgroup analyses of patient based study results we could confirm the higher 
performance of PET/CT over PET on a patient basis (AUC 0.95 for PET/CT vs. 0.92 
for PET, figure IV). The three studies also found that readers were more confident in 
their diagnosis of lesions with PET/CT than with PET only. Kim et al. reported 
highest confidence level scores for PET/CT (91%) compared to 61% for PET and 50% 
for CT.7  
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Figure 5. Diagnostic computed tomography (CT)-image (left) and positron emission tomography 
(PET)-image (right) of a patient who has a clearly visualised para-aortic lesion on PET (arrow), 
which cannot be discerned on CT. 
 
 
Figure 6. CT-image (left) and PET-image (right) of a patient with locally recurrent colorectal 
cancer after a sigmoid resection. On PET a clear hot spot (arrow) is found with increased FDG 
uptake, while on CT it was not recognised as a local recurrence (arrow). 
 
CT had a lower diagnostic performance than PET/CT and PET. The cause may 
be that the accuracy of CT for extrahepatic metastasis detection is lower than that of 
PET and PET/CT. CT is known to be more accurate in the detection of hepatic than in 
the detection of extrahepatic metastases (including local recurrence), making it less 
ideal for whole-body staging. Studies in this meta-analysis have shown that with 
respect to the detection of extrahepatic lesions CT performs worse (sensitivities 53-
71% and specificities 50-85%) than PET (sensitivities 70-100% and specificities 40-
100%).59, 61, 66 Several older reports have reported low diagnostic performance for the 
detection of local recurrence with CT.68, 69 A more recent study by Stückle et al. with 
multi-slice CT acknowledged the low sensitivity (38-82%) for local recurrence 
detection but reported high specificity (97-100%) in the follow-up after surgery.70 
Because the studied populations in our meta-analysis comprised of patients who had 
both local and distant recurrence the diagnostic performance of CT can be influenced 
by the fact that local recurrence detection is difficult with CT (figure VI).  
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Finally, most included studies evaluating whole-body CT were performed around 
the year 2000 and it should be taken into account that since then quality of CT may 
have improved considerably. This may have caused underestimation of the diagnostic 
performance of CT in this meta-analysis. However, a more recent study (2007) 
comparing modern CT technique with PET and PET/CT within the same patient 
population by Nakamoto et al. still showed that CT had lowest diagnostic performance, 
while PET/CT was the most accurate modality.  
An interesting finding in this meta-analysis is that in more recently published 
studies diagnostic performance of PET was significantly worse than in earlier 
publications. This phenomenon is observed more often in diagnostic studies and may be 
explained by publication bias. In the late nineties PET was a relatively new modality, 
so the chance for acceptance for publication was higher for positive study results. 
Another possible explanation is that study design and methodology have improved 
over time leading to more critical evaluation of the modality and thus possibly lower 
diagnostic performance of a modality.  
Awareness of clinical information clearly improved performance. Diagnostic 
performance of studies in which readers were fully blinded was lower than in studies in 
which readers were aware of all clinical information except for results of other imaging 
modalities. The largest difference was observed for PET (AUC 0.91 for full blinding vs. 
0.98 in case of awareness of clinical data). This finding is in agreement with clinical 
experience that knowledge of the clinical information of the patient is considered 
crucial to achieve sufficient diagnostic performance, particularly for PET. These 
findings underline the necessity for clinicians to provide radiologists and nuclear 
physicians with full information about the patient’s clinical status and the importance 
for radiologists and nuclear physicians to be involved in multidisciplinary management 
teams, where they are confronted with the clinical situation.  
One established modality that has been used increasingly in the last decade - in 
particular for the follow-up of patients with suspected local recurrence after surgery for 
rectal cancer - is MRI.71 Although MRI has shown to be feasible for the detection of 
local recurrences, its yield is not high enough to warrant routine use in the follow-up of 
rectal cancer patients.72, 73 The single study that evaluated whole-body MRI showed 
good results, but more evidence is needed to establish the role of MRI in whole-body 
imaging for colorectal cancer.  
Limitations 
There are some limitations to this study. The first important issue is that this is a 
meta-analysis of published studies and therefore heterogeneity between studies is 
present. To account for this heterogeneity we performed subgroup analyses according 
to factors that were likely to cause heterogeneity and still found that CT had lower 
diagnostic performance than PET and PET/CT. However, because of the relatively 
small number of studies per modality, simultaneous correction for more than one study 
factor was not feasible, making our level of evidence less robust. Moreover, residual 
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heterogeneity may have remained unexplained due to some unmeasured or unreported 
study characteristics, which is inherent to meta-analysis based on published data.  
Second, in all studies a combination of pathology and follow-up was used as the 
reference standard. However, undetected lesions will not be discovered until they 
become visible with imaging and therefore there is a chance for verification bias. Most 
studies that used follow-up as the reference standard had a follow-up time of at least 6 
months. However, small missed lesions might become visible after a longer interval. 
Verification bias could then lead to overestimations of accuracy.  
Third, because we aimed to evaluate whole-body staging for the detection of both 
local and distant recurrences of colorectal cancer in patients with suspected recurrence 
based clinical findings or rise in CEA, we excluded studies which merely provided data 
on liver recurrence or local recurrence only.  
Last, most PET/CT studies in our meta-analysis used side-by-side comparison of 
single PET and single CT, and fused PET/CT was only scarcely used.  
Conclusion 
Our study suggests that for whole-body imaging of patients with a (high) suspicion 
for recurrent CRC during follow-up PET/CT is the most accurate imaging modality, 
closely followed by PET, which performs slightly lower than PET/CT on a patient 
basis. CT has lowest diagnostic performance.  
This meta-analysis explored diagnostic performance in the clinical setting in which 
patients had suspected local and/or distant recurrence based on clinical findings or rise 
in CEA. In current clinical practice CT is the mostly used modality for this type of 
patients and only when CT findings are equivocal PET or PET/CT is performed. Our 
meta-analysis shows that instead of CT as the first line imaging modality, PET/CT 
might be the recommended modality for patients with suspected local or distant 
recurrence based on clinical findings or rise in CEA. In such patients, a negative CT 
result does not seem to help in excluding a recurrence and should be followed by 
PET/CT anyhow. Furthermore, when CT findings are equivocal, PET/CT is needed 
to further characterise lesions and when CT detects malignant lesions, PET/CT is 
obligatory to search for additional metastases when curative surgery of the malignant 
lesions is considered. However, while interpreting these results one should keep in 
mind that there were some limitations of this meta-analysis with regard to 
heterogeneity and number of studies, which make the estimate of diagnostic 
performance less precise and less definitive. Furthermore, whether implementation of 
this recommended diagnostic strategy is feasible in clinical practice will also depend on 
the cost-effectiveness of this approach.  
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Wait-and-see studie: visie van de patiënt 
Deze thesis is voornamelijk gericht op de wetenschappelijk en medische kant van 
wait-and-see policy na chemoradiatie. Echter, de mening en visie van de patiënt is ook 
erg belangrijk. Tijdens de studies is het opgevallen dat de patiënt een heel andere 
mening heeft dan de betrokken behandelend arts. Om aandacht te besteden aan dit zeer 
belangrijke patiëntenperspectief hebben we een interview afgenomen bij een patiënte 
die nu 2,5 jaar aan de wait-and-see studie deelneemt. Zij had een lage T3N2 
rectumtumor die geheel in remissie is gegaan na chemoradiatie, waarop ze vanuit een 
ander ziekenhuis naar het MUMC werd verwezen om te evalueren of ze zou kunnen 
deelnemen aan de wait-and-see studie.  
Eerste reactie 
De eerste reactie van patiënte toen ze te horen kreeg dat haar tumor door de 
chemoradiatie verdwenen leek te zijn: ‘Fantastisch! Maar eigenlijk geloof je het niet 
meteen.’ Vooral in de omgeving werd er nuchter gereageerd en er werd zelfs 
gesuggereerd dat er misschien wel nooit sprake van een tumor was geweest. De 
bevinding had veel impact op patiënte omdat het pad eigenlijk al uitgestippeld was: 
‘Alles zou weggehaald worden en ik zou een stoma krijgen, het stoma was al 
aangetekend op mijn buik. Dan hoor je dat het waarschijnlijk weg is en dan weet je het 
niet meer. Je durft eigenlijk niet te hopen dat het zou kunnen zonder operatie. Ik had er 
via mijn radiotherapeut al wat over gehoord, maar die had duidelijk gemaakt dat het 
nog in de kinderschoenen stond’.  
 
Vervolgens werd ze naar Maastricht verwezen, omdat de behandelend arts het erg 
interessant vond dat de tumor weg was. Hij belde ’s avonds en zei: ‘Ga maar gewoon 
naar Maastricht’. Ze was wel angstig dat de behandelend arts haar toch gewoon ging 
opereren, terwijl dit volgens patiënte ‘eigenlijk altijd later nog kan’.   
 
In de periode tussen verwijzing en de afspraken in Maastricht was er eigenlijk 
weinig tijd om na te denken. ‘Je kent de ins en outs niet, je bent een leek. Je bent ook 
erg gereserveerd om je aan de optie over te geven, je beschermt jezelf tegen te veel 
hoop, ondanks dat stemmetje in je hoofd’.  
 
In Maastricht bleek na een aantal onderzoeken dat ze in aanmerking kwam voor 
deelname aan de studie. In Maastricht werden voor- en tegens van deelname aan de 
studie uitgebreid besproken, deze informatie werd als heel objectief ervaren. ‘Het was 
zo veel logischer wat in Maastricht werd verteld, dan wat er in mijn andere ziekenhuis 
(bij diagnose) was gezegd. Daar werd een radicale operatie geboden met een stoma en 
misschien was een anussparende operatie mogelijk, wat allemaal gepaard zou gaan met 
veel langdurige complicaties, zoals incontinentie. Maar ik dacht: het is weg, waarom ga 
je dan opereren? Je wordt zo vaak gecontroleerd en daar voel je je safe bij. Ze zitten er 
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zo kort bovenop, als het weer de kop op steekt, dan kan het dán weggehaald worden, 
maar dat is dán. Je leeft van tevoren.’ 
Voor- en nadelen 
Als we haar vragen naar de nadelen en risico’s van de studie, die ook uitgebreid 
aangekaart werden bij de uitleg over de studie, geeft ze aan dat de voordelen duidelijk 
opwegen tegen de nadelen. ‘Die informatie heeft me niet argwanend of angstig 
gemaakt. Er waren zo veel voordelen. Die kans laat je niet lopen.’ Desgevraagd geeft ze 
aan wat de voordelen zijn. ‘Je wordt zo vaak en met korte tussentijd gecontroleerd en 
dan ga je weer blij de deur uit. Dan heb je thuis geen zorgen meer als je gecontroleerd 
bent. Ik heb heel erg genoten van de dingen na een controle. Je weet: ze hebben me 
binnenstebuiten gekeerd. En natuurlijk is het vermijden van een stoma een ander 
voordeel.’ We zien vaak in de praktijk dat mensen het vermijden van een stoma 
(tijdelijk of permanent) een belangrijk voordeel vinden. Als we de patiënte vragen of ze 
bij een hoger gelegen tumor, waarbij geen permanent stoma nodig is, ook voor 
deelname aan de studie had gekozen, antwoordt ze met overtuiging dat ze nog steeds 
had deelgenomen. ‘Het is toch een zware operatie. Ik heb familieleden die dit ook 
ervaren hebben met veel ellende achteraf.’ 
Een belangrijk risico van de studie is dat het niet met 100% zekerheid is vast te 
stellen dat de tumor echt weg is door de chemoradiatie. ‘Daar denk je heel even over na, 
maar daar geef je niet aan toe. Wat heeft dat voor zin? Je hebt gekozen voor deze weg 
en het geeft zoveel meer comfort in je leven. Ik heb er zo weinig last van ondervonden, 
van de behandeling, van alles. Ik heb altijd gewoon door kunnen werken. Anderen 
hebben zoveel ellende en dan weegt dat zo op tegen de risico’s. Misschien is het dan wel 
gezond om een heel klein beetje struisvogel te spelen en te denken: als het teruggroeit, 
dat zien we dan wel weer. Ik denk dat niemand zekerheid heeft.’  
Wanneer slaat de balans van voordelen en nadelen om? ‘Als de artsen zouden 
zeggen dat de kans groot of reëel is dat er ergens iets anders de kop op steekt of dat er 
hoge risico’s waren. Dan heb ik een grotere kans om met een stoma te blijven leven dan 
om zonder stoma te leven. Maar jullie waren wel erg voorzichtig en duidelijk. Ik heb 
daar vertrouwen in gehad.’ Ze geeft wel aan dat patiënten het goed moeten begrijpen 
en ook moeten weten waar ze aan beginnen. ‘Uitleg is heel belangrijk. Je moet het als 
patiënt wel afwegen. Als die mensen hiervoor kiezen zonder erover na te denken en het 
komt terug, dan heb je straks een patiënt aan je tafel zitten, die zegt: “ja, als je me dat 
had gezegd…” Maar het is je eigen verantwoording en je eigen lijf. Dat kan niemand 
voor je beslissen. Je moet de mensen de mogelijkheid geven en that’s it.’  
De familie speelt ook een rol in de keuze. ‘Je staat ook niet alleen voor die keuze. Ik 
ben best eigenzinnig, ik doe precies wat ik zelf wil. Mijn familie weet gewoon dat je dat 
besluit neemt voor jezelf. Ondanks dat ze wel wat bang waren, accepteerden ze dat wel. 
Maar als de balans van voordelen en nadelen minder gunstig was geweest, dan had ik 
waarschijnlijk ook geen steun van mijn man en kinderen gekregen.’ 
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Huidige situatie 
Het gaat nu heel goed en ze voelt zich nog steeds erg tevreden met haar deelname 
aan de studie. ‘Ik ben actief en we wandelen veel met de honden. Ik heb nog wel soms 
pijn rond mijn bekken, maar dat zal wel van de bestraling zijn. Dat zijn dingen daar 
moet je mee leren leven, dan ga ik even zitten.’ Deelname aan een experimentele studie 
voelt voor haar heel speciaal. ‘Ik denk dan een stapje verder: hoeveel mensen lopen 
dadelijk onnodig rond met een stoma? Na een zware operatie. Hoe meer mensen aan die 
studie mee doen, hoe bereikbaarder het wordt, toch? Ik heb zoveel goede reacties gehad 
van andere mensen: “wauw, hoe kom je daar terecht?” Ik zou het anderen ook 
adviseren. Ik weet ook wel dat ik geluk heb gehad. Mensen waarbij de tumor niet weg 
is, die kunnen niet voor deze keuze staan.’ 
Deelname en controles 
De controles maakten haar alleen in het begin wat onzeker, maar dat is met de tijd 
langzaam verdwenen. De controles zijn niet echt zwaar, maar de endoscopie vind ze 
vreselijk. ‘Daar heb ik tot de dag erna last van. Van de scans heb ik totaal geen last. Na 
de controle kan ik het helemaal loslaten. Als de uitnodigingen weer kwamen, dan werd 
je er weer mee geconfronteerd, dan ga je er over nadenken. Maar ik ben nooit echt bang 
geweest. Ik ben wel blij als je bevestigd hebt gekregen dat het nog altijd prima is. Ik 
ben nog nooit naar een controle gekomen met het idee: het zit helemaal fout. Daarnaast 
was de begeleiding geweldig, op een gelijk niveau met mij. Het beestje werd bij de 
naam genoemd en er was geen afstand tussen de artsen en mij. Ik kreeg in een ander 
ziekenhuis alleen te horen wat de arts goed vond voor me, maar dat is toch onzin, het is 
mijn lijf. Er is ook veel begrip vanuit de artsen, je wordt gebeld met een uitslag in de 
avond als het ziekenhuis eigenlijk al dicht is, omdat ze weten dat je onzeker bent. Dat 
geeft je een goed gevoel.’ Ook haar familie maakt zich geleidelijk minder zorgen. ‘De 
aandacht verslapt, de angst en onzekerheid zijn weg. De gedachte eraan gaat weg. Dat 
gaat geleidelijk en komt ook door de begeleiding.’  
De duur en frequentie van de follow-up is prima, maar af en toe had ze toch ook 
fasen dat ze er een hekel aan had om naar het ziekenhuis te gaan. ‘Je hebt al zoveel in 
het ziekenhuis gezeten.’ Dan was ze blij dat ze weer drie maanden niet meer naar het 
ziekenhuis hoefde te gaan. ‘Maar later als het allemaal zijn gangetje gaat, dan heb je 
daar geen moeite meer mee. Dan is het wel lekker, dan kan ik er weer een half jaar 
tegen. Dat geeft een goed gevoel. Ik zou niet willen stoppen met de controles, dat geeft 
toch geen lekker gevoel. Het doet je toch goed als het goed gaat en je gerustgesteld 
bent.’ Desgevraagd geeft ze aan dat ze momenteel nergens zorgen over heeft: ‘Eerlijk 
niet’.  
Nieuwe opties en de perceptie van artsen 
We vertellen dat er andere manieren (bijvoorbeeld hogere doses bestraling of 
andere chemotherapie) zijn om de kans op een complete respons te verhogen, echter dit 
gaat gepaard met meer bijwerkingen en/of complicaties. Ze geeft aan dat dit iets is wat 
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we zeker moeten gaan aanbieden aan patiënten. Ze is zelfs erg verbaasd dat we het niet 
al aanbieden, ook al hebben de patiënten dan toch nog kans dat het niet helemaal 
weggaat en alsnog een operatie nodig is. ‘Als je de kans hebt dat je de meest voordelige 
uitkomst hebt, dan ga je daar toch voor! Ondanks de bijwerkingen. De operatie is toch 
een veel ingrijpendere bijwerking met dat stoma. Ik zou altijd hiervoor kiezen! Ben ik 
daar apart in?’ 
We geven aan dat artsen dit over het algemeen geen goed idee vinden en dat wait-
and-see überhaupt door veel artsen argwanend wordt bekeken. Hierop reageert ze vol 
verbazing: ‘Echt waar? Ik vind het belangrijkst wat de patiënt ervan vindt. Waar slaat 
dat nou op! Je kwaliteit van leven ervaar je toch zelf, daar kan een dokter toch niks over 
zeggen. Ik bepaal zelf wat ik belangrijk vind.’  
De wait-and-see optie wordt dus zelden aan patiënten aangeboden en er zijn weinig 
patiënten van op de hoogte. Dat merkt ze ook aan de reacties van anderen aan wie ze 
haar verhaal verteld. ‘Zulke mensen zeggen dan “dat kan niet!”, maar het is wel zo! 
Eigenlijk is het raar dat dat bestaat. Het is niet eerlijk, deze mogelijkheid wordt andere 
mensen onthouden. Het is ieders eigen keus, maar er zijn vast ook mensen die 
misschien zo bang zijn dat ze toch voor een operatie kiezen.’ 
We leggen uit dat de terughoudendheid van de artsen vooral wordt veroorzaakt 
door de angst dat het toch niet helemaal weg is en er dus een risico is op teruggroei en 
eventueel ook uitzaaiingen in de tussentijd. ‘Ik kan er niet bij dat jullie zoveel moeite 
moeten doen om dokters te overtuigen. Waarom? Met mijn simpele verstand kan ik me 
daar niks bij voorstellen. Het is toch een veel voordeligere, gunstigere, minder 
belastende behandeling dan een operatie? Wat nou als het bij mij terugkomt als een 
erwt, dan zit het er niet langer dan 3 maanden. Maar ik heb maanden daarmee 
rondgelopen bij de diagnose tijdens de behandeling en daar maken ze zich dan geen 
zorgen over! Ja, het is te druk en er is te weinig personeel en er zijn wachtlijsten en in 
die tijd mag je wel met een tumor rondlopen. Van dat risico ben ik me altijd bewust van 
geweest. In theorie kan er toentertijd al iets in je lichaam verspreid zijn. Dan zeg ik: ik 
ben nu drie jaar verder en gezond.’  
 
De artsen willen graag definitief bewijs dat wait-and-see policy veilig is. Om 
dergelijk definitief bewijs te leveren voor wait-and-see zou in de toekomst een 
onderzoek nodig zijn waarin deelnemers via loting worden toegewezen aan de 
behandeling die u nu volgt of toch een operatie. Er is dan dus een kans van 50% om 
voor de wait-and-see groep te loten en er is dan dus ook 50% kans dat u voor de 
operatieve behandelingsgroep loot. We vragen haar wat ze hiervan vindt en of ze 
daaraan mee zou doen. ‘Dat zou voor mij niks zijn. Ik zou er niet aan meedoen. Bij mij 
zou niet worden geopereerd, ik wil geen kans lopen om geopereerd te worden.’ 
Ze is nu al 2,5 jaar recidiefvrij en dat zou haar visie op de studie kunnen 
beïnvloeden. Zou ze indien ze opnieuw voor de keuze zou staan, echt niet aan een 
dergelijke gerandomiseerde studie deel willen nemen, zeker bij twijfel? ‘Je prakkiseert 
er zo lang over en dan weet je wat je wilt. Ik kan me dat niet voorstellen, ik vind het 
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een beetje raar. Ik kan me niet voorstellen dat als je dat aan iemand voorlegt, misschien 
een enkeling, dat die dan zegt: ‘oké, nou dan trek maar een lootje en dan zien we wel 
wat je met me doet.’  
We vragen haar hoe we die dokters kunnen overtuigen van het feit dat ze niet zo 
terughoudend hoeven te zijn. ‘Ze moeten gewoon reëel zijn, ze doen alsof ze alles in de 
hand hebben en alsof ze alle angst en onzekerheid kunnen voorkomen door heel 
rigoureus in te grijpen. Maar als puntje bij paaltje komt, als je een oncoloog 100% 
zekerheid vraagt, waar je dan ook in je lichaam kanker hebt, dat krijg je niet! Dat zegt 
hij nooit. Waarom weigeren ze je dan nou zo’n gunstige behandeling, met als reden dat 
de arts geen angst en onzekerheid meer heeft. Je hebt altijd angst en onzekerheid en er 
is altijd een risico. Is dat risico dan groter met jullie behandeling?’ We geven aan dat de 
artsen denken dat het risico op een slechtere oncologische uitkomst groter is met wait-
and-see policy, doordat je niet 100% zeker kan weten dat het weg is na de 
chemoradiatie. ‘Je kunt ook overdrijven, of niet? Heeft je leven dan nog kwaliteit als je 
uit angst zo ver gaat? Door angst gedreven, is dat kwaliteit? Als je een tijdje zonder 
stoma kan leven en je door teruggroei van de tumor later een stoma krijgt, dan heb je 
toch langer zonder stoma geleefd. Ik heb een voorbeeld in de familie met een 
vergelijkbare tumor, die heel veel ellende heeft na de operatie. Ook emotioneel komt hij 
dat wereldje van het ziekenhuis niet uit. Hij is al 4 jaar een patiënt, en ik heb daar geen 
last van. Dat is zo’n verschil in kwaliteit.’  
Conclusie 
Uit het relaas van deze patiënte merken we dat het perspectief van de patiënten 
vrijwel haaks op het perspectief van de meeste artsen staat. Blijkbaar liggen de 
prioriteiten voor patiënten anders dan voor hun artsen. Een belangrijk aspect is 
controle: een patiënt moet zelf de controle houden en zelf keuzes kunnen maken. 
Ondanks de uitleg over de vele onzekerheden en risico’s die de artsen zo argwanend 
maken, geeft ze aan dat de onzekerheden en risico’s van de artsen voor haar niet 
meetellen, het is immers haar leven en zij wil zelf beslissen. Daarom is uitleg en 
communicatie zo belangrijk, waarbij ook alle opties, inclusief wait-and-see policy, aan 
bod moeten komen.  
Opvallend is dat de frequente controles als een duidelijk voordeel van de studie 
worden ervaren. Het geeft de patiënt veel geruststelling en zelfs meer geruststelling 
dan de wetenschap dat alles weggehaald is. Deze overweging ervaren we vaker bij 
andere patiënten.  
Een gerandomiseerde studie lijkt haar niet haalbaar, want slechts enkelingen 
zouden de keuze uit handen willen geven. De kans op het achterwege laten van een 
operatie is te aantrekkelijk om dit over te laten aan het lot.  
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Discussion  
During the last decades progress in the treatment of rectal cancer has resulted in a 
very effective local control. This excellent local control is mainly due to an optimal 
surgical technique, the total mesorectal excision, and the introduction of neoadjuvant 
(chemo)radiation.1-3 In our region, the 5-year probability for a local recurrence for all 
tumours, including the locally advanced tumours, is approximately 2-3%. However, the 
combination of total mesorectal excision and (chemo)radiation leads to a high rate of 
treatment related morbidity and mortality and to substantial changes in bowel, urinary 
and sexual function.4, 5 Also, a (temporary or permanent) colostomy is often necessary. 
It has been observed that some patients respond very well to chemoradiation and the 
probability of pathologic complete response (ypT0N0) is approximately 15-20%.6 
Several studies suggested that such a complete response to chemoradiation is indicative 
of a favourable biological tumour profile and is associated with excellent prognosis.7-9 
Therefore, the question can be raised whether it is feasible to reduce morbidity without 
compromising local (or distant) control by treating complete responders to 
chemoradiation with less invasive surgery or even omission of surgery (combined with 
intensive follow-up), the so-called wait-and-see policy. 
 Paradigm shift to less invasive treatment 
The first main aim of this thesis was to evaluate the feasibility, safety and potential 
benefits of a wait-and-see policy for complete responders to chemoradiation. The 
feasibility of a wait-and-see policy depends on a set of prerequisites, which were 
addressed in this thesis and will be discussed.  
 
The first prerequisite is to verify that patients with complete pathologic response 
have a better prognosis than patients who have remaining tumour after 
chemoradiation. In this respect, results from previous studies were equivocal, with 
some reporting significantly better survival8, 10, 11, whereas others failed to find 
statistically significant differences in long-term outcome.12-14 This variation in results 
may be due to small sample sizes and for this reason a pooled analysis was performed 
with individual patient data from multiple studies (chapter 2). Included were studies that 
evaluated prognosis of patients with locally advanced rectal cancer, who were treated 
with total mesorectal excision and chemoradiation. Such a pooled analysis has more 
power than individual studies to detect relevant differences in long-term survival 
according to response to chemoradiation and can also provide a reliable estimate of the 
long-term survival of complete pathologic responders. This estimate can serve as a 
benchmark for comparison of the results of a wait-and-see policy with standard 
treatment by total mesorectal excision. The pooled analysis of individual patient data 
from 14 international centres established that local control, distant-metastasis free 
survival, disease-free survival and overall survival are excellent for complete 
responders treated with surgery. Their prognosis is significantly better than patients 
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with residual tumour after CRT.6 The prognosis of patients with a complete response 
after CRT and surgery for rectal cancer should be used as a reference when evaluating 
less invasive treatment after CRT in clinical complete responders. With such an 
excellent prognosis for complete responders treated with surgery, the bars are set high 
for less invasive treatment after CRT.  
 
A second important prerequisite is accurate identification of patients eligible for a 
wait-and-see policy, i.e. the clinical complete responders to chemoradiation. In chapter 4 
the selection of patients with a complete tumour response for a wait-and-see policy in 
our pilot study is described. MRI played a central role in our response assessment 
strategy. The main issue of restaging rectal cancer after CRT is that many physicians 
are worried that unrecognized residual tumour after chemoradiation will lead to local 
recurrences. Standard T2-weighted MRI can identify complete responders after 
chemoradiation, but only when the rectal wall has regained its normal aspect (which 
occurs only in 25% of the patients15); when there is residual fibrosis or thickening of the 
rectal wall, T2-weighted MRI cannot discern small nests of residual tumour. Standard 
MRI misses only 2-8% of tumour remnants, which is relatively low.16, 17 But 
radiologists tend to overstage the presence of residual tumour because they do not 
want to run the risk of missing residual tumour.16, 18-20 Therefore, there is a tendency 
towards underestimation rather than overestimation of the number of patients with a 
complete response with standard T2-weighted MRI. Due to this cautious approach 
many patients with a complete response are missed (60-100%).17 With the addition of 
diffusion-weighted sequences to standard MRI it can be more accurately assessed 
whether the residual hypo-intense mass in the rectal wall on T2-weighted MRI 
indicates true residual tumour (as indicated by high signal on b1000 diffusion-weighted 
imaging) or fibrosis only (absence of signal on b1000 diffusion-weighted imaging). As a 
consequence, the risk of missing residual tumour remains low, whereas the percentage 
of missed complete responses decreases to 36-44%.17 During the wait-and-see study we 
experienced that endoscopy is an excellent tool for tumour response evaluation after 
chemoradiation.21, 22 Endoscopy has the ability to correct both over- and understaging 
of MRI. Therefore, we feel that endoscopy is an indispensable tool in response 
evaluation when one is considering less invasive treatment after chemoradiation.  
In addition to the evaluation of the response of the primary tumour it is important 
to evaluate the lymph nodes, which are often involved at diagnosis. Whereas for 
primary nodal staging standard MRI is only moderately accurate, nodal restaging after 
CRT has been reported to be more reliable and therefore facilitates selection of patients 
with a negative node status after CRT.20, 23 Therefore, the combination of standard 
MRI, diffusion-weighted MRI and endoscopy seems sufficiently accurate to identify 
complete responders eligible for wait-and-see policy, with an acceptable small risk of 
overlooking residual tumour. 
The third prerequisite is to provide an effective but also tolerable follow-up 
strategy. The follow-up strategy in the pioneer study from Habr-Gama et al. was 
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mainly based on very frequent endoscopic examinations: up to monthly in the first 
year.24 We chose a follow-up strategy with a lower frequency but incorporated MRI in 
addition to endoscopy. Patients did not object to this follow-up strategy, which was 
reflected in the 100% compliance. During follow-up we found that when the typical 
white scar with teleangiectasia (typical endoscopic feature of a complete response) 
remains unchanged during follow-up, it can be assumed that there is a sustained 
complete response.21 MR follow-up features of sustained complete response are hypo-
intense bowel wall thickening that does not change over time or a persistent 
normalized rectal wall.15 The only thing that often does change and is not associated 
with a recurrence is the gradual decrease in submucosal edema.15 Chapter 3 describes 
the experience and results of this follow-up strategy. Until February 2013, 44 patients 
with complete response had been included in a prospective pilot study on the effects of 
a wait-and-see policy. After a follow-up period of 19 (1-91) months, two patients had a 
recurrence that could be detected early and radically resected based on relevant 
features at endoscopy and MRI. One other patient developed peritonitis carcinomatosa 
after 2,5 years of follow-up. 
 
When considering omitting a treatment for cancer, this should lead to benefits in 
other aspects. As mentioned earlier, total mesorectal excision is associated with 
potentially dangerous surgical complications and morbidity on the long term.25 Also, 
there is a substantial mortality risk from this surgery, particularly in the elderly.26 The 
benefits of wait-and-see policy should be derived from gain in functional outcome. It is 
obvious that surgery-related mortality will be absent when leaving out surgical 
treatment. With regard to urogenital and bowel function it is not clear whether 
omission of surgery indeed leads to improvement of residual function compared to 
surgery. It is possible that the chemoradiation has long-term side effects on bowel 
function, which normally go undetected, because the rectum is resected. Moreover, a 
substantial benefit that can be gained from omission of surgery is avoidance of a 
colostomy. Our pilot study showed that in patients following wait-and-see policy a 
permanent colostomy could be avoided in half of the paints and a temporary colostomy 
in the other half (based on height of the tumour). On the contrary, all control patients 
with a complete response who were treated with TME needed a colostomy, of which 
almost half were permanent. When comparing the surgically treated patients without a 
colostomy with the patients who followed wait-and-see, the wait-and-see patients had 
significantly better bowel function and less urogenital problems. Compared to baseline 
the complete responders following wait-and-see policy experienced less alterations in 
bowel function. Furthermore, patients who undergo wait-and-see felt less impaired in 
daily activities by their bowel function than the operated patients with a complete 
response.21  
 
Following the previous paragraphs, physicians and patients considering a wait-
and-see policy face a trade-off between oncological control and functional gain. On the 
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one hand, surgery-related morbidity and mortality will be absent when leaving out 
surgical treatment. On the other hand, a wait-and-see policy will inevitably harbour the 
risk of recurrence in some patients, given the fact that staging will never be entirely 
perfect. The decision on this trade-off is a shared decision made by both the physician 
and the patient, since only the patient can decide which risk he or she is willing to take 
for how much functional gain. Shared decision making, is increasingly implemented in 
clinical practice and is based on several ethical principles, such as a patient’s autonomy, 
benefits and risk assessment and information to the patient.27 The interview with a 
patient in chapter 8 illustrates how valuable this shared decision making is for the 
patient and that this patient was willing to accept a certain risk to win functional gain. 
The risk that this particular patient was willing to take was much higher than her 
primary treating physician deemed acceptable. The acceptable risk will be different for 
each patient and therefore intensive informing of the patient is very important to come 
to an individual decision.  
Paradigm shift from local to distant control 
The second main aim of this thesis was to identify areas for further improvement of 
prognosis of patients with rectal cancer. From chapters 5-7 can be concluded that for 
improvement of prognosis distant control is crucial. Chapter 5 shows that MRI-based 
differentiated treatment according to the risk of a patient for a local recurrence results 
in excellent local control. However, the risk for distant metastasis is rather high. 
Adjuvant chemotherapy is one of the mainstays of distant control in patients with 
locally advanced rectal cancer. Patients who are treated with neoadjuvant 
chemoradiation usually have involved nodes at diagnosis and are therefore often treated 
with adjuvant chemotherapy. Given the absence of involved lymph nodes in complete 
responders and the relatively low risk for distant metastasis, the benefit of adjuvant 
chemotherapy might be limited in these patients. Chapter 7 presents the results from a 
pooled analysis of individual patient data from observational studies, which compared 
prognosis in patients with and without treatment with adjuvant chemotherapy. The 
results point in the direction that in patients with a complete response the benefit from 
adjuvant chemotherapy is considerably smaller than in patients with residual disease 
after chemoradiation. Given the fact that the absolute risk for metastasis in patients 
with a complete response is already very low6, the use of adjuvant chemotherapy is 
questionable. Unfortunately, the data in chapter 7 are not derived from randomized 
trials and therefore, there is a risk for confounding by indication. The results are in 
accordance with a paper by Capirci et al. that questioned the benefit of adjuvant CT for 
complete responders after CRT7, but contradict findings from a subgroup analysis of a 
randomized EORTC trial.28 Definite answers on the benefit of adjuvant chemotherapy 
in patients treated with neoadjuvant CRT will have to be provided by new randomized 
studies or from pooled analysis of randomized data.  
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Future perspectives 
This thesis provides preliminary evidence on the feasibility and safety of less 
invasive treatment for complete responders after CRT for locally advanced rectal 
cancer. The preliminary results from this thesis will have to be confirmed in larger 
studies and after a longer period of follow-up. A randomized controlled trial would be 
the preferred study design to provide definite evidence, but it is unlikely that a 
randomized controlled trial will be feasible. First, there is the unwillingness of patients 
to take part in a study in which chance will determine whether they would be treated 
with or without surgery because patients often like to be involved in such a decision. 
Second, an equivalence trial will be necessary, which requires a very large sample size.29 
It is unrealistic to expect that such a large sample size can be obtained, given the low 
prevalence of a complete response.6 Probably, a large prospective observational 
multicenter study will be the most feasible design to obtain evidence.  
The role of MRI in selecting patients with a complete response has been studied 
quite extensively, but there is only limited evidence for the validity of diagnosis using 
endoscopy.30 Therefore, studies will have to address the additional diagnostic value of 
endoscopy to MRI for selection of complete responders. Additionally, the role of 
endoscopy and MRI in the follow-up during wait-and-see policy should be 
consolidated, as the currently available evidence is limited.21, 30 Also, as described 
earlier we still miss some residual tumours in a small number of patients. This occurs 
in most cases in patients with only small islets of microscopic residual tumour which 
are not picked up by (diffusion-weighted) MRI. To further reduce this small risk, more 
functional types of imaging (e.g. molecular imaging or perfusion based imaging) can 
probably be of help on this issue and sould be the focus of future research.  
The option of transanal endoscopic microsurgery (TEM) after chemoradiation for 
good and complete responders was not addressed in this thesis, but is of major 
importance. Several studies are currently recruiting patients to evaluate the 
complication rates and local control after TEM in irradiated patients.31 Future studies 
will have to show which patients are likely to benefit from TEM and which patients can 
be treated with wait-and-see policy. 
There is a rising interest in techniques to increase complete response rates after 
chemoradiation. The main rationale for this interest is to increase the number of 
patients who might be eligible for less invasive treatment. However, it is yet unclear 
whether patients who achieve a complete response after a different radiation schedule 
than is currently applied have the same prognosis as patients who achieve a complete 
response after standard chemoradiation (capecitabine with 28x1.8 Gy or 25x2 Gy). 
When less invasive treatment after chemoradiation is proven to be safe the first step 
would therefore be to evaluate the prognosis of patients with a complete response after 
alternative radiation schedules, before considering to offer less invasive treatment to 
these patient groups.  
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With regard to the benefit of adjuvant chemotherapy, it would be an important 
next step to pool data from randomized trials in which the administration of adjuvant 
chemotherapy was randomized in patients treated with neoadjuvant chemoradiation. 
Such a pooled analysis (as recently suggested in a systematic review by Bujko et al.32) 
could provide more robust evidence on the value of adjuvant chemotherapy in 
complete, good and poor responders to chemoradiation. However, given the increasing 
number of trials evaluating neoadjuvant chemotherapy, the question whether the 
administration of adjuvant chemotherapy should depend on the degree of response to 
CRT might not be of the same relevance in the future.  
Recommendations 
For clinical practice 
This thesis has shown that a wait-and-see policy can be considered in strictly 
selected patients with a complete response. It can only be applied when the 
combination of high quality MRI with accurate nodal staging and endoscopy is 
available for selection and follow-up. During follow-up any change in MR images or at 
endoscopy should be considered a recurrence. Data on patients with a complete 
response who follow a wait-and-see policy should be prospectively and precisely 
collected, to assure adequate follow-up and monitoring of patients. It can be considered 
to pool data from patients following a wait-and-see policy from multiple centers in one 
dataset, as has been recently suggested by a Danish study group.  
For patients with a complete response the absolute risk for metastasis is small and 
therefore the relative effect of adjuvant chemotherapy is limited. It can thus be 
considered to omit adjuvant chemotherapy for these patients. Conversely, in patients 
with residual disease there is a potential benefit of adjuvant chemotherapy and this 
option should be discussed with these patients. 
For research 
Staging  
There is a need for an improvement of the detection of low volume residual cancer. 
Because of limitations of morphological imaging, new studies on imaging should focus 
on functional imaging modalities (e.g. dynamic-contrast enhanced MRI, perfusion CT) 
which can provide information with for example targeted markers and detect changes 
in texture of tissues, which cannot be discerned visually.   
Furthermore, this thesis supports the initiation of a prospective study to evaluate 
the value of endoscopy in response evaluation after CRT.  
Treatment  
More evidence in a larger patient sample should be obtained on the safety of less 
invasive treatment after CRT. The results as presented in this thesis can be used in the 
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set-up of a large prospective multicentre study. Although a randomized study would 
theoretically be the desired study design, a prospective observational study will 
probably be the most feasible design.  
Because of the lack of sufficient evidence on the effect of adjuvant chemotherapy in 
rectal cancer, a meta-analysis of data from the large randomized trials on adjuvant 
chemotherapy (EORTC trial, QUASAR study) should be performed to determine the 
value of adjuvant chemotherapy after (chemo)radiation for patients with rectal cancer 
and identify factors that determine the benefit of adjuvant chemotherapy for different 
patient groups.  
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Summary 
 The main aims of this thesis are (1) to evaluate the feasibility of a shift towards less 
invasive local treatment of rectal cancer in patients with complete response to 
neoadjuvant chemoradiation and (2) to identify areas for further improvement of the 
prognosis of patients with rectal cancer. The currently available evidence and status 
with regard to these aims are summarised in chapter 1, the introduction.  
Part I – Paradigm shift to less invasive treatment 
 To be able to treat selected patients with less invasive treatment it is important to 
have a reliable estimate of the prognosis of patients who have undergone standard 
treatment (TME) in order to compare outcome after less invasive treatment with. In 
chapter 2 a pooled analysis of individual patient data is described with the aim to 
determine the long-term outcome of patients with a pathologic complete response (pCR 
after chemoradiation (CRT) and standard resection. These patients with a pCR are 
compared with patients with residual tumour after CRT. From 14 international 
hospitals 3105 patients were included, of which 484 had a pCR after CRT and surgery. 
Multivariable analyses showed that patients with a pCR have an excellent and 
significantly better prognosis than patients with residual tumour, with regard to local 
control, distant-metastasis free survival, disease-free survival and overall survival. 
When it is considered to offer less invasive treatment to these patients with a pCR, this 
less invasive treatment will have to compete with this excellent long-term outcome 
after standard treatment.  
 
In chapter 3 less invasive treatment is evaluated in a pilot study. In 21 patients with 
a clinical complete response after CRT wait-and-see policy was performed. With wait-
and-see policy surgery is omitted and regular follow-up is performed. Patients were 
identified to have a clinical complete response with T2-weighted, diffusion-weighted 
and gadofosveset-enhanced MRI combined with endoscopy. Follow-up consisted of the 
same modalities, with additional CEA measurements and CTs of the thorax and 
abdomen. As a control group patients with a pCR after CRT and TME were identified 
from a prospective cohort study.  
After a mean follow-up of more than 2 years, only one patient who followed wait-
and-see policy had a small local tumour regrowth, that could be completely resected by 
transanal endoscopic microsurgery (ypT2). All other patients following wait-and-see 
policy are alive and disease-free. In the control group two patients died; one died from 
distant metastases and the other died as a consequence of complications from 
colostomy closure surgery.  
With questionnaires bowel function and quality of life were measured, which 
showed that both were significantly better in patients following wait-and-see policy 
than in the control group of patients with pCR after CRT and surgery.  
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Chapter 4 describes the MRI morphology of the rectum during follow-up of patients 
following a wait-and-see policy. Four distinct patterns could be identified, of which 
three comprised of fibrosis (minimal, full thickness and irregular fibrosis) and the 
fourth was characterised by a normalised rectal wall. These patterns do not show 
change during follow-up in case of a sustained complete response. In 26% of the 
patients edema was present in the first months after CRT. This edema normalised after 
longer follow-up times. In a patient who developed a local recurrence no specific 
changes were visible on T2-weighted MRI, but a subtle increase in signal intensity was 
identified at diffusion-weighted MRI.  
Part II – Paradigm shift from local to distant control 
 In chapter 5 the results of a multicentre study are reported in which treatment 
stratification was based on the risk for local recurrence as assessed with MRI. Patients 
were categorised into three groups according to their risk for a recurrence: early 
tumour, intermediate tumour and locally advanced tumour, which were treated with 
surgery only, surgery immediately after 5x5 Gy of radiation or surgery after 6-8 weeks 
of neoadjuvant CRT, respectively. The results show an excellent local control with a 
local recurrence rate of only 2.2%. However, the incidence of metachronous distant 
metastases was 16% and the incidence of death was 15% after a median follow-up of 41 
months. Therefore, it can be concluded that the MRI-based treatment strategies led to 
an excellent local control, but the main threat for prognosis is distant metastasis.  
 
The benefit of adjuvant chemotherapy for patients who have been treated with 
neoadjuvant CRT is evaluated in chapter 6. A specific interest was the benefit of 
adjuvant chemotherapy for patients with a pCR after CRT. This study is a continuation 
of the study as described in chapter 2. Again a pooled analysis of individual patient data 
was performed with data from 13 international hospitals. In total, 3313 patients were 
included. Multivariable analyses showed a probable absence of effect of adjuvant 
chemotherapy on long-term outcome in patients with a pCR. Probably, these results 
are linked to the excellent prognosis of these specific patients. Patients with residual 
tumour did have a clear benefit of adjuvant chemotherapy. Subgroup analyses showed 
that patients without involved nodes after CRT do benefit from adjuvant 
chemotherapy, whereas patients with involved nodes after CRT do not. These findings 
are in agreement with the hypothesis that the same factors that predict response to 
CRT are responsible for the sensitivity of tumour cells for adjuvant chemotherapy as 
well. This hypothesis has also been reported in the literature.  
 
Chapter 7 discusses which whole-body imaging modality is most accurate in 
detecting a recurrence in patients with a suspicion of a recurrence during follow-up of 
colorectal cancer. A meta-analysis was performed including 14 studies that evaluated 
whole-body PET, PET-CT and/or CT for recurrence detection in patients with 
suspected recurrent colorectal cancer. Only 1 study on whole-body MRI was identified. 
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The meta-analysis shows that PET-CT is the most accurate whole-body imaging 
modality to detect a local or distant recurrence in patients with colorectal cancer. PET-
CT detects almost all recurrences, is more reliable in case of a negative CT and is 
necessary when hepatic metastases are found to exclude the presence of extrahepatic 
metastases (which is an important flaw of CT). 
Part III – A patient’s perspective 
 Chapter 8 is an interview with a patient who is following the wait-and-see policy, 
which allows us see a patient’s perspective on this treatment strategy. This is an 
interesting point of view, because doctors generally regard the wait-and-see policy with 
great reserve. The aim of the interview was to evaluate the pros and cons of wait-and-
see policy for patients and to also examine the burden of the risk and follow-up. In our 
experience patients have a very positive attitude towards wait-and-see policy. They 
also bear the possible risks associated with wait-and-see policy consciously. 
Furthermore, the patient was asked whether she, if she again faced the choice to follow 
the wait-and-see policy or not, would agree to participate in a randomised controlled 
trial (in which she would be randomly assigned to surgery or the wait-and-see policy). 
She indicated to not be willing to participate in such a randomised trial, because she 
would then risk to be appointed to the surgery arm. This interview suggests that the 
most reliable method to provide definite evidence for the wait-and-see policy, the 
randomised trial, is not appreciated by patients. Therefore, before embarking on a 
randomised trial, its feasibility will have to be examined and alternative study designs 
should be explored.  
 

  
 
 
Dutch summary 
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Nederlandse samenvatting 
 De voornaamste doelen van dit proefschrift zijn (1) om de haalbaarheid van minder 
invasieve behandeling van patiënten met een complete respons na neoadjuvante 
chemoradiatie te evalueren en (2) gebieden te identificeren om de prognose van 
patiënten met een rectumcarcinoom te verbeteren. De huidige bewijslast en status met 
betrekking tot deze doelen staan in hoofdstuk 1, de introductie, beschreven.  
Deel I – Focus verschuiving naar minder invasieve lokale behandeling 
 Om minder invasief te kunnen behandelen bij een geselecteerde patiëntengroep is 
het van belang om ter vergelijking een indicatie van de prognose te hebben van 
patiënten die wel de standaard invasieve behandeling (TME) hebben ondergaan. In 
hoofdstuk 2 wordt daarom een gepoolde analyse van individuele patiëntendata 
beschreven met als doel de prognose van patiënten die een pathologisch complete 
respons (pCR) hebben na behandeld te zijn met chemoradiatie (CRT) en standaard 
resectie. Deze uitkomst wordt vergeleken met die van patiënten die wel resttumor 
hadden na CRT en standaard resectie. Vanuit 14 internationale centra werd de data van 
3105 patiënten geïncludeerd, waarvan er 484 een pCR hadden door de CRT. De 
multivariabele analyses toonden aan dat patiënten met een pCR een uitstekende en 
significant betere prognose hadden dan patiënten die resttumor hadden na de CRT, met 
betrekking tot lokale controle, metastasevrije overleving, ziektevrije overleving en 
algehele overleving. Als dus wordt overwogen om aan deze patiëntengroep een minder 
invasieve behandeling aan te bieden, moet deze minder invasieve behandeling 
concurreren met deze uitstekende prognose na CRT en standaard resectie.  
 
In hoofdstuk 3 wordt de proef op de som genomen: bij 21 patiënten met een klinisch 
complete respons na CRT wordt wait-and-see policy toegepast. Bij wait-and-see policy 
wordt geen operatie uitgevoerd, maar wordt de patiënt regelmatig gecontroleerd. De 
patiënten werden geselecteerd als klinisch complete responders met T2-gewogen, 
diffusie-gewogen en gadofosveset-versterkte MRI en endoscopie. De follow-up bestond 
ook uit deze modaliteiten gecombineerd met bepaling van het CEA en CT-scans van de 
thorax en het abdomen. Als controlegroep werden patiënten met een pCR na CRT en 
standaard resectie geïdentificeerd uit een andere prospectieve studie. Na een 
gemiddelde follow-up van meer dan 2 jaar was er één wait-and-see patiënt met een 
klein recidief na 22 maanden follow-up, dat met transanale endoscopische 
microchirurgie kon worden verwijderd (ypT2). Alle overige patiënten die wait-and-see 
policy volgen waren ziektevrij in leven. In de controlegroep zijn twee patiënten 
overleden; één als gevolg van metastasen en de ander door een complicatie na het 
sluiten van het colostoma.  
Met vragenlijsten werd de darmfunctie en daaraan gerelateerde kwaliteit van leven 
gemeten, waaruit bleek dat deze uitkomstmaten bij de wait-and-see patiënten 
significant beter waren dan bij de patiënten met een pCR na chirurgie.  
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Hoofdstuk 4 gaat in detail in op de MRI morfologie van het rectum tijdens follow-
up van de wait-and-see patiënten. Er werden vier MRI patronen geïdentificeerd bij 
patiënten met een klinisch complete respons. Drie van deze patronen bestaan uit 
fibrose: minimale fibrose, fibrose door de hele rectumwand heen en irregulaire fibrose. 
De vierde groep bestaat uit patiënten met een genormaliseerde rectumwand. De 
patronen ondergaan vrijwel geen verandering gedurende de follow-up bij persisterende 
complete respons. Bij 26% van de patiënten was in de eerste maanden van follow-up 
ook sprake van oedeem dat normaliseerde na langere follow-up duur. Bij de patiënt met 
een lokale teruggroei van de tumor werd op T2-gewogen MRI geen verandering 
gezien, echter op diffusie-gewogen MRI werd een subtiele toename in signaal gezien.  
Deel II – Focus verschuiving van lokale controle naar controle van 
afstandsmetastasen 
 In hoofdstuk 5 worden de resultaten van een multicentrische studie gerapporteerd 
waarbij de behandeling van patiënten werd bepaald door het risico op lokaal recidief 
zoals beoordeeld met behulp van MRI. Patiënten werden in drie groepen ingedeeld 
naar gelang het risico op een recidief: vroege tumor, intermediaire tumor en lokaal 
uitgebreide tumor, welke respectievelijk met alleen chirurgie, chirurgie direct na 5x5 
Gy bestraling en chirurgie 6-8 weken na neoadjuvante CRT werden behandeld. 
Mediane follow-up was 41 maanden. De resultaten tonen een excellente lokale controle 
met een lokaal recidiefpercentage van slechts 2.2%. Daar staat een incidentie van 
metachrone metastasen van 16% en sterfte van 15% tegenover. De op MRI gebaseerde 
behandelstrategie heeft dus een zeer gunstig effect op de lokale controle, echter 
metastasen vormen de belangrijkste bedreiging voor de prognose.  
 
Het belang van adjuvante chemotherapie voor patiënten die behandeld zijn met 
CRT wordt in hoofdstuk 6 behandeld. Specifiek wordt in dit hoofdstuk gekeken naar de 
waarde van adjuvante chemotherapie voor patiënten met een pCR na CRT. Deze studie 
is een vervolgstudie op de studie in hoofdstuk 2. Wederom werd er een gepoolde analyse 
verricht van verzamelde individuele patiëntendata, ditmaal uit 13 internationale centra. 
In totaal werden 3313 patiënten geïncludeerd. Met behulp van multivariabele analyses 
werd gevonden dat patiënten met een pCR na CRT en standaard resectie waarschijnlijk 
geen baat hebben van adjuvante chemotherapie. Vermoedelijk hangen deze resultaten 
samen met de uitstekende prognose van deze specifieke patiëntengroep. Patiënten met 
resttumor na CRT hebben duidelijk wel baat van adjuvante chemotherapie. Bij 
subgroep analyses van patiënten met negatieve en positieve klierstatus na CRT blijkt 
dat patiënten met negatieve klierstatus na CRT wel baat hebben van adjuvante 
chemotherapie en mensen met positieve klierstatus na CRT niet. Deze resultaten lijken 
overeen te komen met de hypothese dat dezelfde factoren die predictief zijn voor de 
respons op CRT ook de gevoeligheid voor adjuvante chemotherapie bepalen. Deze 
hypothese is al eerder in de literatuur geponeerd.  
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Hoofdstuk 7 onderzoekt welke whole-body beeldvormende techniek het meest 
accuraat is voor (lokaal of afstands-) recidiefdetectie bij patiënten met een verdenking 
op recidief colorectaal carcinoom. Met een meta-analyse worden de resultaten van 14 
studies gepoold die whole-body PET, PET-CT en/of CT voor recidiefdectectie na 
colorectaal carcinoom evalueren. Er wordt slechts 1 studie geïdentificeerd die whole-
body MRI onderzocht. Uit de meta-analyse blijkt dat PET-CT de meest accurate 
techniek is. PET-CT detecteert de meeste recidieven, is betrouwbaarder dan CT als er 
geen afwijkingen op CT gevonden worden en is vrijwel altijd geïndiceerd als er 
levermetastasen gevonden worden op CT om extrahepatische metastasen uit te sluiten 
(de achilleshiel van CT).  
Deel III – Patiëntenperspectief 
 In hoofdstuk 8 wordt een patiënt die wait-and-see policy volgt geïnterviewd om een 
kijkje vanuit het patiëntenperspectief te nemen. Het doel van het interview was om de 
voor- en nadelen van wait-and-see policy te onderzoeken en om een idee te krijgen van 
de last van de risico’s en de intensieve follow-up voor de patiënt. Vanuit het 
doktersperspectief is er vooralsnog veel terughoudendheid met betrekking tot wait-
and-see policy. In onze ervaring is dit voor patiënten omgekeerd: zij staan juist zeer 
positief tegenover minder invasieve behandeling en dragen zeer bewust het risico op 
teruggroei van de tumor. De patiënt beaamde dit. De patiënt werd ook gevraagd of zij, 
als ze wederom voor de beslissing stond om wel of niet wait-and-see policy te volgen, 
deel zou nemen aan een gerandomiseerde studie, waarbij ze zou moeten loten tussen 
wait-and-see policy en chirurgie. Zij gaf aan niet deel te willen nemen aan een 
gerandomiseerde studie, aangezien ze niet het risico wilde lopen om te loten voor 
chirurgie. Dit interview suggereert dat de meest betrouwbare methode om definitief 
bewijs te leveren voor wait-and-see policy, de gerandomiseerde studie, weinig 
draagvlak heeft onder patiënten. Voor het starten van een gerandomiseerde studie zal 
de uitvoerbaarheid aldus onderzocht moeten worden en is onderzoek naar een 
alternatieve studie-opzet van belang.  
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Dankwoord 
Allereerst wil ik graag alle patiënten bedanken die mee hebben gewerkt aan mijn 
onderzoek. Zonder jullie deelname was dit proefschrift niet mogelijk geweest. Mijn 
waardering voor jullie inzet en motivatie om deze uitdaging samen met mij aan te gaan 
is onbeschrijflijk. Veel dank! 
 
Dr. Beets, Lieve Geerard. Door jou ben ik dit onderzoek ingerold en daar ben ik je 
ongelooflijk dankbaar voor. Ik heb altijd heel erg prettig met je samengewerkt. Je 
begeleiding was relaxed maar tegelijkertijd ook directief. Hierdoor kan ik nu ook heel 
zelfstandig met het onderzoek aan de slag. Ook heb ik geleerd van jou om door de 
bomen het bos weer te zien als ik vastliep. Jij was ook de reden dat ik graag chirurg 
wilde worden; jij was mijn grote voorbeeld. Gaandeweg kwam ik er echter achter dat 
het niet bij me paste. Gelukkig kon ik toen ook op jouw steun rekenen en heb je me 
geholpen om de moeilijke carrièrekeus te maken. Veel dank voor je steun en 
motiverende begeleiding! 
 
Prof. Beets-Tan, Lieve Regina. Via Geerard rolde ik het onderzoek in en daardoor 
kwam ik ook direct onder jouw vleugels terecht. Je bezielende begeleiding heeft me 
extra gemotiveerd voor het onderzoek. Mijn onderzoek nam hierdoor een vlucht. Je 
stond altijd voor me klaar zowel voor werk- als privégerelateerde kwesties. Ik kan 
altijd bij je binnenlopen en waardeer je toegankelijkheid en vertrouwen in mij enorm. 
Lieve Regina, ik vertrouw jou ook.  
 
Dr. Nelemans, Lieve Patty. Samen hebben we bergen werk verzet. Jij hebt bij mij 
een vuurtje aangewakkerd voor de methodologie en statistiek (iets wat weinig mensen 
echter begrijpen). Ik heb altijd prettig samengewerkt met je en ben dan ook trots dat jij 
mijn copromotor geworden bent! We zitten vrijwel altijd op één lijn. Bij dilemma’s of 
ingewikkelde kwesties had je altijd een nieuwe invalshoek om tot een oplossing te 
komen. Heel veel dank voor je steun, begeleiding en luisterend oor. Ik hoop nog lange 
tijd met je te kunnen samenwerken.  
 
Lieve Doenja. We werden zonder elkaar ooit eerder gezien te hebben bij elkaar 
gezet. Wie had ooit gedacht dat we zo’n dreamteam zouden worden! Met veel plezier 
en ook enige heimwee kijk ik terug naar onze onderzoekstijd. Naast een top 
samenwerking hebben we ook een fantastische klik qua humor en persoonlijkheid. Onze 
vrijdagmiddagmeligheden herinner ik me als de dag van gisteren. Vooral het incident 
met de perforator en de telefoonlijn staat me nog helder voor de ogen. Ook hebben we 
samen veel gereisd: Wenen (4x!), Valencia, Venetië (heel romantisch ;-)), Dresden… Ik 
vergeet jouw snooze-gewoonten nooit meer… Eén van onze hoogtepunten was onze 
succesvolle deelname aan LINGO! Nu zitten we samen in opleiding, wat ook heel 
gezellig is, waardoor we elkaar wel minder vaak zien. Daarom denk ik nog vaak terug 
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aan onze toptijd! Lieve Doenja, bedankt voor onze leuke en gezellige tijd! Je bent een 
superlieve meid en ik ben blij dat ik met jou heb kunnen samenwerken. Ik kan het me 
niet voorstellen zonder jou. Mogen we samen nog veel meer leuke tijden beleven!  
 
Lieve Max, Sanne en Elleke. Jullie waren mijn voorgangers. Vooral met Sanne heb 
ik nog veel en intensief samengewerkt na haar promotietijd. Sanne, ik ben blij dat je me 
je onderzoek hebt laten opvolgen. Ik heb ontzettend veel plezier met je en onze 
samenwerking is top! Max en Elleke, jullie zijn nu ook mijn collega-assistenten en ik 
heb het erg naar mijn zin met jullie. Jullie ook veel dank voor de samenwerking! 
 
Beste Milou en Luc. Als onze opvolgers hadden jullie direct een belangrijke taak: 
alle lopende onderzoeken leren kennen en voortzetten en tegelijkertijd een 
multicentrische studie opzetten. Jullie zitten er nu helemaal in en ik heb er vertrouwen 
in dat jullie een prachtig proefschrift zullen krijgen! 
 
Beste prof. de Haan, beste Michiel. Als opleider is je betrokkenheid bij mijn 
proefschrift beperkt, maar ik ben je toch erg dankbaar. Je flexibiliteit voor het 
vrijmaken van tijd voor onderzoek tijdens de opleiding, maar ook je toegankelijkheid 
zijn voor mij erg belangrijk. Ik vind het fijn om jou als opleider te hebben. 
 
Beste prof. Wildberger, beste Joachim. Je maakt deel uit van mijn leescommissie, 
maar bent in de eerste plaats natuurlijk afdelingshoofd van de afdeling Radiologie in 
het MUMC. Je hebt me geholpen bij mijn carrièrekeus voor de Radiologie. Gelukkig 
maar, want ik ben erg blij met mijn keuze! Dank voor je steun en begeleiding! 
 
Beste professor von Meyenfeldt, beste Maarten. Als voorzitter van mijn 
leescommissie heb je een belangrijke taak vervuld! Je bent ook betrokken geweest bij 
mijn onderzoek en ik heb veel van je geleerd. Hartelijk dank voor het leiden van mijn 
leescommissie, ik ben blij dat je bij mijn verdediging aanwezig kan zijn. Beste prof. 
Tjan-Heijnen, prof. de Wilt en prof. Lambin, hartelijk dank dat jullie deel uit wilden 
maken van mijn leescommissie.  
 
Beste collega’s, ik ga jullie niet allemaal opnoemen, maar ik vind dat we een 
superleuke groep assistenten vormen! Van samenwerken tot samen wintersport: ik heb 
het erg naar mijn zin met jullie! 
 
Beste collega-onderzoekers van de MRI3-gang. Ik heb met jullie een leuke tijd 
gehad. Marc en Jos, zonder jullie had ik het niet gered! Dank voor al jullie hulp maar 
ook voor jullie gezelligheid. Walter, Eline en Cécile, dank voor jullie hulp bij 
onoplosbare technische problemen! Beste Stefan, met jou heb ik oeverloos veel lol 
gehad. Marc, Jos en Stefan nog heel veel dank voor jullie steun bij LINGO!  
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Beste Jan (Verwoerd), hartelijk dank voor je hulp bij het leren begrijpen van de 
MRI en je motiverende en enthousiasmerende uitleg! Ik heb veel van je opgestoken.  
 
Beste Jaap, we hebben heel wat uurtjes doorgebracht achter de pc om mijn cover te 
ontwerpen. Het heeft wat voeten in aarde gehad, maar het resultaat is prachtig! Ik ben 
je eeuwige dank verschuldigd. Beste Ine, jij hebt het binnenwerk van mijn boekje in 
elkaar gezet, wat me een hoop werk heeft bespaard! Veel dank hiervoor. 
 
I would also like to thank all my foreign colleagues for their generosity to share 
data with me and their faith in my research! It was a pleasure to work with you and 
hopefully our collaboration will be continued in the future.  
 
Ook wil ik mijn dank betuigen aan alle collega’s van de afdelingen chirurgie, 
radiologie, radiotherapie, medische oncologie en maag-darm-leverziekten waarmee ik 
heb samengewerkt buiten het MUMC. Zonder jullie participatie en hulp was dit 
onderzoek niet mogelijk geweest.  
 
Lieve Nicole, jij bent mijn paranimf geworden. Je bent een lieve schat en altijd in 
voor een date of feestje! Jij biedt altijd een luisterend oor en kan me altijd weer met 
beide benen op de grond zetten ;-). Lieve Jules, onze vriendschap is heel sterk en hecht, 
ik ben er trots op dat jij mijn vriend bent. Ik weet dat je altijd voor me klaar staat. 
Lieve Marianne, sinds onderwijsgroep 1 zijn we vriendinnen en we hebben veel 
meegemaakt. We raken nooit uitgepraat! Hopelijk blijven we nog lang vriendinnen en 
misschien kunnen we ons 10-jaren-stad-plan nieuw leven inblazen! Lieve Kelly, je bent 
er altijd voor me en ik ben heel blij dat ik jou als vriendin heb! Lieve Sanne (Postma), 
we zien elkaar niet zo vaak, maar als we dan afspreken is het altijd weer reuze gezellig! 
Ik heb veel plezier met je en hoop dat we nog vele eetdates gaan hebben. Lieve Ilknur, 
samen stonden we sterk in Sittard. We zijn inmiddels allebei een andere richting 
opgegaan en ik hoop dat jouw toekomst vol geluk is en dat je de baan mag krijgen die 
je graag wil! Lieve Nathalie, ik hoop dat je vrede en rust hebt gevonden.  
 
Lieve Dennis, je hebt mijn promotietijd niet meegemaakt maar wel de nasleep 
ervan en de totstandkoming van dit boekje. Jij hebt me gesteund en geholpen en me de 
ruimte gegeven. Je hebt me veranderd en mijn hart ingenomen. Ik kan me het leven 
niet meer voorstellen zonder je.  
 
Lieve papa en mama, zonder jullie was dit allemaal niet mogelijk geweest. Ik kan 
met geen woorden beschrijven hoeveel jullie voor me betekenen en hoeveel ik aan jullie 
steun heb. Ik kan me geen betere ouders wensen. Lieve mama, ik ben blij dat je er bij 
bent.  
 
Liefs, Monique 
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Curriculum vitae 
Monique Maas was born on the 5th of January 1983 in 
Eindhoven, The Netherlands. She went to primary school 
‘Nutsschool Hanevoet’ and secondary school ‘S.G. 
Augustinianum (gymnasium)’, both in Eindhoven. She 
graduated with distinction in 2001 and started medical 
training at Maastricht University in the same year. She 
obtained her medical degree in 2007, with distinction. 
During her study she participated in research from 2004-
2007 at the Department of Rheumatology MUMC, 
supervised by dr. Annelies Boonen. It was in this period that 
she gained a large interest in research.  
 
She participated in several elective internships at the Department of Surgery at the 
MUMC from 2004 to 2007. In 2004 she followed an elective internship at the 
Traumatology unit. From 2006 to 2007 she did an elective internship at the 
Department of Gastro-intestinal and Oncological Surgery at the MUMC, combining 
clinical experience with research under supervision of dr. Geerard Beets and drs. 
Ronald van Dam. In this period she got acquainted with the rectal cancer research 
team. She became very enthusiastic about their research. In 2007 she went to Salta 
(Argentina) to follow an extra-curricular internship at the Department of General and 
Paediatric Surgery and the Neonatal Intensive Care Unit. When she returned, she 
started working as a resident of Surgery at the Orbis Medical Centre, Sittard, The 
Netherlands.  
  
After having worked for almost one year in Sittard, she returned to Maastricht to 
work at Maastricht University (GROW) as a PhD student under supervision of dr. 
Geerard Beets and prof. dr. Regina Beets-Tan at the Departments of Surgery and 
Radiology. During this period she won several prizes, among which the Incentive Prize 
of the Pélerin Symposium (2007), a travel grant for best abstract for GASTRO 2009 
and 2012, and prize for best research paper from the ESSO 2010. Also she received a 
grant from the Profileringsfonds MUMC in 2009 and an AGIKO-grant from ZonMW 
in 2011. In 2011 she co-authored a proposal for a Dutch Cancer Society grant on rectal 
cancer staging of approximately 500,000 euros, which was awarded to the rectal cancer 
team at MUMC in the Spring of 2012.  
 
In September 2011 she started her residence at the Department of Radiology at the 
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